@article {pmid36705045,
year = {2023},
author = {Feleszko, W and Okarska-Napierała, M and Buddingh, EP and Bloomfield, M and Sediva, A and Bautista-Rodriguez, C and Brough, HA and Eigenmann, PA and Eiwegger, T and Eljaszewicz, A and Eyerich, S and Gomez-Casado, C and Fraisse, A and Janda, J and Jiménez-Saiz, R and Kallinich, T and Krohn, IK and Mortz, CG and Riggioni, C and Sastre, J and Sokolowska, M and Strzelczyk, Z and Untersmayr, E and Tramper-Stranders, G and , },
title = {Pathogenesis, immunology, and immune-targeted management of the multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper.},
journal = {Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology},
volume = {34},
number = {1},
pages = {e13900},
doi = {10.1111/pai.13900},
pmid = {36705045},
issn = {1399-3038},
mesh = {SARS-CoV-2 ; Child ; Systemic Inflammatory Response Syndrome/diagnosis/therapy ; Humans ; COVID-19 Vaccines ; *COVID-19/complications ; },
abstract = {Multisystem inflammatory syndrome in children (MIS-C) is a rare, but severe complication of coronavirus disease 2019 (COVID-19). It develops approximately 4 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and involves hyperinflammation with multisystem injury, commonly progressing to shock. The exact pathomechanism of MIS-C is not known, but immunological dysregulation leading to cytokine storm plays a central role. In response to the emergence of MIS-C, the European Academy of Allergy and Clinical Immunology (EAACI) established a task force (TF) within the Immunology Section in May 2021. With the use of an online Delphi process, TF formulated clinical statements regarding immunological background of MIS-C, diagnosis, treatment, follow-up, and the role of COVID-19 vaccinations. MIS-C case definition is broad, and diagnosis is made based on clinical presentation. The immunological mechanism leading to MIS-C is unclear and depends on activating multiple pathways leading to hyperinflammation. Current management of MIS-C relies on supportive care in combination with immunosuppressive and/or immunomodulatory agents. The most frequently used agents are systemic steroids and intravenous immunoglobulin. Despite good overall short-term outcome, MIS-C patients should be followed-up at regular intervals after discharge, focusing on cardiac disease, organ damage, and inflammatory activity. COVID-19 vaccination is a safe and effective measure to prevent MIS-C. In anticipation of further research, we propose a convenient and clinically practical algorithm for managing MIS-C developed by the Immunology Section of the EAACI.},
}

SARS-CoV-2
Child
Systemic Inflammatory Response Syndrome/diagnosis/therapy
Humans
COVID-19 Vaccines
*COVID-19/complications

@article {pmid36629948,
year = {2023},
author = {Ishige, T and Shimizu, T and Watanabe, K and Arai, K and Kamei, K and Kudo, T and Kunisaki, R and Tokuhara, D and Naganuma, M and Mizuochi, T and Murashima, A and Inoki, Y and Iwata, N and Iwama, I and Koinuma, S and Shimizu, H and Jimbo, K and Takaki, Y and Takahashi, S and Cho, Y and Nambu, R and Nishida, D and Hagiwara, SI and Hikita, N and Fujikawa, H and Hosoi, K and Hosomi, S and Mikami, Y and Miyoshi, J and Yagi, R and Yokoyama, Y and Hisamatsu, T},
title = {Expert consensus on vaccination in patients with inflammatory bowel disease in Japan.},
journal = {Journal of gastroenterology},
volume = {58},
number = {2},
pages = {135-157},
pmid = {36629948},
issn = {1435-5922},
support = {20316729//Ministry of Health, Labour and Welfare/ ; },
mesh = {Adult ; Pregnancy ; Female ; Humans ; Child ; Consensus ; Japan ; *COVID-19 ; *Inflammatory Bowel Diseases/drug therapy ; Vaccination/adverse effects ; },
abstract = {Immunosuppressive therapies can affect the immune response to or safety of vaccination in patients with inflammatory bowel disease (IBD). The appropriateness of vaccination should be assessed prior to the initiation of IBD treatment because patients with IBD frequently undergo continuous treatment with immunosuppressive drugs. This consensus was developed to support the decision-making process regarding appropriate vaccination for pediatric and adult patients with IBD and physicians by providing critical information according to the published literature and expert consensus about vaccine-preventable diseases (VPDs) [excluding cervical cancer and coronavirus disease 2019 (COVID-19)] in Japan. This consensus includes 19 important clinical questions (CQs) on the following 4 topics: VPDs (6 CQs), live attenuated vaccines (2 CQs), inactivated vaccines (6 CQs), and vaccination for pregnancy, childbirth, and breastfeeding (5 CQs). These topics and CQs were selected under unified consensus by the members of a committee on intractable diseases with support by a Health and Labour Sciences Research Grant. Physicians should provide necessary information on VPDs to their patients with IBD and carefully manage these patients' IBD if various risk factors for the development or worsening of VPDs are present. This consensus will facilitate informed and shared decision-making in daily IBD clinical practice.},
}

Adult
Pregnancy
Female
Humans
Child
Consensus
Japan
*COVID-19
*Inflammatory Bowel Diseases/drug therapy
Vaccination/adverse effects

@article {pmid36599436,
year = {2023},
author = {, and , },
title = {[Expert consensus on treatment of severe COVID-19 caused by Omicron variants].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {46},
number = {2},
pages = {101-110},
doi = {10.3760/cma.j.cn112147-20221230-00994},
pmid = {36599436},
issn = {1001-0939},
support = {2022-NHLHCRF-LX-01-01//National High Level Hospital Clinical Research Funding/ ; 2022-I2M-JB-016//CAMS Innovation Fund for Medical Sciences/ ; 2022YFC2504401//National Key Research and Development Program of China/ ; 2022‑NHLHCRF‑LX‑01‑01//National High Level Hospital Clinical Research Funding/ ; 2022‑I2M‑JB‑016//CAMS Innovation Fund for Medical Sciences/ ; },
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; Consensus ; Critical Care ; China ; },
abstract = {Severe novel coronavirus infection (COVID-19) caused by Omicron variants has arisen in many places of China recently, and critical care is currently the biggest challenge for medical institutions in China. How to manage these patients in a procedural and standardized way to minimize the mortality is a problem that the medical staff with different professional backgrounds has to face. Therefore, the Chinese Thoracic Society and Chinese Association of Chest Physicians Critical Care Group jointly initiated and organized pulmonary and critical care experts to write this recommendation based on the current medical evidence and clinical practice, in order to standardize the clinical treatment of critically ill patients.},
}

Humans
*COVID-19
SARS-CoV-2
Consensus
Critical Care
China

@article {pmid36567574,
year = {2022},
author = {World Federation Of Chinese Medical Societies Emergency Committee, and World Federation Of Chinese Medical Societies Respiratory Diseases, and World Federation Of Chinese Medical Societies Heat Disease Committee, and Chinese Association Of Chinese Medicine Pulmonary Disease Chapter, and The First Aid Group Of Integrated Traditional Chinese And Western Medicine Of The Emergency Branch Of The Chinese Medical Association, and The First Aid Group Of Integrated Traditional Chinese And Western Medicine Of The Emergency Branch Of The Emergency Physician Branch Of The Chinese Medical Doctor Association, and The Emergency Branch Of The Shanghai Chinese Medical Association, and The Institute Of Emergency And Critical Care Of The Shanghai University Of Traditional Chinese Medicine, and National Health Commission's Key Laboratory Of Critical Care Medicine, },
title = {[Expert consensus on traditional Chinese medicine health management in adults with SARS-CoV-2 variant infection at home].},
journal = {Zhonghua wei zhong bing ji jiu yi xue},
volume = {34},
number = {12},
pages = {1233-1237},
doi = {10.3760/cma.j.cn121430-20221210-01079},
pmid = {36567574},
issn = {2095-4352},
mesh = {Adult ; Humans ; SARS-CoV-2 ; *COVID-19 ; Consensus ; East Asian People ; *Drugs, Chinese Herbal/therapeutic use ; China ; Medicine, Chinese Traditional ; },
abstract = {In order to more actively respond to the new situation of prevention and control of coronavirus disease 2019 (COVID-19), and to guide home health management for adults who are asymptomatic carriers or exhibit mild symptoms, the World Federation of Chinese Medical Societies Emergency Committee, World Federation of Chinese Medical Societies Respiratory Diseases, World Federation of Chinese Medical Societies Heat Disease Committee, Chinese Association of Chinese Medicine Pulmonary Disease Chapter, the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Chinese Medical Doctor Association, the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Emergency Physician Branch of the Chinese Medical Association, the Emergency Branch of the Shanghai Chinese Medical Association, the Institute of Emergency and Critical Care of the Shanghai University of Traditional Chinese Medicine, National Health Commission's Key Laboratory of Critical Care Medicine and other academic institutions have organized the medical experts at treating COVID-19 front line in China to investigate and discuss the traditional Chinese medicine (TCM) health management at home for adults infected with SARS-CoV-2 variants, and concluded the "Expert consensus on traditional Chinese medicine health management at home for adults infected with SARS-CoV-2 variants", in combination with "Guideline on SARS-CoV-2 variant infection recover at home" issued by the Joint Prevention and Control Mechanism of the State Council. The expert consensus included home environment, asymptomatic infection, infection with mild symptoms, recovery period, and TCM non-drug therapy intervention, which will provide a guidance to TCM intervention at home to adults infected with SARS-CoV-2 variants.},
}

Adult
Humans
SARS-CoV-2
*COVID-19
Consensus
East Asian People
*Drugs, Chinese Herbal/therapeutic use
China
Medicine, Chinese Traditional

@article {pmid36546318,
year = {2022},
author = {, and Nomura, K and Ebihara, S and Ikebata, Y and Umegaki, H and Ooi, K and Ogawa, S and Katsuya, T and Kobayashi, Y and Sakurai, T and Miyao, M and Yamaguchi, K and Akishita, M},
title = {Japan Geriatrics Society "Statement for the use of telemedicine in geriatric care: Telemedicine as a complement to in-person medical practice": Geriatric Medical Practice Committee consensus statement.},
journal = {Geriatrics & gerontology international},
volume = {22},
number = {11},
pages = {913-916},
pmid = {36546318},
issn = {1447-0594},
support = {19H03984//Japan Society for the Promotion of Science/ ; 19K22821//Japan Society for the Promotion of Science/ ; 22K19760//Japan Society for the Promotion of Science/ ; },
mesh = {Humans ; Aged ; Japan ; *COVID-19 ; *Telemedicine ; *Geriatrics ; *Physicians ; },
abstract = {Telemedicine has changed from a way to treat patients with limited access to hospitals to a necessary method of treatment for non-urgent conditions during the coronavirus disease 2019 pandemic. There are two styles of telemedicine, namely "hybrid medical care" and "gateway medical care," which take advantage of the characteristics of online medical care and might become important in the near future. During hybrid medical care, a patient and their primary care physician have face-to-face medical care while simultaneously being examined by a specialist physician through telemedicine, leading to an overall improvement in the level of local medical care and expansion in the number of treatable diseases. Gateway medical practice is a form of telemedicine used for patients who would otherwise refuse or not receive in-person medical care to engage in consultation with a physician. Telemedicine allows physicians to determine disease severity and triage patients, while reducing unnecessary home visits, emergency hospitalizations and the spread of infection. Telemedicine is less intense than in-person medical care, and allows for easier collaboration with other healthcare providers. However, telemedicine is not optimal for conditions requiring a definitive diagnosis and a comprehensive understanding of the patient's medical history. It is limited by the patient's ability to use telemedicine devices, and the risk of accidental treatments and fraud. The use of telemedicine might result in the development of new, online comprehensive geriatric assessment tools and technologies. Geriatr Gerontol Int 2022; 22: 913-916.},
}

Humans
Aged
Japan
*COVID-19
*Telemedicine
*Geriatrics
*Physicians

@article {pmid36541203,
year = {2023},
author = {Ruberg, FL and Baggish, AL and Hays, AG and Jerosch-Herold, M and Kim, J and Ordovas, KG and Reddy, G and Shenoy, C and Weinsaft, JW and Woodard, PK},
title = {Utilization of Cardiovascular Magnetic Resonance Imaging for Resumption of Athletic Activities Following COVID-19 Infection: An Expert Consensus Document on Behalf of the American Heart Association Council on Cardiovascular Radiology and Intervention Leadership and Endorsed by the Society for Cardiovascular Magnetic Resonance.},
journal = {Circulation. Cardiovascular imaging},
volume = {16},
number = {1},
pages = {e014106},
pmid = {36541203},
issn = {1942-0080},
support = {R01 HL139671/HL/NHLBI NIH HHS/United States ; },
mesh = {Humans ; United States/epidemiology ; *COVID-19 ; SARS-CoV-2 ; Consensus ; American Heart Association ; Leadership ; Magnetic Resonance Imaging ; *Sports ; Magnetic Resonance Spectroscopy ; *Radiology ; },
abstract = {The global pandemic of COVID-19 caused by infection with SARS-CoV-2 is now entering its fourth year with little evidence of abatement. As of December 2022, the World Health Organization Coronavirus (COVID-19) Dashboard reported 643 million cumulative confirmed cases of COVID-19 worldwide and 98 million in the United States alone as the country with the highest number of cases. Although pneumonia with lung injury has been the manifestation of COVID-19 principally responsible for morbidity and mortality, myocardial inflammation and systolic dysfunction though uncommon are well-recognized features that also associate with adverse prognosis. Given the broad swath of the population infected with COVID-19, the large number of affected professional, collegiate, and amateur athletes raises concern regarding the safe resumption of athletic activity (return to play) following resolution of infection. A variety of different testing combinations that leverage ECG, echocardiography, circulating cardiac biomarkers, and cardiovascular magnetic resonance imaging have been proposed and implemented to mitigate risk. Cardiovascular magnetic resonance in particular affords high sensitivity for myocarditis but has been employed and interpreted nonuniformly in the context of COVID-19 thereby raising uncertainty as to the generalizability and clinical relevance of findings with respect to return to play. This consensus document synthesizes available evidence to contextualize the appropriate utilization of cardiovascular magnetic resonance in the return to play assessment of athletes with prior COVID-19 infection to facilitate informed, evidence-based decisions, while identifying knowledge gaps that merit further investigation.},
}

Humans
United States/epidemiology
*COVID-19
SARS-CoV-2
Consensus
American Heart Association
Leadership
Magnetic Resonance Imaging
*Sports
Magnetic Resonance Spectroscopy
*Radiology

@article {pmid36519288,
year = {2023},
author = {DiScala, S and Uritsky, TJ and Brown, ME and Abel, SM and Humbert, NT and Naidu, D},
title = {Society of Pain and Palliative Care Pharmacists White Paper on the Role of Opioid Stewardship Pharmacists.},
journal = {Journal of pain & palliative care pharmacotherapy},
volume = {37},
number = {1},
pages = {3-15},
doi = {10.1080/15360288.2022.2149670},
pmid = {36519288},
issn = {1536-0539},
mesh = {Humans ; *Analgesics, Opioid/adverse effects ; *COVID-19 ; Pain/drug therapy ; Pain Management ; Palliative Care ; Pandemics ; Pharmacists ; United States ; },
abstract = {Opioid stewardship is one essential function of pain and palliative care pharmacists and a critical need in the United States. In recent years, this country has been plagued by two public health emergencies: an opioid crisis and the COVID-19 pandemic, which has exacerbated the opioid epidemic through its economic and psychosocial toll. To develop an opioid stewardship program, a systematic approach is needed. This will be detailed in part here by the Opioid Stewardship Taskforce of the Society of Pain and Palliative Care Pharmacists (SPPCP), focusing on the role of the pharmacist. Many pain and palliative care pharmacists have made significant contributions to the development and daily operation of such programs while also completing other competing clinical tasks, including direct patient care. To ensure dedicated time and attention to critical opioid stewardship efforts, SPPCP recommends and endorses opioid stewardship models employing a full time, opioid stewardship pharmacist in both the inpatient and outpatient setting. Early research suggests that opioid stewardship pharmacists are pivotal to improving opioid metrics and pain care outcomes. However, further research and development in this area of practice is needed and encouraged.},
}

Humans
*Analgesics, Opioid/adverse effects
*COVID-19
Pain/drug therapy
Pain Management
Palliative Care
Pandemics
Pharmacists
United States

@article {pmid36448775,
year = {2022},
author = {Vukoja, M and Kopitovic, I and Lazic, Z and Milenkovic, B and Stankovic, I and Tomic-Spiric, V and Zvezdin, B and Hromis, S and Cekerevac, I and Ilic, A and Vukcevic, M and Dimic-Janjic, S and Stjepanovic, M},
title = {Diagnosis and treatment of adult asthma patients in Serbia: a 2022 experts group position statement.},
journal = {Expert review of respiratory medicine},
volume = {16},
number = {11-12},
pages = {1133-1144},
doi = {10.1080/17476348.2022.2153674},
pmid = {36448775},
issn = {1747-6356},
mesh = {Humans ; Adult ; Serbia ; *Asthma/therapy ; },
abstract = {INTRODUCTION: Asthma is the most common non-communicable chronic lung condition across all ages. Epidemiological data indicate that many asthma patients in Serbia remain undiagnosed and untreated. The implementation of recent global advances in asthma management is limited due to the lack of a systematic approach, drug availability and regulatory affairs. In addition, the global coronavirus disease pandemic has posed a significant challenge, particularly in resource-limited settings.

AREAS COVERED: In this paper, we propose an algorithm for treating adult asthma patients in Serbia. We performed PubMed database search on published asthma clinical trials and guidelines from 1 January 2015 to 10 March 2020. The consensus process incorporated a modified Delphi method that included two rounds of e-mail questionnaires and three rounds of national asthma expert meetings. We focus on 1) objective diagnosis of asthma, 2) the implementation of up-to-date therapeutic options, and 3) the identification and referral of severe asthma patients to newly established severe asthma centers.

EXPERT OPINION: Regional specificities and variations in healthcare systems require the adaptation of evidence-based knowledge. Practical, clinically oriented algorithms designed to overcome local barriers in healthcare delivery may facilitate timely and adequate asthma diagnosis and the local implementation of current advances in asthma management.},
}

Humans
Adult
Serbia
*Asthma/therapy

@article {pmid36427057,
year = {2023},
author = {Strengers, P and O'Brien, SF and Politis, C and Mayr, W and Seifried, E and Spencer, BR},
title = {White paper on pandemic preparedness in the blood supply.},
journal = {Vox sanguinis},
volume = {118},
number = {1},
pages = {8-15},
doi = {10.1111/vox.13378},
pmid = {36427057},
issn = {1423-0410},
mesh = {Humans ; United States ; *COVID-19/epidemiology/prevention & control ; SARS-CoV-2 ; Pandemics/prevention & control ; Austria ; Germany ; },
abstract = {BACKGROUND AND OBJECTIVES: In March 2020, the WHO declared the SARS-CoV-2 corona virus a pandemic which caused a great disruption to global society and had a pronounced effect on the worldwide supply of blood.

MATERIALS AND METHODS: In 2022 an on-line meeting was organised with experts from Austria, Canada, Germany, Greece, Netherlands and United States to explore the opportunities for increasing preparedness within blood systems for a potential future pandemic with similar, or more devastating, consequences. The main themes included the value of preparedness, current risks to the blood supply, supply chain vulnerabilities, and the role of innovation in increasing resiliency and safety.

RESULTS: Seven key recommendations were formulated and including required actions at different levels.

CONCLUSION: Although SARS-CoV-2 might be seen as a unique event, global health risks are expected to increase and will affect blood transfusion medicine if no preparedness plans are developed.},
}

Humans
United States
*COVID-19/epidemiology/prevention & control
SARS-CoV-2
Pandemics/prevention & control
Austria
Germany

@article {pmid36371767,
year = {2023},
author = {Perram, J and Purtill, D and Bajel, A and Butler, J and O'Brien, T and Teh, B and Gilroy, N and Ho, PJ and Doocey, R and Hills, T and Perera, T and Douglas, G and Ramachandran, S and Chee, L and Trotman, J and Weinkove, R and Keogh, S and Fraser, C and Cochrane, T and Watson, AM and Diamond, P and Latimer, M and Irving, I and Blyth, E and Cheah, C and Cole, T and Milliken, S and Yang, H and Greenwood, M and Bardy, P and Kennedy, G and Larsen, S and Conyers, R and Hamad, N},
title = {Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.},
journal = {Internal medicine journal},
volume = {53},
number = {1},
pages = {119-125},
pmid = {36371767},
issn = {1445-5994},
mesh = {Humans ; *Receptors, Chimeric Antigen/therapeutic use ; *COVID-19 ; New Zealand/epidemiology ; T-Lymphocytes ; *Hematopoietic Stem Cell Transplantation ; },
abstract = {Patients with post-haemopoietic stem cell transplant or chimeric antigen receptor T -cell (CAR-T) therapy face a significant risk of morbidity and mortality from coronavirus disease 2019 because of their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance on management in this high-risk population is needed. Whilst we have learned much from international colleagues who faced high infection rates early in the pandemic, guidance relevant to local health system structures, medication availability and emerging therapies is essential to equip physicians to manage our patients optimally.},
}

Humans
*Receptors, Chimeric Antigen/therapeutic use
*COVID-19
New Zealand/epidemiology
T-Lymphocytes
*Hematopoietic Stem Cell Transplantation

@article {pmid36329272,
year = {2022},
author = {Lazarus, JV and Romero, D and Kopka, CJ and Karim, SA and Abu-Raddad, LJ and Almeida, G and Baptista-Leite, R and Barocas, JA and Barreto, ML and Bar-Yam, Y and Bassat, Q and Batista, C and Bazilian, M and Chiou, ST and Del Rio, C and Dore, GJ and Gao, GF and Gostin, LO and Hellard, M and Jimenez, JL and Kang, G and Lee, N and Matičič, M and McKee, M and Nsanzimana, S and Oliu-Barton, M and Pradelski, B and Pyzik, O and Rabin, K and Raina, S and Rashid, SF and Rathe, M and Saenz, R and Singh, S and Trock-Hempler, M and Villapol, S and Yap, P and Binagwaho, A and Kamarulzaman, A and El-Mohandes, A and , },
title = {A multinational Delphi consensus to end the COVID-19 public health threat.},
journal = {Nature},
volume = {611},
number = {7935},
pages = {332-345},
pmid = {36329272},
issn = {1476-4687},
support = {MR/T008768/1/MRC_/Medical Research Council/United Kingdom ; UM1 AI069476/AI/NIAID NIH HHS/United States ; },
mesh = {Humans ; *COVID-19/economics/epidemiology/prevention & control ; *Delphi Technique ; Government ; Pandemics/economics/prevention & control ; *Public Health/economics/methods ; *International Cooperation ; Organizations ; COVID-19 Vaccines ; Communication ; Health Education ; Health Policy ; Public Opinion ; },
abstract = {Despite notable scientific and medical advances, broader political, socioeconomic and behavioural factors continue to undercut the response to the COVID-19 pandemic[1,2]. Here we convened, as part of this Delphi study, a diverse, multidisciplinary panel of 386 academic, health, non-governmental organization, government and other experts in COVID-19 response from 112 countries and territories to recommend specific actions to end this persistent global threat to public health. The panel developed a set of 41 consensus statements and 57 recommendations to governments, health systems, industry and other key stakeholders across six domains: communication; health systems; vaccination; prevention; treatment and care; and inequities. In the wake of nearly three years of fragmented global and national responses, it is instructive to note that three of the highest-ranked recommendations call for the adoption of whole-of-society and whole-of-government approaches[1], while maintaining proven prevention measures using a vaccines-plus approach[2] that employs a range of public health and financial support measures to complement vaccination. Other recommendations with at least 99% combined agreement advise governments and other stakeholders to improve communication, rebuild public trust and engage communities[3] in the management of pandemic responses. The findings of the study, which have been further endorsed by 184 organizations globally, include points of unanimous agreement, as well as six recommendations with >5% disagreement, that provide health and social policy actions to address inadequacies in the pandemic response and help to bring this public health threat to an end.},
}

Humans
*COVID-19/economics/epidemiology/prevention & control
*Delphi Technique
Government
Pandemics/economics/prevention & control
*Public Health/economics/methods
*International Cooperation
Organizations
COVID-19 Vaccines
Communication
Health Education
Health Policy
Public Opinion

@article {pmid36319453,
year = {2022},
author = {, and , },
title = {[Chinse expert consensus on issues related to the protection, treatment and management of patients with solid tumors during COVID-19 (2022 edition)].},
journal = {Zhonghua zhong liu za zhi [Chinese journal of oncology]},
volume = {44},
number = {10},
pages = {1083-1090},
doi = {10.3760/cma.j.cn112152-20220505-00309},
pmid = {36319453},
issn = {0253-3766},
mesh = {Humans ; *COVID-19 ; Pandemics ; Consensus ; *Neoplasms ; China ; },
abstract = {The new coronavirus is still in the global pandemic stage. At present, the Delta strain and the Omicron strain are the main circulating strains. The mutant strain has stronger infectivity than the original virus. In the content of COVID-19 pandemic, social public resources and medical resources may be affected, which lead to the medical treatment being delayed or interrupted in some patients with malignant tumors. Based on relevant research and clinical practice at home and abroad, the Cancer Support Therapy Committee of China Anti-Cancer Association and the Cancer Clinical Chemotherapy Committee of China Anti-Cancer Association, in the light of China's national conditions and the availability of resources such as vaccines and antiviral drug, to formulate a consensus of Chinese experts on issues related to the prevention, treatment and management of patients with solid tumors. The main contents include the vaccination of cancer patients with COVID-19, the optimization of medical resources, and the timing of restarting anti-tumor therapy after COVID-19 infection. This article is aimed at providing reference for clinical practice.},
}

Humans
*COVID-19
Pandemics
Consensus
*Neoplasms
China

@article {pmid36272444,
year = {2023},
author = {Sacks-Zimmerman, A and Bergquist, TF and Farr, EM and Cornwell, MA and Kanellopoulos, D},
title = {Rehabilitation of Neuropsychiatric Symptoms in Patients With Long COVID: Position Statement.},
journal = {Archives of physical medicine and rehabilitation},
volume = {104},
number = {2},
pages = {350-354},
pmid = {36272444},
issn = {1532-821X},
mesh = {Adult ; Humans ; Post-Acute COVID-19 Syndrome ; *COVID-19 ; Quality of Life ; *Mental Disorders ; Chronic Disease ; },
abstract = {Long COVID, a term used to describe ongoing symptoms after COVID-19 infection, parallels the course of other postviral syndromes. Neuropsychiatric symptoms of long COVID can be persistent and interfere with quality of life and functioning. Within the biopsychosocial framework of chronic illness, rehabilitation professionals can address the neuropsychiatric sequelae of long COVID. However, current practice models are not designed to address concurrent psychiatric and cognitive symptoms in adults living with long COVID. Thus, we present a biopsychosocial framework for long COVID and provide treatment strategies based on evidence from current literature of postviral chronic illness. These recommendations will guide rehabilitation professionals in identifying common neuropsychiatric symptoms in long COVID that can be targeted for intervention and addressing these symptoms via integrative interventions taking into account the biopsychosocial presentation of long COVID symptoms.},
}

Adult
Humans
Post-Acute COVID-19 Syndrome
*COVID-19
Quality of Life
*Mental Disorders
Chronic Disease

@article {pmid36178109,
year = {2024},
author = {Castelletti, S and Gervasi, S and Ballardini, E and Casasco, M and Cavarretta, E and Colivicchi, F and Contursi, M and Cuccaro, F and D'Ascenzi, F and Gazale, G and Mos, L and Nistri, S and Palmieri, V and Patrizi, G and Scorcu, M and Spampinato, A and Tiberi, M and Zito, GB and Zorzi, A and Zeppilli, P and Sciarra, L and , },
title = {The athlete after COVID-19 infection: what the scientific evidence? What to do? A position statement.},
journal = {Panminerva medica},
volume = {66},
number = {1},
pages = {63-74},
doi = {10.23736/S0031-0808.22.04723-1},
pmid = {36178109},
issn = {1827-1898},
mesh = {Humans ; *COVID-19 ; Athletes ; Exercise ; Pandemics ; *Pericarditis ; },
abstract = {The Coronavirus-19 disease (COVID-19) related pandemic have deeply impacted human health, economy, psychology and sociality. Possible serious cardiac involvement in the infection has been described, raising doubts about complete healing after the disease in many clinical settings. Moreover, there is the suspicion that the vaccines, especially those based on mRNA technology, can induce myopericarditis. Myocarditis or pericarditis related scars can represent the substrate for life-threatening arrhythmias, triggered by physical activity. A crucial point is how to evaluate an athlete after a COVID-19 infection ensuring a safe return to play without increasing the number of unnecessary disqualifications from sports competitions. The lack of conclusive scientific data significantly increases the difficulty to propose recommendations and guidelines on this topic. At the same time, the psychological and physical negative consequences of unnecessary sports restriction must be taken into account. The present document aims to provide an updated brief review of the current knowledge about the COVID-19 cardiac involvement and how to recognize it and to offer a roadmap for the management of the athletes after a COVID-19 infections, including subsequent impact on exercise recommendations. Our document exclusively refers to cardiovascular implications of the disease, but pulmonary consequences are also considered.},
}

Humans
*COVID-19
Athletes
Exercise
Pandemics
*Pericarditis

@article {pmid36154545,
year = {2022},
author = {Hadda, V and Suri, TM and Iyer, H and Jain, A and Mittal, S and Madan, K and Mohan, A and Seith Bhalla, A and Sindhwani, G and Dutt, N and Venkatnarayan, K and Nath, A and Dhooria, S and Kumar, R and Marwah, V and Karmakar, S and Chaudhry, D and Ayub, II and Dwivedi, DP and Tiwari, P and Koul, P and Behera, AK and Saxena, P and Sengupta, A and Mohapatra, PR and Goyal, A and Christopher, DJ and Guleria, R},
title = {A Delphi consensus statement for the management of post-COVID interstitial lung disease.},
journal = {Expert review of respiratory medicine},
volume = {16},
number = {9},
pages = {983-995},
doi = {10.1080/17476348.2022.2128770},
pmid = {36154545},
issn = {1747-6356},
mesh = {Humans ; Delphi Technique ; *COVID-19/complications ; *Lung Diseases, Interstitial/diagnosis/epidemiology/etiology ; Consensus ; Lung/diagnostic imaging ; },
abstract = {INTRODUCTION: As millions of people worldwide recover from COVID-19, a substantial proportion continue to have persistent symptoms, pulmonary function abnormalities, and radiological findings suggestive of post-COVID interstitial lung disease (ILD). To date, there is limited scientific evidence on the management of post-COVID ILD, necessitating a consensus-based approach.

AREAS COVERED: A panel of experts in pulmonology and thoracic radiology was constituted. Key questions regarding the management of post-COVID ILD were identified. A search was performed on PubMed and EMBASE and updated till 1 March 2022. The relevant literature regarding the epidemiology, pathophysiology, diagnosis and treatment of post-COVID ILD was summarized. Subsequently, suggestions regarding the management of these patients were framed, and a consensus was obtained using the Delphi approach. Those suggestions which were approved by over 80% of the panelists were accepted. The final document was approved by all panel members.

EXPERT OPINION: Dedicated facilities should be established for the care of patients with post-COVID ILD. Symptom screening, pulmonary function testing, and thoracic imaging have a role in the diagnosis. The pharmacologic and non-pharmacologic options for the management of post-COVID ILD are discussed. Further research into the pathophysiology and management of post-COVID ILD will improve our understanding of this condition.},
}

Humans
Delphi Technique
*COVID-19/complications
*Lung Diseases, Interstitial/diagnosis/epidemiology/etiology
Consensus
Lung/diagnostic imaging

@article {pmid36152123,
year = {2022},
author = {Chen, S and Zhao, W and Li, J and Wu, D and , },
title = {Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition).},
journal = {Frontiers of medicine},
volume = {16},
number = {5},
pages = {815-826},
pmid = {36152123},
issn = {2095-0225},
mesh = {Humans ; Consensus ; *Lymphoma, B-Cell/drug therapy ; China ; },
abstract = {Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL) due to their reliable efficacy, manageable safety, high accessibility, and convenience for use. Still, no guidelines or consensus focusing on oral drug therapies for BCL is available. To provide a reference of oral agent-based treatment for mature BCL, a panel of experts from the Lymphocyte Disease Group, Chinese Society of Hematology, Chinese Medical Association conducted an extensive discussion and reached a consensus on oral drugs for Chinese BCL patients on the basis of the current application status of oral drugs in China, combined with the latest authoritative guidelines in the world and current research reports. This consensus reviewed the application of oral drugs in the treatment of BCL and the latest research and provided appropriate recommendations on the use of oral drugs for indolent or aggressive BCL patients. With the deepening of research and the development of standardized clinical applications, oral medications will bring better treatment to BCL patients, enabling more patients to benefit from them.},
}

Humans
Consensus
*Lymphoma, B-Cell/drug therapy
China

@article {pmid36117294,
year = {2022},
author = {Filipiak, KJ and Babkowski, MC and Cameli, M and Carugo, S and Ferri, C and Irisov, DB and Narkiewicz, K and Nizamov, U and Pérez de Isla, L and Tomaszuk-Kazberuk, A and Ungar, A and Gąsecka, A},
title = {TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice.},
journal = {Cardiology journal},
volume = {29},
number = {5},
pages = {730-738},
pmid = {36117294},
issn = {1898-018X},
mesh = {Antihypertensive Agents/therapeutic use ; *COVID-19 ; *Cardiovascular Diseases/diagnosis/epidemiology/prevention & control ; *Dyslipidemias/diagnosis/drug therapy/epidemiology ; Humans ; *Hypertension/diagnosis/drug therapy/epidemiology ; Lipids ; Lipoproteins ; Poland ; Proprotein Convertase 9 ; Risk Factors ; },
abstract = {Hypertension and lipid disorders are two of the main cardiovascular risk factors. Both risk factors - if detected early enough - can be controlled and treated with modern, effective drugs, devoid of significant side effects, available in four countries as different as Italy, Spain, Poland, and Uzbekistan. The aim herein, was to develop this TIMES TO ACT consensus to raise the awareness of the available options of the modern and intensified dyslipidemia and arterial hypertension treatments. The subsequent paragraphs involves consensus and discussion of the deleterious effects of COVID-19 in the cardiovascular field, the high prevalence of hypertension and lipid disorders in our countries and the most important reasons for poor control of these two factors. Subsequently proposed, are currently the most efficient and safe therapeutic options in treating dyslipidemia and arterial hypertension, focusing on the benefits of single-pill combination (SPCs) in both conditions. An accelerated algorithm is proposed to start the treatment with a PCSK9 inhibitor, if the target low-density-lipoprotein values have not been reached. As most patients with hypertension and lipid disorders present with multiple comorbidities, discussed are the possibilities of using new SPCs, combining modern drugs from different therapeutic groups, which mode of action does not confirm the "class effect". We believe our consensus strongly advocates the need to search for patients with cardiovascular risk factors and intensify their lipid-lowering and antihypertensive treatment based on SPCs will improve the control of these two basic cardiovascular risk factors in Italy, Spain, Poland and Uzbekistan.},
}

Antihypertensive Agents/therapeutic use
*COVID-19
*Cardiovascular Diseases/diagnosis/epidemiology/prevention & control
*Dyslipidemias/diagnosis/drug therapy/epidemiology
Humans
*Hypertension/diagnosis/drug therapy/epidemiology
Lipids
Lipoproteins
Poland
Proprotein Convertase 9
Risk Factors

@article {pmid36103964,
year = {2022},
author = {Shang, Y and Wu, J and Liu, J and Long, Y and Xie, J and Zhang, D and Hu, B and Zong, Y and Liao, X and Shang, X and Ding, R and Kang, K and Liu, J and Pan, A and Xu, Y and Wang, C and Xu, Q and Zhang, X and Zhang, J and Liu, L and Zhang, J and Yang, Y and Yu, K and Guan, X and Chen, D and , },
title = {Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {135},
number = {16},
pages = {1913-1916},
pmid = {36103964},
issn = {2542-5641},
mesh = {Humans ; *COVID-19 ; Consensus ; SARS-CoV-2 ; China ; },
}

Humans
*COVID-19
Consensus
SARS-CoV-2
China

@article {pmid36066915,
year = {2023},
author = {Sever, MS and Vanholder, R and Oniscu, G and Abramowicz, D and Van Biesen, W and Maggiore, U and Watschinger, B and Mariat, C and Buturovic-Ponikvar, J and Crespo, M and Mjoen, G and Heering, P and Peruzzi, L and Gandolfini, I and Hellemans, R and Hilbrands, L},
title = {Kidney transplantation during mass disasters - from COVID-19 to other catastrophes A Consensus Statement by the DESCARTES Working Group and Ethics Committee of the ERA.},
journal = {Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
volume = {38},
number = {2},
pages = {300–308},
pmid = {36066915},
issn = {1460-2385},
mesh = {Humans ; *COVID-19/epidemiology/prevention & control ; *Disasters ; Ethics Committees ; *Kidney Transplantation ; Pandemics/prevention & control ; },
abstract = {Mass disasters are characterized by a disparity between health care demand and supply, which hampers complex therapies like kidney transplantation. Considering scarcity of publications on previous disasters, we reviewed transplantation practice during the recent COVID-19 pandemic, and dwelled upon this experience for guiding transplantation strategies in the future pandemic and non-pandemic catastrophes. We strongly suggest continuing transplantation programs during mass disasters, if medical and logistic operational circumstances are appropriate. Postponing transplantations from living donors and referral of urgent cases to safe regions or hospitals are justified. Specific preventative measures in anticipated disasters (such as vaccination programs during pandemics or evacuation in case of hurricanes or wars) may be useful to minimize risks. Immunosuppressive therapies should consider stratifying risk status and avoiding heavy immune suppression in patients with a low probability of therapeutic success. Discharging patients at the earliest convenience is justified during pandemics, whereas delaying discharge is reasonable in other disasters, if infrastructural damage results in unhygienic living environments for the patients. In the outpatient setting, telemedicine is a useful approach to reduce the patient load to hospitals, to minimize the risk of nosocomial transmission in pandemics and the need for transport in destructive disasters. If it comes down to save as many lives as possible, some ethical principles may vary in function of disaster circumstances, but elementary ethical rules are non-negotiable. Patient education is essential to minimize disaster-related complications and to allow for an efficient use of health care resources.},
}

Humans
*COVID-19/epidemiology/prevention & control
*Disasters
Ethics Committees
*Kidney Transplantation
Pandemics/prevention & control

@article {pmid36059208,
year = {2022},
author = {D'Ascenzi, F and Castelletti, S and Adami, PE and Cavarretta, E and Sanz-de la Garza, M and Maestrini, V and Biffi, A and Kantor, P and Pieles, G and Verhagen, E and Tiberi, M and Hanssen, H and Papadakis, M and Niebauer, J and Halle, M},
title = {Cardiac screening prior to return to play after SARS-CoV-2 infection: focus on the child and adolescent athlete: A Clinical Consensus Statement of the Task Force for Childhood Health of the European Association of Preventive Cardiology.},
journal = {European journal of preventive cardiology},
volume = {29},
number = {16},
pages = {2120-2124},
pmid = {36059208},
issn = {2047-4881},
mesh = {Child ; Adolescent ; Humans ; *COVID-19 ; Return to Sport ; *Sports Medicine/methods ; SARS-CoV-2 ; Athletes ; *Cardiology ; *Heart Diseases ; },
abstract = {Cardiac sequelae after COVID-19 have been described in athletes, prompting the need to establish a return-to-play (RTP) protocol to guarantee a safe return to sports practice. Sports participation is strongly associated with multiple short- and long-term health benefits in children and adolescents and plays a crucial role in counteracting the psychological and physical effects of the current pandemic. Therefore, RTP protocols should be balanced to promote safe sports practice, particularly after an asymptomatic SARS-CoV-2 infection that represents the common manifestation in children. The present consensus document aims to summarize the current evidence on the cardiac sequelae of COVID-19 in children and young athletes, providing key messages for conducting the RTP protocol in paediatric athletes to promote a safe sports practice during the COVID-19 era.},
}

Child
Adolescent
Humans
*COVID-19
Return to Sport
*Sports Medicine/methods
SARS-CoV-2
Athletes
*Cardiology
*Heart Diseases

@article {pmid36043581,
year = {2022},
author = {Cheah, FC and Thong, MK and Zulkifli, I and Zilfalil, A and Amir Hamzah, AL and Chan, PWK and Khoo, EJ and Noran, NH},
title = {COVID-19 vaccination for children in Malaysia - A position statement by the College of Paediatrics, Academy of Medicine of Malaysia.},
journal = {The Malaysian journal of pathology},
volume = {44},
number = {2},
pages = {177-185},
pmid = {36043581},
issn = {0126-8635},
mesh = {Adolescent ; *COVID-19/prevention & control ; COVID-19 Vaccines ; Child ; Child, Preschool ; Humans ; Malaysia ; *Pediatrics ; SARS-CoV-2 ; Vaccination ; *Vaccines ; },
abstract = {The availability of COVID-19 vaccines and mass vaccination programmes in adults have significantly reduced the case attack rates and disease burden. COVID-19 vaccination successfully decreases the population at risk of infection, allowing for the safer re-opening of economies and reducing the pandemic's crippling impact on healthcare systems. However, the rapidly mutating severe acute respiratory syndrome-coronavirus-2 poses challenges in diminishing vaccine-induced immunity and vaccinating a significant proportion of adults to achieve herd immunity. These challenges necessitated adolescent vaccination. With the recent emergence of the highly transmissible Omicron variant and the increasing COVID-19 hospitalisation rates of children below 12 years old, many countries opted to also vaccinate younger children. Phase II/III clinical trials and real-world experience demonstrate that COVID-19 vaccinations are effective and safe for younger children and adolescents. Before Malaysia introduced its national COVID-19 vaccination programme for children 5-11 years old (which ran between March and June 2022), an expert advisory statement was issued by the College of Paediatrics, Academy of Medicine of Malaysia, to highlight the benefits and importance of vaccinating children. The advisory statement included clarifications about vaccine-related side effects such as post-vaccination myocarditis and allergic reactions to encourage informed decision making by healthcare providers and parents. This paper, which was prepared based on the critical appraisal of the current evidence, evaluation of the international experiences and the positive impact of COVID-19 vaccination in children, collectively sums up the rationale to support and ensure the success of the nationwide vaccination programme for children. Hence, the College recommends COVID-19 vaccination for children in Malaysia.},
}

Adolescent
*COVID-19/prevention & control
COVID-19 Vaccines
Child
Child, Preschool
Humans
Malaysia
*Pediatrics
SARS-CoV-2
Vaccination
*Vaccines

@article {pmid35970790,
year = {2022},
author = {Feng, LZ and Jiang, HY and Yi, J and Qian, LL and Xu, JD and Zheng, LB and Ma, ZB and Peng, SJ and Jiang, ST and Xu, EF and Chen, LH and Wang, LD and Gao, WZ and Yang, W},
title = {[Introduction and implications of WHO position paper: vaccines against influenza, May 2022].},
journal = {Zhonghua yi xue za zhi},
volume = {102},
number = {30},
pages = {2315-2318},
doi = {10.3760/cma.j.cn112137-20220518-01090},
pmid = {35970790},
issn = {0376-2491},
support = {2021-RC330-002//Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences/ ; INV-023808/GATES/Bill & Melinda Gates Foundation/United States ; },
mesh = {*COVID-19 ; Humans ; *Influenza Vaccines ; *Influenza, Human/epidemiology/prevention & control ; SARS-CoV-2 ; World Health Organization ; },
abstract = {On May 13, 2022, World Health Organization(WHO) Position Paper on Influenza Vaccine (2022 edition) was published. This position paper updates information on influenza epidemiology, high risk population, the impact of immunization on disease, influenza vaccines and effectiveness and safety, and propose WHO's position and recommendation that all countries should consider implementing seasonal influenza vaccine immunization programmes to prepare for an influenza pandemic. In addition, it proposes that the influenza surveillance platform can be integrated with the surveillance of other respiratory viruses, such as SARS-CoV-2 and Respiratory Syncytial Virus. This position paper has some implications for the prevention and control of influenza and other respiratory infectious diseases in China: (1) Optimize influenza vaccine policies to facilitate the implementation of immunization services; (2) Influenza prevention and control should from the perspective of Population Medicine focus on the individual and community to integrate with "Promotion, Prevention, Diagnosis, Control, Treatment, Rehabilitation"; (3) Incorporate prevention and control of other respiratory infectious diseases such as influenza, COVID-19, respiratory syncytial virus and adenovirus, and intelligently monitor by integrating multi-channel data to achieve the goal of co-prevention and control of multiple diseases.},
}

*COVID-19
Humans
*Influenza Vaccines
*Influenza, Human/epidemiology/prevention & control
SARS-CoV-2
World Health Organization

@article {pmid35953263,
year = {2023},
author = {Aletaha, D and Kerschbaumer, A and Kastrati, K and Dejaco, C and Dougados, M and McInnes, IB and Sattar, N and Stamm, TA and Takeuchi, T and Trauner, M and van der Heijde, D and Voshaar, M and Winthrop, KL and Ravelli, A and Betteridge, N and Burmester, GR and Bijlsma, JW and Bykerk, V and Caporali, R and Choy, EH and Codreanu, C and Combe, B and Crow, MK and de Wit, M and Emery, P and Fleischmann, RM and Gabay, C and Hetland, ML and Hyrich, KL and Iagnocco, A and Isaacs, JD and Kremer, JM and Mariette, X and Merkel, PA and Mysler, EF and Nash, P and Nurmohamed, MT and Pavelka, K and Poor, G and Rubbert-Roth, A and Schulze-Koops, H and Strangfeld, A and Tanaka, Y and Smolen, JS},
title = {Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.},
journal = {Annals of the rheumatic diseases},
volume = {82},
number = {6},
pages = {773-787},
doi = {10.1136/ard-2022-222784},
pmid = {35953263},
issn = {1468-2060},
support = {G1001518/MRC_/Medical Research Council/United Kingdom ; },
mesh = {Adult ; Humans ; Arthritis, Rheumatoid/drug therapy ; COVID-19 ; Interleukin-6 ; *Receptors, Interleukin-6/antagonists & inhibitors ; Still's Disease, Adult-Onset/drug therapy ; *Inflammation/drug therapy ; },
abstract = {BACKGROUND: Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway.

METHODS: A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document.

RESULTS: The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring.

CONCLUSIONS: The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.},
}

Adult
Humans
Arthritis, Rheumatoid/drug therapy
COVID-19
Interleukin-6
*Receptors, Interleukin-6/antagonists & inhibitors
Still's Disease, Adult-Onset/drug therapy
*Inflammation/drug therapy

@article {pmid35926987,
year = {2022},
author = {Zhang, Y and Li, YX and Zhong, DL and Liu, XB and Zhu, YY and Jin, RJ and Li, J},
title = {Clinical practice guidelines and expert consensus statements on rehabilitation for patients with COVID-19: protocol for a systematic review.},
journal = {BMJ open},
volume = {12},
number = {8},
pages = {e060767},
pmid = {35926987},
issn = {2044-6055},
mesh = {*COVID-19/rehabilitation ; China ; Consensus ; Humans ; Medicine, Chinese Traditional ; Pandemics ; Practice Guidelines as Topic ; Research Design ; Systematic Reviews as Topic ; },
abstract = {INTRODUCTION: COVID-19 is a highly infectious disease, characterised by respiratory, physical and psychological dysfunctions. Rehabilitation could effectively alleviate the symptoms and promote recovery of the physical and mental health of patients with COVID-19. Recently, rehabilitation medical institutions have issued clinical practice guidelines (CPGs) and expert consensus statements involving recommendations for rehabilitation assessments and rehabilitation therapies for COVID-19. This systematic review aims to assess the methodological quality and reporting quality of the guidance documents, evaluate the heterogeneity of the recommendations and summarise the recommendations with respect to rehabilitation assessments and rehabilitation therapies for COVID-19 to provide a quick reference for front-line clinicians, therapists and patients as well as reasonable suggestions for future guidelines.

METHODS AND ANALYSIS: The electronic databases including PubMed, Embase, Chinese Biomedical Literature Database (CBM), Chinese Science and Technology Periodical Database (VIP), Wanfang Database and China National Knowledge Infrastructure (CNKI) and websites of governments or organisations (eg, National Guideline Clearinghouse, Guidelines International Network, National Institute for Health and Clinical Excellence, Scottish Intercollegiate Guidelines Network and WHO) will be searched for eligible CPGs and expert consensus statements from inception to August 2022. CPGs and expert consensus statements published in Chinese or English and presenting recommendations for modern functional rehabilitation techniques and/or traditional Chinese medicine rehabilitation techniques for COVID-19 will be included. Reviews, interpretations, old versions of CPGs and expert consensus statements and those for the management of other diseases during the pandemic will be excluded. Two reviewers will independently review each article, extract data, appraise the methodological quality following the Appraisal of Guidelines for Research & Evaluation II tool and assess the reporting quality with the Reporting Items for Practice Guidelines in Healthcare statement. The Measurement Scale of Rate of Agreement will be used to evaluate the heterogeneity of the recommendations in different CPGs and expert consensus statements. Agreement between reviewers will be calculated using the intraclass correlation coefficient. We will also summarise the recommendations for rehabilitation in patients with COVID-19. The results will be narratively described and presented as tables or figures.

ETHICS AND DISSEMINATION: Ethics approval is not needed for this systematic review because information from published documents will be used. The findings will be submitted for publication in a peer-reviewed journal and reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

PROSPERO REGISTRATION NUMBER: CRD42020190761.},
}

*COVID-19/rehabilitation
China
Consensus
Humans
Medicine, Chinese Traditional
Pandemics
Practice Guidelines as Topic
Research Design
Systematic Reviews as Topic

@article {pmid35921761,
year = {2022},
author = {Beretta, GD and Casolino, R and Corsi, DC and Perrone, F and Di Maio, M and Cinieri, S and Gobber, G and Bellani, M and Petrini, F and Zocchi, MT and Traclò, F and Zagonel, V and , and , and , and , and , and , },
title = {Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement.},
journal = {ESMO open},
volume = {7},
number = {4},
pages = {100538},
pmid = {35921761},
issn = {2059-7029},
mesh = {*COVID-19 ; Ecosystem ; Humans ; *Medical Oncology ; Neoplasms ; Pandemics ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has severely affected cancer care and research by disrupting the prevention and treatment paths as well as the preclinical, clinical, and translational research ecosystem. In Italy, this has been particularly significant given the severity of the pandemic's impact and the intrinsic vulnerabilities of the national health system. However, whilst detrimental, disruption can also be constructive and may stimulate innovation and progress. The Italian Association of Medical Oncology (AIOM) has recognized the impact of COVID-19 on cancer care continuum and research and proposes the '2021 Matera statement' which aims at providing pragmatic guidance for policymakers and health care institutions to mitigate the impact of the global health crisis on Italian oncology and design the recovery plan for the post-pandemic scenario. The interventions are addressed both to the pillars (prevention, diagnosis, treatment, follow-up, health care professionals) and foundations of cancer care (communication and care relationship, system organization, resources, research, networking). The priorities to be implemented can be summarized in the MATERA acronym: Multidisciplinarity; Access to cancer care; Telemedicine and Territoriality; Equity, ethics, education; Research and resources; Alliance between stakeholders and patients.},
}

*COVID-19
Ecosystem
Humans
*Medical Oncology
Neoplasms
Pandemics

@article {pmid35868584,
year = {2022},
author = {Marjot, T and Eberhardt, CS and Boettler, T and Belli, LS and Berenguer, M and Buti, M and Jalan, R and Mondelli, MU and Moreau, R and Shouval, D and Berg, T and Cornberg, M},
title = {Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.},
journal = {Journal of hepatology},
volume = {77},
number = {4},
pages = {1161-1197},
pmid = {35868584},
issn = {1600-0641},
support = {102176/B/13/Z/WT_/Wellcome Trust/United Kingdom ; },
mesh = {*COVID-19 ; Humans ; *Liver Diseases/epidemiology/surgery ; *Liver Transplantation ; *Neoplasms ; Pandemics ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic has presented a serious challenge to the hepatology community, particularly healthcare professionals and patients. While the rapid development of safe and effective vaccines and treatments has improved the clinical landscape, the emergence of the omicron variant has presented new challenges. Thus, it is timely that the European Association for the Study of the Liver provides a summary of the latest data on the impact of COVID-19 on the liver and issues guidance on the care of patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation, as the world continues to deal with the consequences of the COVID-19 pandemic.},
}

*COVID-19
Humans
*Liver Diseases/epidemiology/surgery
*Liver Transplantation
*Neoplasms
Pandemics
SARS-CoV-2

@article {pmid35816710,
year = {2022},
author = {Crowley, R and Atiq, O and Hilden, D and , },
title = {Long-Term Services and Supports for Older Adults: A Position Paper From the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {175},
number = {8},
pages = {1172-1174},
doi = {10.7326/M22-0864},
pmid = {35816710},
issn = {1539-3704},
mesh = {Aged ; *Assisted Living Facilities ; *COVID-19/epidemiology ; Humans ; Long-Term Care ; Pandemics ; *Physicians ; United States ; },
abstract = {The number of Americans aged 65 years or older is expected to increase in the coming decades. Because the risk for disability increases with age, more persons will need long-term services and supports (LTSS) to help with bathing, eating, dressing, and other everyday tasks. Long-term services and supports are delivered in nursing homes, assisted living facilities, the person's home, and other settings. However, the LTSS sector faces several challenges, including keeping patients and staff safe during the COVID-19 pandemic, workforce shortages, quality problems, and fragmented coverage options. In this position paper, the American College of Physicians offers policy recommendations on LTSS coverage, financing, workforce, safety and quality, and emergency preparedness and calls on policymakers and other stakeholders to reform and improve the LTSS sector so that care is high quality, accessible, equitable, and affordable.},
}

Aged
*Assisted Living Facilities
*COVID-19/epidemiology
Humans
Long-Term Care
Pandemics
*Physicians
United States

@article {pmid35771684,
year = {2022},
author = {Fuller, R and Goddard, VCT and Nadarajah, VD and Treasure-Jones, T and Yeates, P and Scott, K and Webb, A and Valter, K and Pyorala, E},
title = {Technology enhanced assessment: Ottawa consensus statement and recommendations.},
journal = {Medical teacher},
volume = {44},
number = {8},
pages = {836-850},
doi = {10.1080/0142159X.2022.2083489},
pmid = {35771684},
issn = {1466-187X},
mesh = {*COVID-19 ; Curriculum ; Humans ; Learning ; *Pandemics ; Technology ; },
abstract = {INTRODUCTION: In 2011, a consensus report was produced on technology-enhanced assessment (TEA), its good practices, and future perspectives. Since then, technological advances have enabled innovative practices and tools that have revolutionised how learners are assessed. In this updated consensus, we bring together the potential of technology and the ultimate goals of assessment on learner attainment, faculty development, and improved healthcare practices.

METHODS: As a material for the report, we used the scholarly publications on TEA in both HPE and general higher education, feedback from 2020 Ottawa Conference workshops, and scholarly publications on assessment technology practices during the Covid-19 pandemic.

RESULTS AND CONCLUSION: The group identified areas of consensus that remained to be resolved and issues that arose in the evolution of TEA. We adopted a three-stage approach (readiness to adopt technology, application of assessment technology, and evaluation/dissemination). The application stage adopted an assessment 'lifecycle' approach and targeted five key foci: (1) Advancing authenticity of assessment, (2) Engaging learners with assessment, (3) Enhancing design and scheduling, (4) Optimising assessment delivery and recording learner achievement, and (5) Tracking learner progress and faculty activity and thereby supporting longitudinal learning and continuous assessment.},
}

*COVID-19
Curriculum
Humans
Learning
*Pandemics
Technology

@article {pmid35771014,
year = {2022},
author = {Indolfi, C and Barillà, F and Basso, C and Ciccone, MM and Curcio, A and Gargiulo, P and Nodari, S and Mercuro, G and Mancone, M and Muscoli, S and Pedrinelli, R and Porcari, A and Spaccarotella, C and Romeo, F and Sinagra, G and Filardi, PP},
title = {[Italian Society of Cardiology (SIC) Expert consensus document: Post-acute cardiovascular sequelae of SARS-CoV-2 infection].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {23},
number = {7},
pages = {491-503},
doi = {10.1714/3831.38166},
pmid = {35771014},
issn = {1972-6481},
mesh = {*COVID-19/complications ; Cardiology ; *Cardiovascular Diseases/virology ; Consensus ; Humans ; SARS-CoV-2 ; Societies, Medical ; Post-Acute COVID-19 Syndrome ; },
abstract = {Although the clinical course of COVID-19 in its acute phase is now delineated, less known is its late phase characterized by a heterogeneous series of sequelae affecting various organs and systems, including the cardiovascular system, which continue after the acute episode or arise after their resolution. This syndrome, now referred with the new acronym "PASC" (post-acute sequelae of SARS-CoV-2 infection) has been formally recognized by various scientific societies and international organizations that have proposed various definitions. The World Health Organization defines PASC, distinguishing it from "ongoing symptomatic COVID-19", as a condition that arises few weeks after infection, persists at least 8 weeks, and cannot be explained by alternative diagnoses.There are multiple mechanisms responsible for PASC: inflammation, immune activation, viral persistence, activation of latent viruses, endothelial dysfunction, impaired response to exercise, and profound cardiac deconditioning following viral infection. The key symptoms of PASC are palpitations, effort dyspnea, chest pain, exercise intolerance, and postural orthostatic tachycardia syndrome.For PASC treatment, it may be useful to take salt and fluid loading, to reduce symptoms such as tachycardia, palpitations, and/or orthostatic hypotension, or in some subjects the use of drugs such as beta-blockers, non-dihydropyridine calcium channel blockers, ivabradine, and fludrocortisone.Finally, in PASC a gradual resumption of physical activity is recommended, starting with recumbent or semi-recumbent exercise, such as cycling, swimming, or rowing, and then moving on to exercise in an upright position such as running when the ability to stand improves without dyspnea appearance. Exercise duration should also be short initially (5 to 10 min per day), with gradual increases as functional capacity improves.},
}

*COVID-19/complications
Cardiology
*Cardiovascular Diseases/virology
Consensus
Humans
SARS-CoV-2
Societies, Medical
Post-Acute COVID-19 Syndrome

@article {pmid35759767,
year = {2022},
author = {Serchen, J and Atiq, O and Hilden, D and , },
title = {Strengthening Food and Nutrition Security to Promote Public Health in the United States: A Position Paper From the American College of Physicians.},
journal = {Annals of internal medicine},
volume = {175},
number = {8},
pages = {1170-1171},
doi = {10.7326/M22-0390},
pmid = {35759767},
issn = {1539-3704},
mesh = {*COVID-19/epidemiology ; Child ; Humans ; Pandemics/prevention & control ; *Physicians ; Poverty ; Public Health ; United States ; },
abstract = {Food insecurity functions as a social driver of health, directly negatively impacting health status and outcomes, which can further negatively impact employment and income and increase medical expenditures-all of which exacerbates food insecurity. Progress in meaningfully reducing the food-insecurity rate has stalled in recent years. Although rates have decreased since their peak during the Great Recession, these gains have been reversed by the economic implications of the COVID-19 pandemic. As the federal government is the largest provider of food assistance, there is much potential in better leveraging nutrition assistance programs like the Supplemental Nutrition Assistance Program (SNAP) and the Child Nutrition Programs to increase access to healthful foods and improve public health. However, these programs face many funding challenges and internal shortcomings that create uncertainties and prevent maximal effect. Physicians and other medical professionals also have a role in improving nutritional health by screening for food insecurity and serving as connectors between patients, community organizations, and government services. Governments and payers must support these efforts by providing sufficient resources to practices to fulfill this role. In this position paper, the American College of Physicians (ACP) offers several policy recommendations to strengthen the federal food-insecurity response and empower physicians and other medical professionals to better address those social drivers of health occurring beyond the office doors.},
}

*COVID-19/epidemiology
Child
Humans
Pandemics/prevention & control
*Physicians
Poverty
Public Health
United States

@article {pmid35715014,
year = {2022},
author = {Kohan, L and Pellis, Z and Provenzano, DA and Pearson, ACS and Narouze, S and Benzon, HT},
title = {American Society of Regional Anesthesia and Pain Medicine contrast shortage position statement.},
journal = {Regional anesthesia and pain medicine},
volume = {47},
number = {9},
pages = {511-518},
doi = {10.1136/rapm-2022-103830},
pmid = {35715014},
issn = {1532-8651},
mesh = {*Anesthesia, Conduction ; Humans ; Pain ; Pain Management ; *Physicians ; Societies, Medical ; United States ; },
abstract = {The medical field has been experiencing numerous drug shortages in recent years. The most recent shortage to impact the field of interventional pain medicine is that of iodinated contrast medium. Pain physicians must adapt to these changes while maintaining quality of care. This position statement offers guidance on adapting to the shortage.},
}

*Anesthesia, Conduction
Humans
Pain
Pain Management
*Physicians
Societies, Medical
United States

@article {pmid35692364,
year = {2022},
author = {Kaap-Fröhlich, S and Ulrich, G and Wershofen, B and Ahles, J and Behrend, R and Handgraaf, M and Herinek, D and Mitzkat, A and Oberhauser, H and Scherer, T and Schlicker, A and Straub, C and Waury Eichler, R and Wesselborg, B and Witti, M and Huber, M and Bode, SFN},
title = {Position paper of the GMA Committee Interprofessional Education in the Health Professions - current status and outlook.},
journal = {GMS journal for medical education},
volume = {39},
number = {2},
pages = {Doc17},
pmid = {35692364},
issn = {2366-5017},
mesh = {*COVID-19/epidemiology ; Curriculum ; Health Occupations ; Humans ; *Interprofessional Education ; Pandemics ; },
abstract = {In the wake of local initiatives and developmental funding programs, interprofessionality is now included in national curricula in the German-speaking countries. Based on the 3P model (presage, process, product), this position paper presents the development of interprofessional education in recent years in Germany, Austria and Switzerland and places it in an international context. Core aspects as legal frameworks, including amendments to occupational regulations as well as the formation of networks and faculty development are basic requirements for interprofessional education. New topics and educational settings take shape in the process of interprofessional education: patient perspectives and teaching formats, such as online courses, become more important or are newly established. The influence of the COVID-19 pandemic on interprofessional education is explored as well. Among many new interprofessional courses, particularly the implementation of interprofessional training wards in Germany and Switzerland are positive examples of successful interprofessional education. The objective of interprofessional education continues to be the acquisition of interprofessional competencies. The main focus is now centered on evaluating this educational format and testing for the corresponding competencies. In the future, more capacities will be required for interprofessional continuing education and post-graduate education. Structured research programs are essential to ascertain the effects of interprofessional education in the German-speaking countries. In this position paper the GMA committee on interprofessional education encourages further advancement of this topic and expresses the aim to continue cooperating with other networks to strengthen and intensify interprofessional education and collaboration in healthcare.},
}

*COVID-19/epidemiology
Curriculum
Health Occupations
Humans
*Interprofessional Education
Pandemics

@article {pmid35680591,
year = {2022},
author = {, and , },
title = {[Experts' consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases in China (2022)].},
journal = {Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi},
volume = {43},
number = {5},
pages = {359-364},
pmid = {35680591},
issn = {0253-2727},
mesh = {Adult ; *COVID-19/prevention & control ; China ; Consensus ; *Hematologic Diseases ; Humans ; SARS-CoV-2 ; Vaccination ; },
}

Adult
*COVID-19/prevention & control
China
Consensus
*Hematologic Diseases
Humans
SARS-CoV-2
Vaccination

@article {pmid35579481,
year = {2022},
author = {Khan, NA and Stergiou, GS and Omboni, S and Kario, K and Renna, N and Chapman, N and McManus, RJ and Williams, B and Parati, G and Konradi, A and Islam, SM and Itoh, H and Mooi, CS and Green, BB and Cho, MC and Tomaszewski, M},
title = {Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension.},
journal = {Journal of hypertension},
volume = {40},
number = {8},
pages = {1435-1448},
doi = {10.1097/HJH.0000000000003205},
pmid = {35579481},
issn = {1473-5598},
mesh = {Adult ; Blood Pressure ; Blood Pressure Monitoring, Ambulatory ; *COVID-19 ; Humans ; *Hypertension/diagnosis/drug therapy/epidemiology ; Pandemics ; },
abstract = {The coronavirus disease 2019 pandemic caused an unprecedented shift from in person care to delivering healthcare remotely. To limit infectious spread, patients and providers rapidly adopted distant evaluation with online or telephone-based diagnosis and management of hypertension. It is likely that virtual care of chronic diseases including hypertension will continue in some form into the future. The purpose of the International Society of Hypertension's (ISH) position paper is to provide practical guidance on the virtual management of hypertension to improve its diagnosis and blood pressure control based on the currently available evidence and international experts' opinion for nonpregnant adults. Virtual care represents the provision of healthcare services at a distance with communication conducted between healthcare providers, healthcare users and their circle of care. This statement provides consensus guidance on: selecting blood pressure monitoring devices, accurate home blood pressure assessments, delivering patient education virtually, health behavior modification, medication adjustment and long-term virtual monitoring. We further provide recommendations on modalities for the virtual assessment and management of hypertension across the spectrum of resource availability and patient ability.},
}

Adult
Blood Pressure
Blood Pressure Monitoring, Ambulatory
*COVID-19
Humans
*Hypertension/diagnosis/drug therapy/epidemiology
Pandemics

@article {pmid35533736,
year = {2022},
author = {Burns, SP and Fleming, TK and Webb, SS and Kam, ASH and Fielder, JDP and Kim, GJ and Hu, X and Hill, MT and Kringle, EA},
title = {Stroke Recovery During the COVID-19 Pandemic: A Position Paper on Recommendations for Rehabilitation.},
journal = {Archives of physical medicine and rehabilitation},
volume = {103},
number = {9},
pages = {1874-1882},
pmid = {35533736},
issn = {1532-821X},
support = {K23 HL159240/HL/NHLBI NIH HHS/United States ; },
mesh = {*COVID-19/epidemiology ; Communicable Disease Control ; Humans ; Pandemics ; *Stroke/epidemiology ; *Stroke Rehabilitation ; },
abstract = {Health care delivery shifted and adapted with the COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2. Stroke care was negatively affected across the care continuum and may lead to poor community living outcomes in those who survived a stroke during the ongoing pandemic. For instance, delays in seeking care, changes in length of stays, and shifts in discharge patterns were observed during the pandemic. Those seeking care were younger and had more severe neurologic effects from stroke. Increased strain was placed on caregivers and public health efforts, and community-wide lockdowns, albeit necessary to reduce the spread of COVID-19, had detrimental effects on treatment and recommendations to support community living outcomes. The American Congress of Rehabilitation Medicine Stroke Interdisciplinary Special Interest Group Health and Wellness Task Force convened to (1) discuss international experiences in stroke care and rehabilitation and (2) review recently published literature on stroke care and outcomes during the pandemic. Based on the findings in the literature, the task force proposes recommendations and interdisciplinary approaches at the (1) institutional and societal level; (2) health care delivery level; and (3) individual and interpersonal level spanning across the care continuum and into the community.},
}

*COVID-19/epidemiology
Communicable Disease Control
Humans
Pandemics
*Stroke/epidemiology
*Stroke Rehabilitation

@article {pmid35508059,
year = {2022},
author = {Moreira, HG and Oliveira Júnior, MT and Valdigem, BP and Martins, CN and Polanczyk, CA},
title = {Position Statement on Cardiovascular Safety of Vaccines Against COVID-19 - 2022.},
journal = {Arquivos brasileiros de cardiologia},
volume = {118},
number = {4},
pages = {789-796},
pmid = {35508059},
issn = {1678-4170},
mesh = {*COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; *Cardiovascular System ; Humans ; SARS-CoV-2 ; *Vaccines ; },
}

*COVID-19/prevention & control
COVID-19 Vaccines/adverse effects
*Cardiovascular System
Humans
SARS-CoV-2
*Vaccines

@article {pmid35460319,
year = {2022},
author = {Rakusa, M and Öztürk, S and Moro, E and Helbok, R and Bassetti, CL and Beghi, E and Bereczki, D and Bodini, B and Di Liberto, G and Jenkins, TM and Macerollo, A and Maia, LF and Martinelli-Boneschi, F and Pisani, A and Priori, A and Sauerbier, A and Soffietti, R and Taba, P and von Oertzen, TJ and Zedde, M and Crean, M and Burlica, A and Cavallieri, F and Sellner, J and , },
title = {COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.},
journal = {European journal of neurology},
volume = {29},
number = {8},
pages = {2163-2172},
pmid = {35460319},
issn = {1468-1331},
mesh = {*COVID-19/complications/prevention & control ; *COVID-19 Vaccines/administration & dosage ; Humans ; *Nervous System Diseases ; Pandemics ; SARS-CoV-2 ; Vaccination/psychology ; *Vaccination Hesitancy ; Post-Acute COVID-19 Syndrome ; },
abstract = {BACKGROUND AND PURPOSE: Health risks associated with SARS-CoV-2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID-19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID-19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID-19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID-19 course.

METHODS: In this position paper, the NeuroCOVID-19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage, and formulates strategies to overcome vaccination hesitancy. A survey among the Task Force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation.

RESULTS: The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS-CoV-2 vaccination. The prevailing concerns included the chance of worsening the pre-existing neurological condition, vaccination-related adverse events, and drug interaction.

CONCLUSIONS: The EAN NeuroCOVID-19 Task Force reinforces the key role of neurologists as advocates of COVID-19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID-19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, its concerns, and the emergence of potential safety signals.},
}

*COVID-19/complications/prevention & control
*COVID-19 Vaccines/administration & dosage
Humans
*Nervous System Diseases
Pandemics
SARS-CoV-2
Vaccination/psychology
*Vaccination Hesitancy
Post-Acute COVID-19 Syndrome

@article {pmid35434988,
year = {2022},
author = {Parthasaradhi, A and Ganguly, S and Kar, BR and Thomas, J and Neema, S and Tahiliani, S and Sathishkumar, D and Parasramani, SG and Chalam, KV and Komeravalli, H},
title = {Coronavirus disease 2019 vaccination in patients with psoriasis: A position statement from India by SIG psoriasis (IADVL Academy).},
journal = {Indian journal of dermatology, venereology and leprology},
volume = {88},
number = {3},
pages = {286-290},
doi = {10.25259/IJDVL_773_2021},
pmid = {35434988},
issn = {0973-3922},
mesh = {*COVID-19/epidemiology/prevention & control ; COVID-19 Vaccines ; Humans ; India/epidemiology ; *Psoriasis/diagnosis/drug therapy/epidemiology ; SARS-CoV-2 ; Vaccination ; *Vaccines ; },
abstract = {Coronavirus disease 2019 (COVID-19) pandemic has affected every sphere of life including management of psoriasis. The availability of COVID-19 vaccines has given rise to hope and at the same time some apprehensions as well. With the general population becoming eligible for vaccination, there is some confusion, on the eligibility of patients with different medical conditions and patients on immunosuppressive or immunomodulating medications for COVID-19 vaccination. Dermatologists treating psoriasis patients frequently face questions from them, whether they can undergo coronavirus disease 2019 vaccination. A PUBMED search was performed using the following strategy: 'COVID-19' AND 'Vaccine' AND 'Psoriasis'. We also performed a PUBMED search using the following strategy: 'SARS-CoV-2' AND 'Vaccine' AND 'Psoriasis'. All articles irrespective of language and publication date were included to arrive at this position statement. This position statement deals with the safety, eligibility and modifications of treatment, if needed among psoriasis patients with regards to the coronavirus disease 2019 vaccines currently available in India.},
}

*COVID-19/epidemiology/prevention & control
COVID-19 Vaccines
Humans
India/epidemiology
*Psoriasis/diagnosis/drug therapy/epidemiology
SARS-CoV-2
Vaccination
*Vaccines

@article {pmid35381631,
year = {2022},
author = {, },
title = {[Chinese expert consensus on the use of Omalizumab in allergic asthma (2021 version)].},
journal = {Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases},
volume = {45},
number = {4},
pages = {341-354},
doi = {10.3760/cma.j.cn112147-20220115-00051},
pmid = {35381631},
issn = {1001-0939},
support = {82161138020, U1801286//National Natural Science Foundation of China/ ; 202102010011//Science and Technology Program of Guangzhou/ ; ZNSA-2020013, ZNSA-2020003//Zhongnanshan Medical Foundation of Guangdong Province/ ; },
mesh = {*Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; *Asthma/drug therapy ; *COVID-19 ; Consensus ; Humans ; Omalizumab/therapeutic use ; Quality of Life ; },
abstract = {As the first targeted biotherapy for asthma, Omalizumab, was officially approved in China in August 2017, and was applied in clinical practice since March, 2018. Dozens of experts in Respirology and Allergy from China fully discussed the important clinical issues on the use of Omalizumab in allergic asthma by referring to the relevant publications over the world and the first version of consensus published in March 2018. Until now, over 30, 000 allergic asthma patients have received the treatment of Omalizumab. Therefore, with the latest evidence of clinical and basic research around the world, we updated the consensus with the following issues: (1) The mechanisms and available evidence on anti-IgE treatment; (2) Selection and exclusion criteria for patients using Omalizumab; (3) Cautions on the administration of Omalizumab and highlights of the use of Omalizumab with various vaccines, including novel Coronavirus vaccines, and key points to note during a Novel Coronavirus pandemic; (4) Long-term use and safety; (5) The use of Omalizumab in specific populations; (6) Clinical applications of omalizumab with other targeted therapies and allergen-specific immunotherapy. Omalizumab, combining to the Cε3 area of IgE, reduces the free IgE level, and downregulates the expression of FcεRⅠ, which inhibits the release of inflammatory mediators of mast cell sources, and leads to reduced asthma exacerbation, decreased rate of emergency visit and hospitalization, improved symptoms and quality of life, as well as less concomitant moderate to severe asthma, poorly controlled after at least 3 months treatment of ICS/LABA, and confirmed with allergic status through skin prick test or serum total IgE or specific IgE. Conditions that exclude the use of Omalizumab include patients who are suspected to be allergic to drug ingredients. Omalizumab is administered based on dosing tables by subcutaneous injection. Omalizumab should be administered by a health care professional (doctor or nurse) in a medical institution equipped with facilities for post-injection observation and rescue treatment for anaphylactic shock. After the injection, the patient should be closely monitored whether there is an anaphylactic reaction. The duration of Omalizumab treatment should be at least 16 weeks to judge its effectiveness, after 16 weeks, Omalizumab treatment will be continued or withdrawn based on the overall asthma control evaluation. Patients should be followed every 3 months to assess the disease control and dosing adjustment. The common adverse reactions were injection sites reactions. Based on the latest evidence around the word, we focused on updating the relevant treatment course, administration method and use of specific populations, in order to guide clinicians in the use of Omalizumab. The use of Omalizumab in China still requires long-term observation and further research. With the increase of clinical evidence, this consensus will be continuously improved and supplemented.},
}

*Anti-Asthmatic Agents/therapeutic use
Antibodies, Monoclonal/therapeutic use
Antibodies, Monoclonal, Humanized/therapeutic use
*Asthma/drug therapy
*COVID-19
Consensus
Humans
Omalizumab/therapeutic use
Quality of Life

@article {pmid35353681,
year = {2022},
author = {Carrasco-Sánchez, FJ and Carretero-Anibarro, E and Gargallo, MÁ and Gómez-Huelgas, R and Merino-Torres, JF and Orozco-Beltrán, D and Pines Corrales, PJ and Ruiz Quintero, MA},
title = {Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19.},
journal = {Endocrinologia, diabetes y nutricion},
volume = {69},
number = {3},
pages = {209-218},
pmid = {35353681},
issn = {2530-0180},
mesh = {Humans ; *COVID-19 ; *Diabetes Mellitus, Type 2/complications/drug therapy ; *Dipeptidyl-Peptidase IV Inhibitors/pharmacology/therapeutic use ; Pandemics ; },
abstract = {BACKGROUND: This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic.

MATERIALS AND METHODS: A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus.

RESULTS: Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and the need for mechanical ventilation (evidence 2b).

CONCLUSIONS: The use of iDPP-4 appears to be safe in patients with COVID-19, and quality studies are needed to clarify their possible advantages further.},
}

Humans
*COVID-19
*Diabetes Mellitus, Type 2/complications/drug therapy
*Dipeptidyl-Peptidase IV Inhibitors/pharmacology/therapeutic use
Pandemics

@article {pmid35343485,
year = {2021},
author = {Violini, R and De Rosa, S and Leonardi, S and Doronzo, B and Cremonesi, A and Callea, G and Spandonaro, F and Tarantini, G and Esposito, G and Cernetti, C and Indolfi, C and Berti, S and Marchese, A and Saia, F and Monti, F},
title = {[GISE (Italian Society of Interventional Cardiology) Position paper: Short-term hospitalization for percutaneous coronary intervention; a helpful tool to manage post-COVID-19 backlogs].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {12 Suppl 2},
pages = {4-15},
doi = {10.1714/3723.37134},
pmid = {35343485},
issn = {1972-6481},
mesh = {*COVID-19 ; *Cardiology ; Hospitalization ; Humans ; Length of Stay ; Pandemics/prevention & control ; *Percutaneous Coronary Intervention/adverse effects ; },
abstract = {Minimization of hospital lengths of stay has always been a key goal for healthcare systems. More so during the current COVID-19 pandemic. In fact, we have faced a reduction in no-COVID-19 admissions with the generation of huge backlogs. Low-risk patients undergoing elective percutaneous coronary intervention (PCI) can be candidate for short-term hospitalization, with consequent reduction of waiting lists. Several single-center and multicenter observational studies, multiple randomized trials and some meta-analyses have addressed this topic.In this position paper, we present a proposal for short hospitalization for elective PCI procedures in selected patients who present complications only exceptionally and exclusively immediately after the procedure, if the inclusion and exclusion criteria are met. Each Center can choose between admission in day surgery or one day surgery, extending hospital length of stay only for patients who present complications or who are candidate for urgent surgery. Short-term hospitalization considerably reduces costs even if, with the current model, it generally results in a parallel reduction in reimbursement. Hence, we present an actual model, already tested successfully in an Italian hospital, that warrants sustainability. This approach can then be tailored to single Centers.},
}

*COVID-19
*Cardiology
Hospitalization
Humans
Length of Stay
Pandemics/prevention & control
*Percutaneous Coronary Intervention/adverse effects

@article {pmid35280024,
year = {2022},
author = {, },
title = {[Chinese expert consensus on prevention and control of COVID-19 eye disease (2022)].},
journal = {[Zhonghua yan ke za zhi] Chinese journal of ophthalmology},
volume = {58},
number = {3},
pages = {176-181},
doi = {10.3760/cma.j.cn112142-20211124-00561},
pmid = {35280024},
issn = {0412-4081},
mesh = {*COVID-19 ; China/epidemiology ; *Eye Diseases/prevention & control ; Humans ; Medicine, Chinese Traditional ; SARS-CoV-2 ; },
abstract = {Accumulated evidence has shown that novel coronavirus disease 2019 (COVID-19) could contribute to eye disease during its pandemic, which is called COVID-19 eye disease. Currently, there is a lack of uniform and standardized guidelines for the protection of medical staff in the diagnosis and treatment process. Most ophthalmologists treat this disease according to their clinical experience. Therefore, the experts of the Public Health Ophthalmology Branch of Chinese Preventive Medicine Association have developed this consensus statement after thorough discussions, hoping to provide guiding opinions on the further prevention and control of COVID-19 eye disease in China.},
}

*COVID-19
China/epidemiology
*Eye Diseases/prevention & control
Humans
Medicine, Chinese Traditional
SARS-CoV-2

@article {pmid35266533,
year = {2022},
author = {Rienks, R and Holdsworth, D and Davos, CH and Halle, M and Bennett, A and Parati, G and Guettler, N and Nicol, ED},
title = {Cardiopulmonary assessment prior to returning to high-hazard occupations post-symptomatic COVID-19 infection: a position statement of the Aviation and Occupational Cardiology Task Force of the European Association of Preventive Cardiology.},
journal = {European journal of preventive cardiology},
volume = {29},
number = {13},
pages = {1724-1730},
pmid = {35266533},
issn = {2047-4881},
mesh = {Humans ; *COVID-19 ; SARS-CoV-2 ; Occupations ; *Cardiology ; *Aviation ; Post-Acute COVID-19 Syndrome ; },
abstract = {This article provides an overview of the recommendations of the Aviation and Occupational Cardiology Task Force of the European Association of Preventive Cardiology on returning individuals to work in high-hazard occupations (such as flying, diving, and workplaces that are remote from healthcare facilities) following symptomatic Coronavirus Disease 2019 (COVID-19) infection. This process requires exclusion of significant underlying cardiopulmonary disease and this consensus statement (from experts across the field) outlines the appropriate screening and investigative processes that should be undertaken. The recommended response is based on simple screening in primary healthcare to determine those at risk, followed by first line investigations, including an exercise capacity assessment, to identify the small proportion of individuals who may have circulatory, pulmonary, or mixed disease. These individuals can then receive more advanced, targeted investigations. This statement provides a pragmatic, evidence-based approach for those (in all occupations) to assess employee health and capacity prior to a return to work following severe disease, or while continuing to experience significant post-COVID-19 symptoms (so-called 'long-COVID' or post-COVID-19 syndrome).},
}

Humans
*COVID-19
SARS-CoV-2
Occupations
*Cardiology
*Aviation
Post-Acute COVID-19 Syndrome

@article {pmid35257524,
year = {2022},
author = {Choi, JH and Moon, J and Kim, S and Bae, H and Lee, J and Choe, YJ},
title = {Expert Consensus on COVID-19 Vaccination in Korean Adolescents: A Modified Delphi Survey.},
journal = {Journal of Korean medical science},
volume = {37},
number = {9},
pages = {e69},
pmid = {35257524},
issn = {1598-6357},
support = {2021-10-023//Korea Disease Control and Prevention Agency/Korea ; },
mesh = {Adolescent ; Adult ; *COVID-19/prevention & control ; *COVID-19 Vaccines ; Child ; Consensus ; Humans ; Republic of Korea ; Vaccination ; },
abstract = {The effectiveness of coronavirus disease 2019 (COVID-19) vaccines had been shown in many studies in adult population, however, the real-world evidence in the childhood population was scarce. We aimed to organize the collective expert's opinions on adolescent vaccination against COVID-19 in Korea, therefore to guide the vaccination policy in the setting of available evidence. The Delphi panels responded that adolescents were greatly impacted by the quarantine measures, and COVID-19 is an important health problem for adolescents. Panels responded that in general, the benefits of the COVID-19 vaccine overweigh the potential risks in Korean adolescents. Continuing monitoring of available data is needed to provide the best vaccination practices in adolescents guided by the updated evidence.},
}

Adolescent
Adult
*COVID-19/prevention & control
*COVID-19 Vaccines
Child
Consensus
Humans
Republic of Korea
Vaccination

@article {pmid35240931,
year = {2022},
author = {Kwasnicka, D and Keller, J and Perski, O and Potthoff, S and Ten Hoor, GA and Ainsworth, B and Crutzen, R and Dohle, S and van Dongen, A and Heino, M and Henrich, JF and Knox, L and König, LM and Maltinsky, W and McCallum, C and Nalukwago, J and Neter, E and Nurmi, J and Spitschan, M and Van Beurden, SB and Van der Laan, LN and Wunsch, K and Levink, JJJ and Sanderman, R},
title = {White Paper: Open Digital Health - accelerating transparent and scalable health promotion and treatment.},
journal = {Health psychology review},
volume = {16},
number = {4},
pages = {475-491},
doi = {10.1080/17437199.2022.2046482},
pmid = {35240931},
issn = {1743-7202},
mesh = {Humans ; *Pandemics/prevention & control ; *COVID-19 ; Health Promotion ; Global Health ; },
abstract = {In this White Paper, we outline recommendations from the perspective of health psychology and behavioural science, addressing three research gaps: (1) What methods in the health psychology research toolkit can be best used for developing and evaluating digital health tools? (2) What are the most feasible strategies to reuse digital health tools across populations and settings? (3) What are the main advantages and challenges of sharing (openly publishing) data, code, intervention content and design features of digital health tools? We provide actionable suggestions for researchers joining the continuously growing Open Digital Health movement, poised to revolutionise health psychology research and practice in the coming years. This White Paper is positioned in the current context of the COVID-19 pandemic, exploring how digital health tools have rapidly gained popularity in 2020-2022, when world-wide health promotion and treatment efforts rapidly shifted from face-to-face to remote delivery. This statement is written by the Directors of the not-for-profit Open Digital Health initiative (n = 6), Experts attending the European Health Psychology Society Synergy Expert Meeting (n = 17), and the initiative consultant, following a two-day meeting (19-20th August 2021).},
}

Humans
*Pandemics/prevention & control
*COVID-19
Health Promotion
Global Health

@article {pmid35236726,
year = {2022},
author = {Van Braeckel, E and Page, I and Davidsen, JR and Laursen, CB and Agarwal, R and Alastruey-Izquierdo, A and Barac, A and Cadranel, J and Chakrabarti, A and Cornely, OA and Denning, DW and Flick, H and Gangneux, JP and Godet, C and Hayashi, Y and Hennequin, C and Hoenigl, M and Irfan, M and Izumikawa, K and Koh, WJ and Kosmidis, C and Lange, C and Lamprecht, B and Laurent, F and Munteanu, O and Oladele, R and Patterson, TF and Watanabe, A and Salzer, HJF and , },
title = {Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement.},
journal = {The European respiratory journal},
volume = {59},
number = {6},
pages = {},
doi = {10.1183/13993003.02950-2021},
pmid = {35236726},
issn = {1399-3003},
mesh = {Consensus ; Humans ; Persistent Infection ; *Pulmonary Aspergillosis/diagnosis/drug therapy ; Treatment Outcome ; },
}

Consensus
Humans
Persistent Infection
*Pulmonary Aspergillosis/diagnosis/drug therapy
Treatment Outcome

@article {pmid35212510,
year = {2022},
author = {Öz, TK and Cader, FA and Dakhil, ZA and Parapid, B and Kadavath, S and Bond, R and Chieffo, A and Gimelli, A and Mihailidou, AS and Ramu, B and Cavarretta, E and Michos, ED and Kaya, E and Buchanan, L and Patil, M and Aste, M and Alasnag, M and Babazade, N and Burgess, S and Manzo-Silberman, S and Paradies, V and Thamman, R},
title = {International consensus statement on challenges for women in cardiovascular practice and research in the COVID-19 era.},
journal = {Minerva cardiology and angiology},
volume = {70},
number = {6},
pages = {641-651},
doi = {10.23736/S2724-5683.22.05935-X},
pmid = {35212510},
issn = {2724-5772},
mesh = {Humans ; Female ; *COVID-19 ; Pandemics/prevention & control ; *Cardiology/education ; *Cardiologists/education ; *Heart Failure ; },
abstract = {The challenges to academic and professional development and career advancement of women in cardiology (WIC), imposed by the pandemic, not only impinge the female cardiologists' "leaky pipeline" but also make the "leakiness" more obvious. This consensus document aims to highlight the pandemic challenges WIC face, raise awareness of the gender equity gap, and propose mitigating actionable solutions derived from the data and experiences of an international group of female cardiovascular clinicians and researchers. This changing landscape has led to the need for highly specialized cardiologists who may have additional training in critical care, imaging, advanced heart failure, or interventional cardiology. Although women account for most medical school graduates, the number of WIC, particularly in mentioned sub-specialties, remains low. Moreover, women have been more affected by systemic issues within these challenging work environments, limiting their professional progression, career advancement, and economic potential. Therefore, it is imperative that tangible action points be noted and undertaken to ensure the representation of women in leadership, advocacy, and decision-making, and increase diversity in academia. Strategies to mitigate the negative impacts of the pandemic need to be taken during this COVID-19 pandemic to ensure WIC have a place in the field of Cardiology.},
}

Humans
Female
*COVID-19
Pandemics/prevention & control
*Cardiology/education
*Cardiologists/education
*Heart Failure

@article {pmid35201615,
year = {2022},
author = {Furlong, E and Kotecha, RS and Conyers, R and O'Brien, TA and Hansford, JR and Super, L and Downie, P and Eisenstat, DD and Haeusler, G and McMullan, B and Phillips, MB and Padhye, B and Dalla-Pozza, L and Alvaro, F and Fraser, CJ and Nicholls, W and Clark, JE and O'Connor, M and Saxon, BR and Tapp, H and Heath, J and Hunter, SE and Tsui, K and Winstanley, M and Lyver, A and Best, EJ and Wadia, U and Yeoh, D and Blyth, CC and Gottardo, NG},
title = {COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children's Haematology/Oncology Group consensus statement.},
journal = {The Medical journal of Australia},
volume = {216},
number = {6},
pages = {312-319},
pmid = {35201615},
issn = {1326-5377},
mesh = {Adolescent ; Australia/epidemiology ; *COVID-19/prevention & control ; COVID-19 Vaccines ; Child ; Child, Preschool ; *Hematology ; Humans ; *Neoplasms/therapy ; New Zealand/epidemiology ; Vaccination ; },
abstract = {INTRODUCTION: The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19. There remains a paucity of data regarding the immune response to COVID-19 vaccines in immunosuppressed paediatric populations, with data suggestive of reduced immunogenicity of the vaccine in immunocompromised adults.

RECOMMENDATIONS: Considering the safety profile of mRNA COVID-19 vaccines and the increased risk of severe COVID-19 in immunocompromised children and adolescents, COVID-19 vaccination is strongly recommended for this at-risk population. We provide a number of recommendations regarding COVID-19 vaccination in this population where immunosuppressive, chemotherapeutic and/or targeted biological agents are used. These include the timing of vaccination in patients undergoing active treatment, management of specific situations where vaccination is contraindicated or recommended under special precautions, and additional vaccination recommendations for severely immunocompromised patients. Finally, we stress the importance of upcoming clinical trials to identify the safest and most efficacious vaccination regimen for this population.

This consensus statement provides recommendations for COVID-19 vaccination in children and adolescents aged ≥ 5 years with cancer and immunocompromising non-malignant haematological conditions, based on evidence, national and international guidelines and expert opinion.

ENDORSED BY: The Australian and New Zealand Children's Haematology/Oncology Group.},
}

Adolescent
Australia/epidemiology
*COVID-19/prevention & control
COVID-19 Vaccines
Child
Child, Preschool
*Hematology
Humans
*Neoplasms/therapy
New Zealand/epidemiology
Vaccination

@article {pmid35195701,
year = {2022},
author = {Al Knawy, B and McKillop, MM and Abduljawad, J and Tarkoma, S and Adil, M and Schaper, L and Chee, A and Bates, DW and Klag, M and Lee, U and Kozlakidis, Z and Crooks, G and Rhee, K},
title = {Successfully Implementing Digital Health to Ensure Future Global Health Security During Pandemics: A Consensus Statement.},
journal = {JAMA network open},
volume = {5},
number = {2},
pages = {e220214},
doi = {10.1001/jamanetworkopen.2022.0214},
pmid = {35195701},
issn = {2574-3805},
support = {001/WHO_/World Health Organization/International ; },
mesh = {*COVID-19 ; Consensus ; Digital Technology/standards ; Forecasting ; Global Health/*standards ; Health Plan Implementation/*standards ; Humans ; *Pandemics ; SARS-CoV-2 ; Stakeholder Participation ; Telemedicine/*standards ; },
abstract = {IMPORTANCE: COVID-19 has highlighted widespread chronic underinvestment in digital health that hampered public health responses to the pandemic. Recognizing this, the Riyadh Declaration on Digital Health, formulated by an international interdisciplinary team of medical, academic, and industry experts at the Riyadh Global Digital Health Summit in August 2020, provided a set of digital health recommendations for the global health community to address the challenges of current and future pandemics. However, guidance is needed on how to implement these recommendations in practice.

OBJECTIVE: To develop guidance for stakeholders on how best to deploy digital health and data and support public health in an integrated manner to overcome the COVID-19 pandemic and future pandemics.

EVIDENCE REVIEW: Themes were determined by first reviewing the literature and Riyadh Global Digital Health Summit conference proceedings, with experts independently contributing ideas. Then, 2 rounds of review were conducted until all experts agreed on the themes and main issues arising using a nominal group technique to reach consensus. Prioritization was based on how useful the consensus recommendation might be to a policy maker.

FINDINGS: A diverse stakeholder group of 13 leaders in the fields of public health, digital health, and health care were engaged to reach a consensus on how to implement digital health recommendations to address the challenges of current and future pandemics. Participants reached a consensus on high-priority issues identified within 5 themes: team, transparency and trust, technology, techquity (the strategic development and deployment of technology in health care and health to achieve health equity), and transformation. Each theme contains concrete points of consensus to guide the local, national, and international adoption of digital health to address challenges of current and future pandemics.

CONCLUSIONS AND RELEVANCE: The consensus points described for these themes provide a roadmap for the implementation of digital health policy by all stakeholders, including governments. Implementation of these recommendations could have a significant impact by reducing fatalities and uniting countries on current and future battles against pandemics.},
}

*COVID-19
Consensus
Digital Technology/standards
Forecasting
Global Health/*standards
Health Plan Implementation/*standards
Humans
*Pandemics
SARS-CoV-2
Stakeholder Participation
Telemedicine/*standards

@article {pmid35194788,
year = {2022},
author = {El-Boghdadly, K and Cook, TM and Goodacre, T and Kua, J and Denmark, S and McNally, S and Mercer, N and Moonesinghe, SR and Summerton, DJ},
title = {Timing of elective surgery and risk assessment after SARS-CoV-2 infection: an update: A multidisciplinary consensus statement on behalf of the Association of Anaesthetists, Centre for Perioperative Care, Federation of Surgical Specialty Associations, Royal College of Anaesthetists, Royal College of Surgeons of England.},
journal = {Anaesthesia},
volume = {77},
number = {5},
pages = {580-587},
pmid = {35194788},
issn = {1365-2044},
mesh = {Anesthetists ; *COVID-19 ; Humans ; Perioperative Care ; Risk Assessment ; SARS-CoV-2 ; *Surgeons ; },
abstract = {The impact of vaccination and new SARS-CoV-2 variants on peri-operative outcomes is unclear. We aimed to update previously published consensus recommendations on timing of elective surgery after SARS-CoV-2 infection to assist policymakers, administrative staff, clinicians and patients. The guidance remains that patients should avoid elective surgery within 7 weeks of infection, unless the benefits of doing so exceed the risk of waiting. We recommend individualised multidisciplinary risk assessment for patients requiring elective surgery within 7 weeks of SARS-CoV-2 infection. This should include baseline mortality risk calculation and assessment of risk modifiers (patient factors; SARS-CoV-2 infection; surgical factors). Asymptomatic SARS-CoV-2 infection with previous variants increased peri-operative mortality risk three-fold throughout the 6 weeks after infection, and assumptions that asymptomatic or mildly symptomatic omicron SARS-CoV-2 infection does not add risk are currently unfounded. Patients with persistent symptoms and those with moderate-to-severe COVID-19 may require a longer delay than 7 weeks. Elective surgery should not take place within 10 days of diagnosis of SARS-CoV-2 infection, predominantly because the patient may be infectious, which is a risk to surgical pathways, staff and other patients. We now emphasise that timing of surgery should include the assessment of baseline and increased risk, optimising vaccination and functional status, and shared decision-making. While these recommendations focus on the omicron variant and current evidence, the principles may also be of relevance to future variants. As further data emerge, these recommendations may be revised.},
}

Anesthetists
*COVID-19
Humans
Perioperative Care
Risk Assessment
SARS-CoV-2
*Surgeons

@article {pmid35147382,
year = {2022},
author = {Płaczkiewicz-Jankowska, E and Czupryniak, L and Gajos, G and Lewiński, A and Ruchała, M and Stasiak, M and Strojek, K and Szczepanek-Parulska, E and Wyleżoł, M and Ostrowska, L and Jankowski, P},
title = {Management of obesity in the times of climate change and COVID-19: an interdisciplinary expert consensus report.},
journal = {Polish archives of internal medicine},
volume = {132},
number = {3},
pages = {},
doi = {10.20452/pamw.16216},
pmid = {35147382},
issn = {1897-9483},
mesh = {*COVID-19 ; Climate Change ; Consensus ; Humans ; Obesity/complications/therapy ; *Quality of Life ; United States ; },
abstract = {Obesity is a chronic disease associated with increased metabolic and cardiovascular risk, excessive morbidity and mortality worldwide. The authors of the present consensus, clinicians representing medical specialties related to the treatment of obesity and its complications, reviewed a number of European and American guidelines, published mostly in 2019-2021, and summarized the principles of obesity management to provide a practical guidance considering the impact that increased adiposity poses to health. From a clinical perspective, the primary goal of obesity treatment is to prevent or slow down the progression of diseases associated with obesity, reduce metabolic and cardiovascular risk, and improve the quality of life by achieving adequate and stable weight reduction. However, obesity should be not only considered a disease requiring treatment in an individual patient, but also a civilization disease requiring preventive measures at the populational level. Despite the evident benefits, obesity management within the health care system-whether through pharmacotherapy or bariatric surgery-is only a symptomatic treatment, with all its limitations, and will not ultimately solve the problem of obesity. The important message is that available treatment options fail to correct the true drivers of the obesity pandemic. To this end, new solutions and efforts to prevent obesity in the populations are needed.},
}

*COVID-19
Climate Change
Consensus
Humans
Obesity/complications/therapy
*Quality of Life
United States

@article {pmid35133441,
year = {2022},
author = {Queiroga, AC and Dunne, C and Manino, LA and van der Linden, T and Mecrow, T and Bierens, J},
title = {Resuscitation of Drowned Persons During the COVID-19 Pandemic: A Consensus Statement.},
journal = {JAMA network open},
volume = {5},
number = {2},
pages = {e2147078},
doi = {10.1001/jamanetworkopen.2021.47078},
pmid = {35133441},
issn = {2574-3805},
mesh = {COVID-19/prevention & control/*transmission ; *Cardiopulmonary Resuscitation ; Drowning/*prevention & control ; Emergency Medical Services/*organization & administration/standards ; *Emergency Medical Technicians ; Heart Arrest/etiology/*therapy ; Humans ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Pandemics ; Personal Protective Equipment ; SARS-CoV-2 ; },
abstract = {IMPORTANCE: Resuscitation is a niche example of how the COVID-19 pandemic has affected society in the long term. Those trained in cardiopulmonary resuscitation (CPR) face the dilemma that attempting to save a life may result in their own harm. This is most of all a problem for drowning, where hypoxia is the cause of cardiac arrest and ventilation is the essential first step in reversing the situation.

OBJECTIVE: To develop recommendations for water rescue organizations in providing their rescuers with safe drowning resuscitation procedures during the COVID-19 pandemic.

EVIDENCE REVIEW: Two consecutive modified Delphi procedures involving 56 participants from 17 countries with expertise in drowning prevention research, resuscitation, and programming were performed from March 28, 2020, to March 29, 2021. In parallel, PubMed and Google Scholar were searched to identify new emerging evidence relevant to each core element, acknowledge previous studies relevant in the new context, and identify knowledge gaps.

FINDINGS: Seven core elements, each with their own specific recommendations, were identified in the initial consensus procedure and were grouped into 4 categories: (1) prevention and mitigation of the risks of becoming infected, (2) resuscitation of drowned persons during the COVID-19 pandemic, (3) organizational responsibilities, and (4) organizations unable to meet the recommended guidelines. The common measures of infection risk mitigation, personal protective equipment, and vaccination are the base of the recommendations. Measures to increase drowning prevention efforts reduce the root cause of the dilemma. Additional infection risk mitigation measures include screening all people entering aquatic facilities, defining criteria for futile resuscitation, and avoiding contact with drowned persons by rescuers with a high-risk profile. Ventilation techniques must balance required skill level, oxygen delivery, infection risk, and costs of equipment and training. Bag-mask ventilation with a high-efficiency particulate air filter by 2 trained rescuers is advised. Major implications for the methods, facilities, and environment of CPR training have been identified, including nonpractical skills to avoid being infected or to infect others. Most of all, the organization is responsible for informing their members about the impact of the COVID-19 pandemic and taking measures that maximize rescuer safety. Research is urgently needed to better understand, develop, and implement strategies to reduce infection transmission during drowning resuscitation.

CONCLUSIONS AND RELEVANCE: This consensus document provides an overview of recommendations for water rescue organizations to improve the safety of their rescuers during the COVID-19 pandemic and balances the competing interests between a potentially lifesaving intervention and risk to the rescuer. The consensus-based recommendations can also serve as an example for other volunteer organizations and altruistic laypeople who may provide resuscitation.},
}

COVID-19/prevention & control/*transmission
*Cardiopulmonary Resuscitation
Drowning/*prevention & control
Emergency Medical Services/*organization & administration/standards
*Emergency Medical Technicians
Heart Arrest/etiology/*therapy
Humans
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Pandemics
Personal Protective Equipment
SARS-CoV-2

@article {pmid35125460,
year = {2022},
author = {Iyer, S and Bovonratwet, P and Samartzis, D and Schoenfeld, AJ and An, HS and Awwad, W and Blumenthal, SL and Cheung, JPY and Derman, PB and El-Sharkawi, M and Freedman, BA and Hartl, R and Kang, JD and Kim, HJ and Louie, PK and Ludwig, SC and Neva, MH and Pham, MH and Phillips, FM and Qureshi, SA and Radcliff, KE and Riew, KD and Sandhu, HS and Sciubba, DM and Sethi, RK and Valacco, M and Zaidi, HA and Zygourakis, CC and Makhni, MC},
title = {Appropriate Telemedicine Utilization in Spine Surgery: Results From a Delphi Study.},
journal = {Spine},
volume = {47},
number = {8},
pages = {583-590},
doi = {10.1097/BRS.0000000000004339},
pmid = {35125460},
issn = {1528-1159},
mesh = {*COVID-19/epidemiology ; Consensus ; Delphi Technique ; Humans ; Patient Satisfaction ; *Telemedicine ; },
abstract = {STUDY DESIGN: Delphi expert panel consensus.

OBJECTIVE: To obtain expert consensus on best practices for appropriate telemedicine utilization in spine surgery.

SUMMARY OF BACKGROUND DATA: Several studies have shown high patient satisfaction associated with telemedicine during the COVID-19 peak pandemic period as well as after easing of restrictions. As this technology will most likely continue to be employed, there is a need to define appropriate utilization.

METHODS: An expert panel consisting of 27 spine surgeons from various countries was assembled in February 2021. A two-round consensus-based Delphi method was used to generate consensus statements on various aspects of telemedicine (separated as video visits or audio visits) including themes, such as patient location and impact of patient diagnosis, on assessment of new patients. Topics with ≥75% agreement were categorized as having achieved a consensus.

RESULTS: The expert panel reviewed a total of 59 statements. Of these, 32 achieved consensus. The panel had consensus that video visits could be utilized regardless of patient location and that video visits are appropriate for evaluating as well as indicating for surgery multiple common spine pathologies, such as lumbar stenosis, lumbar radiculopathy, and cervical radiculopathy. Finally, the panel had consensus that video visits could be appropriate for a variety of visit types including early, midterm, longer term postoperative follow-up, follow-up for imaging review, and follow-up after an intervention (i.e., physical therapy, injection).

CONCLUSION: Although telemedicine was initially introduced out of necessity, this technology most likely will remain due to evidence of high patient satisfaction and significant cost savings. This study was able to provide a framework for appropriate telemedicine utilization in spine surgery from a panel of experts. However, several questions remain for future research, such as whether or not an in-person consultation is necessary prior to surgery and which physical exam maneuvers are appropriate for telemedicine.Level of Evidence: 4.},
}

*COVID-19/epidemiology
Consensus
Delphi Technique
Humans
Patient Satisfaction
*Telemedicine

@article {pmid35112371,
year = {2022},
author = {Barbaud, A and Garvey, LH and Arcolaci, A and Brockow, K and Mori, F and Mayorga, C and Bonadonna, P and Atanaskovic-Markovic, M and Moral, L and Zanoni, G and Pagani, M and Soria, A and Jošt, M and Caubet, JC and Carmo, A and Mona, AA and Alvarez-Perea, A and Bavbek, S and Benedetta, B and Bilo, MB and Blanca-López, N and Bogas, HG and Buonomo, A and Calogiuri, G and Carli, G and Cernadas, J and Cortellini, G and Celik, G and Demir, S and Doña, I and Dursun, AB and Eberlein, B and Faria, E and Fernandes, B and Garcez, T and Garcia-Nunez, I and Gawlik, R and Gelincik, A and Gomes, E and Gooi, JHC and Grosber, M and Gülen, T and Hacard, F and Hoarau, C and Janson, C and Johnston, SL and Joerg, L and Kepil Özdemir, S and Klimek, L and Košnik, M and Kowalski, ML and Kuyucu, S and Kvedariene, V and Laguna, JJ and Lombardo, C and Marinho, S and Merk, H and Meucci, E and Morisset, M and Munoz-Cano, R and Murzilli, F and Nakonechna, A and Popescu, FD and Porebski, G and Radice, A and Regateiro, FS and Röckmann, H and Romano, A and Sargur, R and Sastre, J and Scherer Hofmeier, K and Sedláčková, L and Sobotkova, M and Terreehorst, I and Treudler, R and Walusiak-Skorupa, J and Wedi, B and Wöhrl, S and Zidarn, M and Zuberbier, T and Agache, I and Torres, MJ},
title = {Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper.},
journal = {Allergy},
volume = {77},
number = {8},
pages = {2292-2312},
doi = {10.1111/all.15241},
pmid = {35112371},
issn = {1398-9995},
mesh = {*Anaphylaxis/diagnosis ; *COVID-19/prevention & control ; *COVID-19 Vaccines/adverse effects ; *Drug Hypersensitivity/diagnosis/etiology/therapy ; Humans ; *Vaccines ; Vaccines, Synthetic ; mRNA Vaccines ; },
abstract = {BACKGROUND: Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized.

METHOD: Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed.

RESULTS: No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1-anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2-anaphylaxis to oral/topical PEG containing products; 3-recurrent anaphylaxis of unknown cause; 4-suspected or confirmed allergy to any mRNA vaccine; and 5-confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left-over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable.

CONCLUSIONS: These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.},
}

*Anaphylaxis/diagnosis
*COVID-19/prevention & control
*COVID-19 Vaccines/adverse effects
*Drug Hypersensitivity/diagnosis/etiology/therapy
Humans
*Vaccines
Vaccines, Synthetic
mRNA Vaccines

@article {pmid35103926,
year = {2022},
author = {Cosentini, R and Groff, P and Brambilla, AM and Camajori Todeschini, R and Gangitano, G and Ingrassia, S and Marino, R and Nori, F and Pagnozzi, F and Panero, F and Ferrari, R and , },
title = {SIMEU position paper on non-invasive respiratory support in COVID-19 pneumonia.},
journal = {Internal and emergency medicine},
volume = {17},
number = {4},
pages = {1175-1189},
pmid = {35103926},
issn = {1970-9366},
mesh = {*COVID-19/complications/therapy ; *Emergency Medicine ; Humans ; *Noninvasive Ventilation/methods ; Respiration, Artificial ; *Respiratory Insufficiency ; SARS-CoV-2 ; },
abstract = {The rapid worldwide spread of the Coronavirus disease (COVID-19) crisis has put health systems under pressure to a level never experienced before, putting intensive care units in a position to fail to meet an exponentially growing demand. The main clinical feature of the disease is a progressive arterial hypoxemia which rapidly leads to ARDS which makes the use of intensive care and mechanical ventilation almost inevitable. The difficulty of health systems to guarantee a corresponding supply of resources in intensive care, together with the uncertain results reported in the literature with respect to patients who undergo early conventional ventilation, make the search for alternative methods of oxygenation and ventilation and potentially preventive of the need for tracheal intubation, such as non-invasive respiratory support techniques particularly valuable. In this context, the Emergency Department, located between the area outside the hospital and hospital ward and ICU, assumes the role of a crucial junction, due to the possibility of applying these techniques at a sufficiently early stage and being able to rapidly evaluate their effectiveness. This position paper describes the indications for the use of non-invasive respiratory support techniques in respiratory failure secondary to COVID-19-related pneumonia, formulated by the Non-invasive Ventilation Faculty of the Italian Society of Emergency Medicine (SIMEU) on the base of what is available in the literature and on the authors' direct experience. Rationale, literature, tips & tricks, resources, risks and expected results, and patient interaction will be discussed for each one of the escalating non-invasive respiratory techniques: standard oxygen, HFNCO, CPAP, NIPPV, and awake self-repositioning. The final chapter describes our suggested approach to the failing patient.},
}

*COVID-19/complications/therapy
*Emergency Medicine
Humans
*Noninvasive Ventilation/methods
Respiration, Artificial
*Respiratory Insufficiency
SARS-CoV-2

@article {pmid35057603,
year = {2022},
author = {Chopra, HK and Nair, T and Ponde, CK and Kaul, S and Mehta, Y and Vora, A and Mukhopadhyay, P and Jayagopal, PB and Behera, M and Patil, R and Deshpande, M and Anantharaman, R},
title = {COVID-Inflicted Coagulopathy: Expert Consensus on Management with Novel Oral Anticoagulants in India.},
journal = {The Journal of the Association of Physicians of India},
volume = {69},
number = {12},
pages = {11-12},
pmid = {35057603},
issn = {0004-5772},
mesh = {Administration, Oral ; Anticoagulants/therapeutic use ; *COVID-19 ; Consensus ; *Heparin, Low-Molecular-Weight ; Humans ; India/epidemiology ; Pandemics ; SARS-CoV-2 ; },
abstract = {Coronavirus disease 2019 (COVID-19) is a highly hypercoagulable viral infection complicated as COVID-inflicted coagulopathy (CIC), that is associated with increased risk of morbidity and mortality. International guidelines recommend low molecular weight heparin (LMWH) to treat CIC in both in-hospital and in-home settings. However, in India, using subcutaneous LMWH may not be a feasible option for a vast majority of patients under home management. Additionally, while some evidence advocates the use of novel oral anticoagulants (NOACs), in hospitalized settings, most guidelines find no role of NOACs in hospital settings. On the other hand, the resource crunch faced in recent COVID-19 pandemic in India forced physicians to treat many patients in home settings. These patients had been usually prescribed NOACs for ease of administration and adherence. Therefore, there is a need to form a consensus on the use of NOACs to manage CIC in India.},
}

Administration, Oral
Anticoagulants/therapeutic use
*COVID-19
Consensus
*Heparin, Low-Molecular-Weight
Humans
India/epidemiology
Pandemics
SARS-CoV-2

@article {pmid35019782,
year = {2022},
author = {Scotland, KB and Tailly, T and Chew, BH and Bhojani, N and Smith, D and , },
title = {Consensus Statement on Urinary Stone Treatment During a Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative.},
journal = {Journal of endourology},
volume = {36},
number = {3},
pages = {335-344},
doi = {10.1089/end.2021.0477},
pmid = {35019782},
issn = {1557-900X},
mesh = {*COVID-19 ; Humans ; *Kidney Calculi/therapy ; *Lithotripsy ; Pandemics ; *Ureteral Calculi/therapy ; *Urinary Calculi/surgery ; *Urolithiasis/therapy ; },
abstract = {Introduction: The novel coronavirus disease (COVID-19) pandemic has had a significant impact on the care of patients with urolithiasis. Recommendations and prioritization of endourologic surgical procedures vary among regions, and a comprehensive overall international directive is needed. We used the Delphi method to obtain international consensus on managing urolithiasis patients during the pandemic. Methods: A three-round Delphi process was used to elicit expert consensus (53 global key opinion leaders within the Endourological Society from 36 countries) on an extensive survey on management of endourologic patients in a pandemic. Questions addressed general management, inpatient and outpatient procedures, clinic visits, follow-up care, and best practices for suspension and resumption of routine care. Results: Consensus was achieved in 64/84 (76%) questions. Key consensus findings included the following: consultations should be delivered remotely when possible. Invasive surgical procedures for urolithiasis patients should be reserved for high-risk situations (infection, renal failure, etc.). To prevent aerosolization, spinal anesthesia is preferred over general, whenever feasible. Treatment of asymptomatic renal stones should be deferred. Primary definitive treatment of obstructing or symptomatic stones (both renal and ureteral) is preferred over temporizing drainage. Extracorporeal shockwave lithotripsy should be continued for obstructive ureteral stones. There was consensus on treatment modalities and drainage strategies depending on location and size of the stone. Conclusion: International endourologist members of the Endourological Society participated in this Delphi initiative to provide expert consensus on management of urolithiasis during a pandemic. These results can be applied currently and during a future pandemic.},
}

*COVID-19
Humans
*Kidney Calculi/therapy
*Lithotripsy
Pandemics
*Ureteral Calculi/therapy
*Urinary Calculi/surgery
*Urolithiasis/therapy

@article {pmid34973937,
year = {2022},
author = {Manzano-Aquiahuatl, C and Tobar-Fredes, R and Zavala-Solares, MR and Salle-Levy, D and Imamura, R and Morales-Fernández, R and Ojeda-Peña, L and Parra-Reyes, D and Santoro, P and Ton, V and Trujillo-Benavides, OE and Vargas-García, MA and Furkim, AM},
title = {Position statement of the Latin American Dysphagia Society for the management of oropharyngeal and esophageal dysphagia during the COVID-19 pandemic.},
journal = {Revista de gastroenterologia de Mexico (English)},
volume = {87},
number = {1},
pages = {63-79},
pmid = {34973937},
issn = {2255-534X},
mesh = {*COVID-19 ; *Deglutition Disorders/epidemiology/therapy ; Humans ; Latin America/epidemiology ; Pandemics ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: The SARS-CoV-2 virus that causes the COVID-19 disease is transmitted through the inhalation of droplets or aerosols and inoculation via the oronasal or ocular routes, transforming the management of swallowing disorders into a challenge for healthcare teams, given their proximity to the aerodigestive tract and the high probability of aerosol generation during patient evaluation and treatment.

AIM: To provide essential guidance for Latin American multidisciplinary teams, regarding the evaluation and treatment of oropharyngeal and esophageal dysphagia, at the different levels of healthcare. The position statement was formulated for the purpose of maintaining medical service continuity, in the context of a pandemic, and minimizing the propagation and infection risks of the virus.

METHODS: Thirteen experts in swallowing disorders were summoned by the Latin American Dysphagia Society to formulate a series of clinical suggestions, based on available evidence and clinical experience, for the management of dysphagia, taking the characteristics of Latin American healthcare systems into account.

RESULTS: The position statement of the Latin American Dysphagia Society provides a series of clinical suggestions directed at the multidisciplinary teams that manage patients with oropharyngeal and esophageal dysphagia. It presents guidelines for evaluation and treatment in different contexts, from hospitalization to home care.

CONCLUSIONS: The present statement should be analyzed by each team or healthcare professional, to reduce the risk for COVID-19 infection and achieve the best therapeutic results, while at the same time, being mindful of the reality of each Latin American country.},
}

*COVID-19
*Deglutition Disorders/epidemiology/therapy
Humans
Latin America/epidemiology
Pandemics
SARS-CoV-2

@article {pmid34933747,
year = {2021},
author = {Wyckoff, MH and Singletary, EM and Soar, J and Olasveengen, TM and Greif, R and Liley, HG and Zideman, D and Bhanji, F and Andersen, LW and Avis, SR and Aziz, K and Bendall, JC and Berry, DC and Borra, V and Böttiger, BW and Bradley, R and Bray, JE and Breckwoldt, J and Carlson, JN and Cassan, P and Castrén, M and Chang, WT and Charlton, NP and Cheng, A and Chung, SP and Considine, J and Costa-Nobre, DT and Couper, K and Dainty, KN and Davis, PG and de Almeida, MF and de Caen, AR and de Paiva, EF and Deakin, CD and Djärv, T and Douma, MJ and Drennan, IR and Duff, JP and Eastwood, KJ and El-Naggar, W and Epstein, JL and Escalante, R and Fabres, JG and Fawke, J and Finn, JC and Foglia, EE and Folke, F and Freeman, K and Gilfoyle, E and Goolsby, CA and Grove, A and Guinsburg, R and Hatanaka, T and Hazinski, MF and Heriot, GS and Hirsch, KG and Holmberg, MJ and Hosono, S and Hsieh, MJ and Hung, KKC and Hsu, CH and Ikeyama, T and Isayama, T and Kapadia, VS and Kawakami, MD and Kim, HS and Kloeck, DA and Kudenchuk, PJ and Lagina, AT and Lauridsen, KG and Lavonas, EJ and Lockey, AS and Malta Hansen, C and Markenson, D and Matsuyama, T and McKinlay, CJD and Mehrabian, A and Merchant, RM and Meyran, D and Morley, PT and Morrison, LJ and Nation, KJ and Nemeth, M and Neumar, RW and Nicholson, T and Niermeyer, S and Nikolaou, N and Nishiyama, C and O'Neil, BJ and Orkin, AM and Osemeke, O and Parr, MJ and Patocka, C and Pellegrino, JL and Perkins, GD and Perlman, JM and Rabi, Y and Reynolds, JC and Ristagno, G and Roehr, CC and Sakamoto, T and Sandroni, C and Sawyer, T and Schmölzer, GM and Schnaubelt, S and Semeraro, F and Skrifvars, MB and Smith, CM and Smyth, MA and Soll, RF and Sugiura, T and Taylor-Phillips, S and Trevisanuto, D and Vaillancourt, C and Wang, TL and Weiner, GM and Welsford, M and Wigginton, J and Wyllie, JP and Yeung, J and Nolan, JP and Berg, KM and , },
title = {2021 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Neonatal Life Support; Education, Implementation, and Teams; First Aid Task Forces; and the COVID-19 Working Group.},
journal = {Resuscitation},
volume = {169},
number = {},
pages = {229-311},
pmid = {34933747},
issn = {1873-1570},
support = {K24 HL157621/HL/NHLBI NIH HHS/United States ; },
mesh = {Adult ; *COVID-19 ; *Cardiopulmonary Resuscitation ; Child ; Consensus ; *Emergency Medical Services ; First Aid ; Humans ; Infant ; Infant, Newborn ; *Out-of-Hospital Cardiac Arrest/therapy ; SARS-CoV-2 ; },
abstract = {The International Liaison Committee on Resuscitation initiated a continuous review of new, peer-reviewed published cardiopulmonary resuscitation science. This is the fifth annual summary of the International Liaison Committee on Resuscitation International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations; a more comprehensive review was done in 2020. This latest summary addresses the most recently published resuscitation evidence reviewed by International Liaison Committee on Resuscitation task force science experts. Topics covered by systematic reviews in this summary include resuscitation topics of video-based dispatch systems; head-up cardiopulmonary resuscitation; early coronary angiography after return of spontaneous circulation; cardiopulmonary resuscitation in the prone patient; cord management at birth for preterm and term infants; devices for administering positive-pressure ventilation at birth; family presence during neonatal resuscitation; self-directed, digitally based basic life support education and training in adults and children; coronavirus disease 2019 infection risk to rescuers from patients in cardiac arrest; and first aid topics, including cooling with water for thermal burns, oral rehydration for exertional dehydration, pediatric tourniquet use, and methods of tick removal. Members from 6 International Liaison Committee on Resuscitation task forces have assessed, discussed, and debated the quality of the evidence, according to the Grading of Recommendations Assessment, Development, and Evaluation criteria, and their statements include consensus treatment recommendations or good practice statements. Insights into the deliberations of the task forces are provided in Justification and Evidence-to-Decision Framework Highlights sections. In addition, the task forces listed priority knowledge gaps for further research.},
}

Adult
*COVID-19
*Cardiopulmonary Resuscitation
Child
Consensus
*Emergency Medical Services
First Aid
Humans
Infant
Infant, Newborn
*Out-of-Hospital Cardiac Arrest/therapy
SARS-CoV-2

@article {pmid34933373,
year = {2022},
author = {Gralnek, IM and Hassan, C and Ebigbo, A and Fuchs, A and Beilenhoff, U and Antonelli, G and Bisschops, R and Arvanitakis, M and Bhandari, P and Bretthauer, M and Kaminski, MF and Lorenzo-Zuniga, V and Rodriguez de Santiago, E and Siersema, PD and Tham, TC and Triantafyllou, K and Tringali, A and Voiosu, A and Webster, G and de Pater, M and Fehrke, B and Gazic, M and Gjergek, T and Maasen, S and Waagenes, W and Dinis-Ribeiro, M and Messmann, H},
title = {ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants.},
journal = {Endoscopy},
volume = {54},
number = {2},
pages = {211-216},
doi = {10.1055/a-1700-4897},
pmid = {34933373},
issn = {1438-8812},
mesh = {*COVID-19 ; Endoscopy, Gastrointestinal ; *Gastroenterology ; Humans ; SARS-CoV-2 ; *Vaccines ; },
}

*COVID-19
Endoscopy, Gastrointestinal
*Gastroenterology
Humans
SARS-CoV-2
*Vaccines

@article {pmid34915764,
year = {2021},
author = {Wang, X and Gkrouzman, E and Andrade, DCO and Andreoli, L and Barbhaiya, M and Belmont, HM and Branch, DW and de Jesús, GR and Efthymiou, M and Ríos-Garcés, R and Gerosa, M and El Hasbani, G and Knight, J and Meroni, PL and Pazzola, G and Petri, M and Rand, J and Salmon, J and Tektonidou, M and Tincani, A and Uthman, IW and Zuily, S and Zuo, Y and Lockshin, M and Cohen, H and Erkan, D and , },
title = {COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION).},
journal = {Lupus},
volume = {30},
number = {14},
pages = {2276-2285},
pmid = {34915764},
issn = {1477-0962},
support = {R01 AR069572/AR/NIAMS NIH HHS/United States ; },
mesh = {*Antibodies, Antiphospholipid ; *Antiphospholipid Syndrome ; *COVID-19/pathology ; Humans ; *Thrombosis/virology ; },
abstract = {Coronavirus disease 2019 (COVID-19) is associated with a high rate of thrombosis. Prolonged activated partial thromboplastin times (aPTT) and antiphospholipid antibodies (aPL) are reported in COVID-19 patients. The majority of publications have not reported whether patients develop clinically relevant persistent aPL, and the clinical significance of new aPL-positivity in COVID-19 is currently unknown. However, the reports of aPL-positivity in COVID-19 raised the question whether common mechanisms exist in the pathogenesis of COVID-19 and antiphospholipid syndrome (APS). In both conditions, thrombotic microangiopathy resulting in microvascular injury and thrombosis is hypothesized to occur through multiple pathways, including endothelial damage, complement activation, and release of neutrophil extracellular traps (NETosis). APS-ACTION, an international APS research network, created a COVID-19 working group that reviewed common mechanisms, positive aPL tests in COVID-19 patients, and implications of COVID-19 infection for patients with known aPL positivity or APS, with the goals of proposing guidance for clinical management and monitoring of aPL-positive COVID-19 patients. This guidance also serves as a call and focus for clinical and basic scientific research.},
}

*Antibodies, Antiphospholipid
*Antiphospholipid Syndrome
*COVID-19/pathology
Humans
*Thrombosis/virology

@article {pmid34905405,
year = {2022},
author = {Avutu, V and Monga, V and Mittal, N and Saha, A and Andolina, JR and Bell, DE and Fair, DB and Flerlage, JE and Frediani, JN and Heath, JL and Kahn, JM and Reichek, JL and Super, L and Terao, MA and Freyer, DR and Roth, ME},
title = {Use of Communication Technology to Improve Clinical Trial Participation in Adolescents and Young Adults With Cancer: Consensus Statement From the Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network.},
journal = {JCO oncology practice},
volume = {18},
number = {3},
pages = {224-231},
pmid = {34905405},
issn = {2688-1535},
support = {U10 CA180886/CA/NCI NIH HHS/United States ; },
mesh = {Adolescent ; Adult ; *COVID-19/epidemiology ; Child ; Communication ; Humans ; *Neoplasms/therapy ; Pandemics ; SARS-CoV-2 ; Technology ; Young Adult ; },
abstract = {Adolescents and young adults (AYAs; age 15-39 years) with cancer are under-represented in cancer clinical trials because of patient, provider, and institutional barriers. Health care technology is increasingly available to and highly used among AYAs and has the potential to improve cancer care delivery. The COVID-19 pandemic forced institutions to rapidly adopt novel approaches for enrollment and monitoring of patients on cancer clinical trials, many of which have the potential for improving AYA trial participation overall. This consensus statement from the Children's Oncology Group AYA Oncology Discipline Committee reviews opportunities to use technology to optimize AYA trial enrollment and study conduct, as well as considerations for widespread implementation of these practices. The use of remote patient eligibility screening, electronic informed consent, virtual tumor boards, remote study visits, and remote patient monitoring are recommended to increase AYA access to trials and decrease the burden of participation. Widespread adoption of these strategies will require new policies focusing on reimbursement for telehealth, license portability, facile communication between electronic health record systems and advanced safeguards to maintain patient privacy and security. Studies are needed to determine optimal approaches to further incorporate technology at every stage of the clinical trial process, from enrollment through study completion.},
}

Adolescent
Adult
*COVID-19/epidemiology
Child
Communication
Humans
*Neoplasms/therapy
Pandemics
SARS-CoV-2
Technology
Young Adult

@article {pmid34864375,
year = {2022},
author = {Al Hashmi, A and von Bandemer, S and Shuaib, A and Mansour, OY and Wassy, M and Ozdemir, AO and Farhoudi, M and Al Jehani, H and Khan, A and John, S and Saqqur, M and , },
title = {Lessons learned in stroke care during COVID-19 pandemic and preparing for future pandemics in the MENA+ region: A consensus statement from the MENA+-SINO.},
journal = {Journal of the neurological sciences},
volume = {432},
number = {},
pages = {120060},
pmid = {34864375},
issn = {1878-5883},
mesh = {Africa, Northern ; *COVID-19 ; Humans ; Middle East/epidemiology ; Pandemics ; SARS-CoV-2 ; *Stroke/epidemiology/therapy ; },
abstract = {BACKGROUND: COVID-19 pandemic has negatively impacted stroke care services at multiple levels. There was a decline in acute stroke admissions. Fewer interventions have been performed. Increased "door-to-needle times and "door-to-groin puncture" during this pandemic. These factors combined have led to declining in the favoured outcomes of stroke patients' globally. Yet this pandemic permits an opportunity for higher preparedness for future pandemics.

OBJECTIVES AND METHODS: This paper aims to shed light on the main lessons learned in the field of stroke care during the first wave of COVID-19 pandemic. Here we are presenting proposals and initiatives for better preparedness in future similar emergencies. These proposals are based primarily on literature review of COVID-19 publications, as well as the first-hand experience gained during the first wave at the regional level. In addition to the consensus and collective ride of stroke experts in the Middle East North Africa Stroke and Interventional Neurotherapies Organization (MENA+-SINO) and interaction and collaboration with international stroke specialists from the Stroke World Organization (WSO), European Stroke Organization (ESO) and stroke and COVID-19 papers authors.

CONCLUSION: Stroke care is very complex, particularly in the initial hours after onset of symptoms. A successful outcome requires very close collaboration between clinical personnel from multiple specialties. Preparedness for future pandemics requires the improvement of care plans that allow for rapid assessment of stroke patients and ensuring that regular 'mock exercises' familiarize quintessential services that care for the stroke patients.},
}

Africa, Northern
*COVID-19
Humans
Middle East/epidemiology
Pandemics
SARS-CoV-2
*Stroke/epidemiology/therapy

@article {pmid34855691,
year = {2022},
author = {Keder, RD and Mittal, S and Stringer, K and Wallis, KE and Wallace, JE and Soares, NS},
title = {Society for Developmental & Behavioral Pediatrics Position Statement on Telehealth.},
journal = {Journal of developmental and behavioral pediatrics : JDBP},
volume = {43},
number = {1},
pages = {55-59},
doi = {10.1097/DBP.0000000000001046},
pmid = {34855691},
issn = {1536-7312},
mesh = {*COVID-19 ; Humans ; Pandemics ; *Pediatrics ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {Telehealth has long held promise as a way to increase access to subspecialty care for children and families, including in developmental and behavioral pediatrics (DBP). The coronavirus disease 2019 (COVID-19) pandemic necessitated rapid uptake of telehealth to continue care delivery that was facilitated by "temporary" policy changes related to the pandemic. As a result, the field of DBP has recognized telehealth as a potential model of care for performing home-based diagnostic assessments, providing medication management follow-up, and delivering therapeutic interventions for children with neurodevelopmental disorders. Telehealth has been helpful in mitigating barriers families often face when attending in-person visits (lack of transportation and child care, missed work hours, etc) but has also highlighted additional determinants of health that need to be addressed to provide equitable access to care (broadband connectivity, device access, digital literacy, access to interpretation and sign language services, etc). Anticipating the lifting of pandemic-related emergency declaration and expiration of temporary policies around telehealth, the ability to continue to deliver DBP care by telehealth is uncertain. The purpose of this policy statement is to advocate for legislation and policies that support ongoing, equitable, home-based telehealth care for patients seen by DBP providers while ensuring equitable access to DBP in general. In addition, there is a need to recognize the benefits and challenges of telehealth versus in-person care and to identify clinical scenarios that favor 1 model of care versus the other.},
}

*COVID-19
Humans
Pandemics
*Pediatrics
SARS-CoV-2
*Telemedicine

@article {pmid34845404,
year = {2021},
author = {Curcio, A and Spaccarotella, C and Brunetti, ND and Molinari, G and Carugo, S and Basso, C and Ciccone, MM and Filardi, PP and Mancone, M and Mercuro, G and Muscoli, S and Nodari, S and Pedrinelli, R and Barillà, F and Sinagra, G and Indolfi, C},
title = {[Italian Society of Cardiology (SIC) Position paper: Technical, instrumental and standards of interpretation for electrocardiography, ambulatory electrocardiographic and blood pressure monitoring in telemedicine].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {12},
pages = {1017-1023},
doi = {10.1714/3698.36881},
pmid = {34845404},
issn = {1972-6481},
mesh = {Blood Pressure ; Blood Pressure Monitoring, Ambulatory ; *COVID-19 ; *Cardiology ; Electrocardiography, Ambulatory ; Humans ; Pandemics ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {The current COVID-19 pandemic has renewed interest in providing healthcare services based on the implementation of innovative technologies. Such strategy capillarizes the therapeutic opportunities for larger urban areas, mostly when people are living under extraordinarily difficult circumstances. Improving care delivery in cardiovascular diseases appears particularly feasible when telemedicine is pursued, especially with regard to baseline standard 12-lead electrocardiography, ambulatory electrocardiographic monitoring, and 24-hour ambulatory blood pressure monitoring. Nowadays, these first-line cardiovascular examinations are also available in health centers and pharmacies, and in recent months, there has been an increasing demand of such local services in the absence of specific rules and regulations regarding technical requirements and standards of interpretation that ensure a high quality clinical consultation.The purpose of this position paper is to provide critical requirements for the type/model of devices to be used, training dedicated to healthcare personnel, ensuring security of sensitive data, highlighting type of platforms to be used, as well as for maintaining high reporting quality and standards.},
}

Blood Pressure
Blood Pressure Monitoring, Ambulatory
*COVID-19
*Cardiology
Electrocardiography, Ambulatory
Humans
Pandemics
SARS-CoV-2
*Telemedicine

@article {pmid34841822,
year = {2021},
author = {Latif, A and Faull, C and Waring, J and Wilson, E and Anderson, C and Avery, A and Pollock, K},
title = {Managing medicines at the end of life: a position paper for health policy and practice.},
journal = {Journal of health organization and management},
volume = {35},
number = {9},
pages = {368-377},
pmid = {34841822},
issn = {1758-7247},
mesh = {*COVID-19 ; Death ; Health Policy ; Humans ; *Pandemics ; SARS-CoV-2 ; },
abstract = {PURPOSE: The impact of population ageing is significant, multifaceted and characterised by frailty and multi-morbidity. The COVID-19 pandemic has accelerated care pathways and policies promoting self-management and home-based care. One under-researched area is how patients and family caregivers manage the complexity of end-of-life therapeutic medicine regimens. In this position paper the authors bring attention to the significant strain that patients and family caregivers experience when navigating and negotiating this aspect of palliative and end-of-life care.

DESIGN/METHODOLOGY/APPROACH: Focussing on self-care and organisation of medicines in the United Kingdom (UK) context, the paper examines, builds on and extends the debate by considering the underlying policy assumptions and unintended consequences for individual patients and family care givers as they assume greater palliative and end-of-life roles and responsibilities.

FINDINGS: Policy makers and healthcare professionals often lack awareness of the significant burden and emotional work associated with managing and administering often potent high-risk medicines (i.e. opioids) in the domiciliary setting. The recent "revolution" in professional roles associated with the COVID-19 pandemic, including remote consultations and expanding community-based care, means there are opportunities for commissioners to consider offering greater support. The prospect of enhancing the community pharmacist's medicine optimisation role to further support the wider multi-disciplinary team is considered.

ORIGINALITY/VALUE: The paper takes a person-focused perspective and adopts a holistic view of medicine management. The authors argue for urgent review, reform and investment to enable and support terminally ill patients and family caregivers to more effectively manage medicines in the domiciliary setting. There are clear implications for pharmacists and these are discussed in the context of public awareness, inter-professional collaboration, organisational drivers, funding and regulation and remote care delivery.},
}

*COVID-19
Death
Health Policy
Humans
*Pandemics
SARS-CoV-2

@article {pmid34815248,
year = {2024},
author = {Dewhurst, F and Hanratty, B and Frew, K and Paes, P and Walker, R and Barnes, C and Maddock, H and Elverson, J and Byrne-Davis, L},
title = {Palliative medicine trainees be should learn about frailty: meta-synthesis and Delphi study to establish curriculum content.},
journal = {BMJ supportive & palliative care},
volume = {13},
number = {e3},
pages = {e1008-e1018},
doi = {10.1136/bmjspcare-2021-003013},
pmid = {34815248},
issn = {2045-4368},
mesh = {Aged ; Humans ; Curriculum ; Delphi Technique ; *Frailty/therapy ; Palliative Care ; *Palliative Medicine ; },
abstract = {OBJECTIVES: Frailty is common and highly associated with morbidity and mortality, a fact that has been highlighted by COVID-19. Understanding how to provide palliative care for frail individuals is an international priority, despite receiving limited mention in Palliative Medicine curricula or examinations worldwide. This study aimed to synthesise evidence and establish expert consensus on what should be included in a Palliative-Medicine Specialist Training Curriculum for frailty.

METHODS: Literature Meta-synthesis conducted by palliative medicine, frailty and education experts produced a draft curriculum with Bologna based Learning-Outcomes. A Delphi study asked experts to rate the importance of Learning-Outcomes for specialist-training completion and propose additional Learning-Outcomes. This process was repeated until 70% consensus was achieved for over 90% of Learning-Outcomes. Experts divided Learning-Outcomes into specific (for inclusion in a frailty subsection) or generic (applicable to other palliative conditions). The Delphi panel was Subject Matter Experts: Palliative-Medicine Consultants (n=14) and Trainees (n=10), representing hospital, community, hospice and care home services and including committee members of key national training organisations. A final reviewing panel of Geriatric Medicine Specialists including experts in research methodology, national training requirements and frailty were selected.

RESULTS: The meta-synthesis produced 114 Learning-Outcomes. The Delphi Study and Review by Geriatric Medicine experts resulted in 46 essential and 33 desirable Learning-Outcomes.

CONCLUSIONS: This frailty curriculum is applicable internationally and highlights the complex and unique palliative needs of frail patients. Future research is required to inform implementation, educational delivery and service provision.},
}

Aged
Humans
Curriculum
Delphi Technique
*Frailty/therapy
Palliative Care
*Palliative Medicine

@article {pmid34810293,
year = {2022},
author = {Bharadva, K and Bellad, RM and Tiwari, S and Somasekar, R and Phadke, M and Bodhankar, U and Bang, A and Kinikar, AA and Mallikarjuna, HB and Shah, J and Khurana, O and Gunasingh, D and Basavaraja, GV and Kumar, R and Gupta, P},
title = {Breastfeeding in Coronavirus Disease 2019 (COVID-19): Position Statement of Indian Academy of Pediatrics and Infant and Young Child Feeding Chapter.},
journal = {Indian pediatrics},
volume = {59},
number = {1},
pages = {58-62},
pmid = {34810293},
issn = {0974-7559},
mesh = {Breast Feeding ; *COVID-19 ; Child ; Female ; Humans ; Infant ; Pandemics ; *Pediatrics ; SARS-CoV-2 ; },
abstract = {JUSTIFICATION: Recent research has provided evidence for lack of transmission of SARS-CoV-2 through human milk and breastfeeding. Updating the practice guidelines will help in providing appropriate advice and support regarding breastfeeding during the coronavirus 2019 (COVID-19) pandemic.

OBJECTIVES: To provide evidence-based guidelines to help the healthcare professionals to advise optimal breastfeeding practices during the COVID-19 pandemic.

PROCESS: Formulation of key questions was done under the chairmanship of President of the IAP. It was followed by review of literature and the recommendations of other international and national professional bodies. Through Infant and Young child (IYCF) focused WhatsApp group opinion of all members was taken. The final document was prepared after the consensus and approval by all members of the committee.

RECOMMENDATIONS: The IYCF Chapter of IAP strongly recommends unabated promotion, protection and support to breastfeeding during the COVID-19 pandemic with due precautions.},
}

Breast Feeding
*COVID-19
Child
Female
Humans
Infant
Pandemics
*Pediatrics
SARS-CoV-2

@article {pmid34788734,
year = {2021},
author = {Blasi, F and Di Pasquale, M and Gramegna, A and Viale, P and Iacobello, C and Gori, A and Tumbarello, M and Esposito, S and Richeldi, L and Bassetti, M},
title = {A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: A SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement.},
journal = {Respiratory medicine},
volume = {190},
number = {},
pages = {106674},
pmid = {34788734},
issn = {1532-3064},
mesh = {Adolescent ; Adult ; Aged ; Aged, 80 and over ; *COVID-19/prevention & control ; Female ; *Health Promotion ; Health Services Needs and Demand ; Humans ; *Influenza Vaccines ; Influenza, Human/*prevention & control ; Italy ; Male ; Middle Aged ; *Pandemics ; Pneumococcal Infections/microbiology/*prevention & control ; *Pneumococcal Vaccines ; Pulmonary Medicine/*organization & administration ; Societies, Medical/*organization & administration ; Streptococcus pneumoniae ; *Vaccination ; Young Adult ; },
abstract = {Influenza and pneumococcal disease represent a well-known burden on healthcare systems worldwide, as well as they still have an attributed morbidity and mortality, especially in elderly individuals and vulnerable populations. In the context of the ongoing pandemic of COVID-19, a series of considerations in favor of extensive influenza and pneumococcal vaccination campaign are emerging, including a possible reduction of hospital extra burden and saving of sanitary resources. In addition, recent studies have suggested that prior vaccinations towards non SARS-CoV-2 pathogens might confer some protection against COVID-19. In this paper the authors consider all factors in support of these hypotheses and provide a consensus statement to encourage influenza and pneumococcal vaccinations in targeted populations.},
}

Adolescent
Adult
Aged
Aged, 80 and over
*COVID-19/prevention & control
Female
*Health Promotion
Health Services Needs and Demand
Humans
*Influenza Vaccines
Influenza, Human/*prevention & control
Italy
Male
Middle Aged
*Pandemics
Pneumococcal Infections/microbiology/*prevention & control
*Pneumococcal Vaccines
Pulmonary Medicine/*organization & administration
Societies, Medical/*organization & administration
Streptococcus pneumoniae
*Vaccination
Young Adult

@article {pmid34724404,
year = {2022},
author = {Boggiano, C and Eisinger, RW and Lerner, AM and Anderson, JM and Woodcock, J and Fauci, AS and Collins, FS},
title = {Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19.},
journal = {Annals of internal medicine},
volume = {175},
number = {1},
pages = {119-126},
pmid = {34724404},
issn = {1539-3704},
mesh = {Antibodies, Monoclonal/adverse effects/immunology/*therapeutic use ; COVID-19/immunology/*prevention & control/*therapy ; Humans ; Immunization, Passive/adverse effects ; National Institutes of Health (U.S.) ; SARS-CoV-2/*immunology ; United States ; United States Food and Drug Administration ; COVID-19 Serotherapy ; },
abstract = {As the fourth wave of the SARS-CoV-2 pandemic encircles the globe, there remains an urgent challenge to identify safe and effective treatment and prevention strategies that can be implemented in a range of health care and clinical settings. Substantial advances have been made in the use of anti-SARS-CoV-2 antibodies to mitigate the morbidity and mortality associated with COVID-19. On 15 June 2021, the National Institutes of Health, in collaboration with the U.S. Food and Drug Administration, convened a virtual summit to summarize existing knowledge on anti-SARS-CoV-2 antibodies and to identify key unanswered scientific questions to further catalyze the clinical development and implementation of antibodies.},
}

Antibodies, Monoclonal/adverse effects/immunology/*therapeutic use
COVID-19/immunology/*prevention & control/*therapy
Humans
Immunization, Passive/adverse effects
National Institutes of Health (U.S.)
SARS-CoV-2/*immunology
United States
United States Food and Drug Administration
COVID-19 Serotherapy

@article {pmid34711104,
year = {2022},
author = {Pandian, JD and Panagos, PD and Sebastian, IA and Sampaio Silva, G and Furie, KL and Liu, L and Owolabi, MO and Caso, V and Alrukn, SA},
title = {Maintaining stroke care during the COVID-19 pandemic in lower- and middle-income countries: World Stroke Organization Position Statement endorsed by American Stroke Association and American Heart Association.},
journal = {International journal of stroke : official journal of the International Stroke Society},
volume = {17},
number = {1},
pages = {9-17},
pmid = {34711104},
issn = {1747-4949},
support = {D43 TW012030/TW/FIC NIH HHS/United States ; R01 NS107900/NS/NINDS NIH HHS/United States ; R01 NS115944/NS/NINDS NIH HHS/United States ; U54 HG007479/HG/NHGRI NIH HHS/United States ; },
mesh = {American Heart Association ; *COVID-19 ; Developing Countries ; Humans ; Pandemics ; SARS-CoV-2 ; *Stroke/epidemiology/therapy ; United States/epidemiology ; },
abstract = {For more than a year, the SARS-CoV-2 pandemic has had a devastating effect on global health. High-, low-, and middle-income countries are struggling to cope with the spread of newer mutant strains of the virus. Delivery of acute stroke care remains a priority despite the pandemic. In order to maintain the time-dependent processes required to optimize delivery of intravenous thrombolysis and endovascular therapy, most countries have reorganized infrastructure to optimize human resources and critical services. Low-and-middle income countries (LMIC) have strained medical resources at baseline and often face challenges in the delivery of stroke systems of care (SSOC). This position statement aims to produce pragmatic recommendations on methods to preserve the existing SSOC during COVID-19 in LMIC and propose best stroke practices that may be low cost but high impact and commonly shared across the world.},
}

American Heart Association
*COVID-19
Developing Countries
Humans
Pandemics
SARS-CoV-2
*Stroke/epidemiology/therapy
United States/epidemiology

@article {pmid34697918,
year = {2021},
author = {Desmarais, J and Rosenbaum, JT and Costenbader, KH and Ginzler, EM and Fett, N and Goodman, S and O'Dell, J and Pineau, CA and Schmajuk, G and Werth, VP and Link, MS and Kovacs, R},
title = {American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.},
journal = {Arthritis & rheumatology (Hoboken, N.J.)},
volume = {73},
number = {12},
pages = {2151-2160},
doi = {10.1002/art.41934},
pmid = {34697918},
issn = {2326-5205},
mesh = {Antimalarials/adverse effects/*therapeutic use ; Cardiotoxicity/*etiology ; Chloroquine/adverse effects/*therapeutic use ; Humans ; Hydroxychloroquine/adverse effects/*therapeutic use ; *COVID-19 Drug Treatment ; },
abstract = {Hydroxychloroquine (HCQ) and chloroquine (CQ) are well-established medications used in treating systemic lupus erythematosus and rheumatoid arthritis, as well as skin conditions such as cutaneous lupus erythematosus. In rare cases, arrhythmias and conduction system abnormalities, as well as cardiomyopathy, have been reported in association with HCQ/CQ use. Recently, however, the corrected QT interval (QTc)-prolonging potential of these medications, and risk of torsade de pointes (TdP) in particular, have been highlighted in the setting of their experimental use for COVID-19 infection. This report was undertaken to summarize the current understanding of HCQ/CQ cardiac toxicity, describe QTc prolongation and TdP risks, and discuss areas of priority for future research. A working group of experts across rheumatology, cardiology, and dermatology performed a nonsystematic literature review and offered a consensus-based expert opinion. Current data clearly indicate that HCQ and CQ are invaluable medications in the management of rheumatic and dermatologic diseases, but they are associated with QTc prolongation by directly affecting cardiac repolarization. Prescribing clinicians should be cognizant of this small effect, especially in patients taking additional medications that prolong the QTc interval. Long-term use of HCQ/CQ may lead to a cardiomyopathy associated with arrhythmias and heart failure. Risk and benefit assessment should be considered prior to initiation of any medication, and both initial and ongoing risk-benefit assessments are important with regard to prescription of HCQ/CQ. While cardiac toxicity related to HCQ/CQ treatment of rheumatic diseases is rarely reported, it can be fatal. Awareness of the potential adverse cardiac effects of HCQ and CQ can increase the safe use of these medications. There is a clear need for additional research to allow better understanding of the cardiovascular risk and safety profile of these therapies used in the management of rheumatic and cutaneous diseases.},
}

Antimalarials/adverse effects/*therapeutic use
Cardiotoxicity/*etiology
Chloroquine/adverse effects/*therapeutic use
Humans
Hydroxychloroquine/adverse effects/*therapeutic use
*COVID-19 Drug Treatment

@article {pmid34694652,
year = {2021},
author = {Viswanathan, S and Hiew, FL and Siritho, S and Apiwattanakul, M and Tan, K and Quek, AML and Estiasari, R and Remli, R and Bhaskar, S and Islam, BM and Aye, SMM and Ohnmar, O and Umapathi, T and Keosodsay, SS and Hoang, NTT and Yeo, T and Pasco, PM},
title = {Impact of Covid-19 on the therapeutic plasma exchange service within the South East Asian region: Consensus recommendations and global perspectives.},
journal = {Journal of clinical apheresis},
volume = {36},
number = {6},
pages = {849-863},
pmid = {34694652},
issn = {1098-1101},
mesh = {Asia, Southeastern/epidemiology ; *COVID-19/complications/epidemiology/therapy ; Consensus ; Humans ; Nervous System Diseases/complications/therapy ; Neurologists ; Pandemics ; *Plasma Exchange/methods/statistics & numerical data ; SARS-CoV-2 ; Surveys and Questionnaires ; },
abstract = {INTRODUCTION: Therapeutic plasma exchange (TPE) for neuroimmunological disorders has played an increasingly important role within the Southeast Asian (SEA) region. The South East Asian Therapeutic Plasma exchange Consortium (SEATPEC) was formed in 2018 to promote education and research on TPE within the region. The advent of the Covid-19 pandemic has produced challenges for the development and expansion of this service.

METHODOLOGY: A qualitative and semi-quantitative questionnaire-based survey was conducted by SEATPEC member countries from January to June 2020 (Phase 1) and then from July 2020 to January 2021 in (Phase 2) to assess the impact of Covid-19 on regional TPE.

OBJECTIVES: The study's main objectives were to explore the challenges experienced and adaptations/adjustments taken by SEATPEC countries in order to continue safe and efficient TPE during the Covid-19 pandemic.

RESULTS: The pandemic was found to disrupt the delivery of TPE services in all SEATPEC countries. Contributing factors were multifactorial due to overstretched medical services, staff shortages, quarantines and redeployments, fear of acquiring Covid-19, movement restriction orders, and patient's psychological fear of attending hospitals/testing for Covid-19. All SEATPEC countries practiced careful stratification of cases for TPE (electives vs emergencies, Covid-19 vs non-Covid-19 cases). SEATPEC countries had to modify TPE treatment protocols to include careful preprocedure screening of patient's for Covid-19, use of personal protective equipment (PPE) and post-TPE sanitization of machines and TPE suites.

CONCLUSION: Based on the responses of the survey, SEATPEC countries produced a consensus statement with five recommendations for safe and effective TPE within the region.},
}

Asia, Southeastern/epidemiology
*COVID-19/complications/epidemiology/therapy
Consensus
Humans
Nervous System Diseases/complications/therapy
Neurologists
Pandemics
*Plasma Exchange/methods/statistics & numerical data
SARS-CoV-2
Surveys and Questionnaires

@article {pmid34694269,
year = {2022},
author = {Nicastro, E and Ebel, NH and Kehar, M and Czubkowski, P and Ng, VL and Michaels, MG and Lobritto, SJ and Martinez, M and Indolfi, G},
title = {The Impact of Severe Acute Respiratory Syndrome Coronavirus Type 2 on Children With Liver Diseases: A Joint European Society for Pediatric Gastroenterology, Hepatology and Nutrition and Society of Pediatric Liver Transplantation Position Paper.},
journal = {Journal of pediatric gastroenterology and nutrition},
volume = {74},
number = {1},
pages = {159-170},
pmid = {34694269},
issn = {1536-4801},
mesh = {*COVID-19/complications ; Child ; *Gastroenterology ; Humans ; *Liver Diseases ; *Liver Transplantation ; RNA, Viral ; SARS-CoV-2 ; Systemic Inflammatory Response Syndrome ; },
abstract = {Children are seldom affected by severe forms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2) infection; however, the impact of comorbidities in the clinical presentation and outcome of SARS-CoV2 in children is poorly characterized including that of chronic liver disease (CLD) and those taking immunosuppressive medications for autoimmune liver disease or following liver transplantation (LT). Although not the main target organ, a spectrum of liver involvement has been described in children infected with SARS-CoV2 and those presenting with Multisystem Inflammatory Syndrome in Children (MIS-C). The Hepatology Committee of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the Society of Pediatric Liver Transplantation (SPLIT) present an evidence-based position paper on liver involvement in children with SARS-CoV2 infection and its impact on those with CLD as well as LT recipients. All children may exhibit acute liver injury from SARS-CoV2 infection, and those with CLD and may experience hepatic decompensation. Preventative and therapeutic measures are discussed.},
}

*COVID-19/complications
Child
*Gastroenterology
Humans
*Liver Diseases
*Liver Transplantation
RNA, Viral
SARS-CoV-2
Systemic Inflammatory Response Syndrome

@article {pmid34692391,
year = {2021},
author = {, and Ferat, LR and Forrest, R and Sehmi, K and Santos, RD and Stewart, D and Boulton, AJM and Jiménez, BY and Riley, P and Burger, D and Jones, ESW and Tomaszewski, M and Milanese, MR and Laffin, P and Jha, V and Borisch, B and Moore, M and Pinto, FJ and Piñeiro, D and Eiselé, JL and Lackland, DT and Whelton, PK and Zhang, XH and Stavdal, A and Li, D and Hobbs, R and Pandian, JD and Brainin, M and Feigin, V},
title = {Preventing the Next Pandemic: The Case for Investing in Circulatory Health - A Global Coalition for Circulatory Health Position Paper.},
journal = {Global heart},
volume = {16},
number = {1},
pages = {66},
pmid = {34692391},
issn = {2211-8179},
mesh = {Aged ; Humans ; *COVID-19 ; Global Health ; *Noncommunicable Diseases/epidemiology/prevention & control ; Pandemics/prevention & control ; SARS-CoV-2 ; },
abstract = {The Coronavirus Disease 2019 (COVID-19) has had a continuous and robust impact on world health. The resulting COVID-19 pandemic has had a devastating physical, mental and fiscal impact on the millions of people living with noncommunicable diseases (NCDs). In addition to older age, people living with CVD, stroke, obesity, diabetes, kidney disease, and hypertension are at a particularly greater risk for severe forms of COVID-19 and its consequences. Meta-analysis indicates that hypertension, diabetes, chronic kidney disease, and thrombotic complications have been observed as both the most prevalent and most dangerous co-morbidities in COVID-19 patients. And despite the nearly incalculable physical, mental, emotional, and economic toll of this pandemic, forthcoming public health figures continue to place cardiovascular disease as the number one cause of death across the globe in the year 2020. The world simply cannot wait for the next pandemic to invest in NCDs. Social determinants of health cannot be addressed only through the healthcare system, but a more holistic multisectoral approach with at its basis the Sustainable Development Goals (SDGs) is needed to truly address social and economic inequalities and build more resilient systems. Yet there is reason for hope: the 2019 UN Political Declaration on UHC provides a strong framework for building more resilient health systems, with explicit calls for investment in NCDs and references to fiscal policies that put such investment firmly within reach. By further cementing the importance of addressing circulatory health in a future Framework Convention on Emergency Preparedness, WHO Member States can take concrete steps towards a pandemic-free future. As the chief representatives of the global circulatory health community and patients, the Global Coalition for Circulatory Health calls for increased support for the healthcare workforce, global vaccine equity, embracing new models of care and digital health solutions, as well as fiscal policies on unhealthy commodities to support these investments.},
}

Aged
Humans
*COVID-19
Global Health
*Noncommunicable Diseases/epidemiology/prevention & control
Pandemics/prevention & control
SARS-CoV-2

@article {pmid34689343,
year = {2021},
author = {Milch, V and Wang, R and Der Vartanian, C and Austen, M and Hector, D and Anderiesz, C and Keefe, D},
title = {Cancer Australia consensus statement on COVID-19 and cancer care: embedding high value changes in practice.},
journal = {The Medical journal of Australia},
volume = {215},
number = {10},
pages = {479-484},
pmid = {34689343},
issn = {1326-5377},
mesh = {Australia ; COVID-19/*epidemiology ; Decision Making, Shared ; *Delivery of Health Care ; Early Detection of Cancer ; Health Literacy ; Humans ; Neoplasms/diagnosis/prevention & control/*therapy ; Palliative Care ; *Pandemics ; Patient Care Team ; Patient-Centered Care ; SARS-CoV-2 ; Scholarly Communication ; Social Support ; Telemedicine ; },
abstract = {INTRODUCTION: Driven by the need to reduce risk of SARS-CoV-2 infection and optimise use of health system resources, while maximising patient outcomes, the COVID-19 pandemic has prompted unprecedented changes in cancer care. Some new or modified health care practices adopted during the pandemic will be of long term value in improving the quality and resilience of cancer care in Australia and internationally. The Cancer Australia consensus statement is intended to guide and enhance the delivery of cancer care during the pandemic and in a post-pandemic environment. This article summarises the full statement, which is available at https://www.canceraustralia.gov.au/covid-19/covid-19-recovery-implications-cancer-care.

MAIN RECOMMENDATIONS: The statement is informed by a desktop literature review and input from cancer experts and consumers at a virtual roundtable, held in July 2020, on key elements of cancer care that changed during the pandemic. It describes targeted strategies (at system, service, practitioner and patient levels) to retain, enhance and embed high value changes in practice. Principal strategies include: implementing innovative models of care that are digitally enabled and underpinned by clear governance, policies and procedures to guide best practice cancer care; enabling health professionals to deliver evidence-based best practice and coordinated, person-centred cancer care; and empowering patients to improve health literacy and enhancing their ability to engage in informed, shared decision making.

Widespread adoption of high value health care practices across all levels of the cancer control sector will be of considerable benefit to the delivery of optimal cancer care into the future.},
}

Australia
COVID-19/*epidemiology
Decision Making, Shared
*Delivery of Health Care
Early Detection of Cancer
Health Literacy
Humans
Neoplasms/diagnosis/prevention & control/*therapy
Palliative Care
*Pandemics
Patient Care Team
Patient-Centered Care
SARS-CoV-2
Scholarly Communication
Social Support
Telemedicine

@article {pmid34668835,
year = {2022},
author = {Piñana, JL and Vázquez, L and Martino, R and de la Cámara, R and Sureda, A and Rodríguez-Veiga, R and Garrido, A and Sierra, J and Ribera, JM and Torrent, A and Mateos, MV and de la Rubia, J and Tormo, M and Díez-Campelo, M and García-Gutiérrez, V and Álvarez-Larrán, A and Sancho, JM and MartínGarcía-Sancho, A and Yañez, L and Pérez Simón, JA and Barba, P and Abrisqueta, P and Álvarez-Twose, I and Bonanad, S and Lecumberri, R and Ruiz-Camps, I and Navarro, D and Hernández-Rivas, JÁ and Cedillo, Á and García-Sanz, R and Bosch, F},
title = {Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.},
journal = {Leukemia & lymphoma},
volume = {63},
number = {3},
pages = {538-550},
pmid = {34668835},
issn = {1029-2403},
mesh = {*COVID-19/epidemiology/prevention & control ; COVID-19 Vaccines/therapeutic use ; Consensus ; *Hematology ; Humans ; Pandemics/prevention & control ; SARS-CoV-2 ; Vaccination ; },
abstract = {In the midst of the COVID-19 pandemic, different vaccines in front of SARS-CoV-2 have been approved and administered in different vulnerable populations. As patients with cancer were excluded from pivotal trials of vaccination, little is known on their immunogenic response to these vaccines, particularly in patients with severely impaired immune system. In response to that uncertainty, the Spanish Society of Hematology and Hemotherapy launched an initiative aimed to provide recommendations for vaccination of the main hematological conditions. This document is based on the available information on COVID-19 outcomes, prior knowledge on vaccination in hematological patients, recent published data on serological response in oncohematological patients and expert opinions. New information about SARS-CoV-2 vaccination will be gathered in the near future, providing new scientific grounds to delineate the most adequate management of vaccination in patients with hematological diseases. The current limited data on SARS-CoV-2 vaccines in hematological patients represents a major limitation of this expert consensus opinion. In fact, the speed in which this field evolves may reduce their validity in the near future.},
}

*COVID-19/epidemiology/prevention & control
COVID-19 Vaccines/therapeutic use
Consensus
*Hematology
Humans
Pandemics/prevention & control
SARS-CoV-2
Vaccination

@article {pmid34620212,
year = {2021},
author = {Venturini, E and Montagnani, C and Garazzino, S and Donà, D and Pierantoni, L and Lo Vecchio, A and Krzysztofiak, A and Nicolini, G and Bianchini, S and Galli, L and Villani, A and Gattinara, GC and , },
title = {Treatment of children with COVID-19: update of the Italian Society of Pediatric Infectious Diseases position paper.},
journal = {Italian journal of pediatrics},
volume = {47},
number = {1},
pages = {199},
pmid = {34620212},
issn = {1824-7288},
mesh = {COVID-19/epidemiology/*therapy ; Child ; *Disease Management ; Female ; Humans ; *Infectious Disease Medicine ; Italy ; Male ; *Periodicals as Topic ; Practice Guidelines as Topic ; *SARS-CoV-2 ; *Societies, Medical ; },
}

COVID-19/epidemiology/*therapy
Child
*Disease Management
Female
Humans
*Infectious Disease Medicine
Italy
Male
*Periodicals as Topic
Practice Guidelines as Topic
*SARS-CoV-2
*Societies, Medical

@article {pmid34612556,
year = {2021},
author = {Rosano, G and Jankowska, EA and Ray, R and Metra, M and Abdelhamid, M and Adamopoulos, S and Anker, SD and Bayes-Genis, A and Belenkov, Y and Gal, TB and Böhm, M and Chioncel, O and Cohen-Solal, A and Farmakis, D and Filippatos, G and González, A and Gustafsson, F and Hill, L and Jaarsma, T and Jouhra, F and Lainscak, M and Lambrinou, E and Lopatin, Y and Lund, LH and Milicic, D and Moura, B and Mullens, W and Piepoli, MF and Ponikowski, P and Rakisheva, A and Ristic, A and Savarese, G and Seferovic, P and Senni, M and Thum, T and Tocchetti, CG and Van Linthout, S and Volterrani, M and Coats, AJS},
title = {COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.},
journal = {European journal of heart failure},
volume = {23},
number = {11},
pages = {1806-1818},
pmid = {34612556},
issn = {1879-0844},
mesh = {Aged ; *COVID-19 ; COVID-19 Vaccines ; *Cardiology ; Frail Elderly ; *Heart Failure ; Humans ; *Iron Deficiencies ; SARS-CoV-2 ; Vaccination ; },
abstract = {Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.},
}

Aged
*COVID-19
COVID-19 Vaccines
*Cardiology
Frail Elderly
*Heart Failure
Humans
*Iron Deficiencies
SARS-CoV-2
Vaccination

@article {pmid34570120,
year = {2021},
author = {Di Tano, G and Di Lenarda, A and Iacoviello, M and Oliva, F and Urbinati, S and Aspromonte, N and Cipriani, M and Caldarola, P and Murrone, A and Gulizia, MM and Colivicchi, F and Gabrielli, D},
title = {[ANMCO Position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {10},
pages = {854-860},
doi = {10.1714/3666.36517},
pmid = {34570120},
issn = {1972-6481},
mesh = {Aminobutyrates ; Angiotensin Receptor Antagonists ; Biphenyl Compounds ; *COVID-19 ; Drug Combinations ; *Heart Failure/drug therapy ; Humans ; Pandemics ; Prospective Studies ; SARS-CoV-2 ; Stroke Volume ; Tetrazoles ; Treatment Outcome ; Valsartan ; },
abstract = {Sacubitril/valsartan (S/V) has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms in chronic heart failure with reduced ejection fraction compared to enalapril. After 7 years since the publication of the results of PARADIGM-HF, further insight has been gained with potential new indications. Two prospective randomized multicenter studies (PIONEER-HF and TRANSITION) in patients hospitalized for acute heart failure (AHF) have shown an improved clinical outcome and biomarker profile as compared to enalapril, and good tolerability, safety and feasibility of initiating in-hospital administration of S/V. Furthermore, some studies have highlighted the favorable effects of S/V in attenuating adverse myocardial remodeling, supporting an early benefit after treatment. Observational data from non-randomized studies in AHF report that in-hospital and pre-discharge prescription of evidence-based drugs associated with better survival still remains suboptimal. Additionally, the COVID-19 pandemic has also negatively impacted on outpatient activities. Therefore, hospitalization, a real crossroads in the history of heart failure, must become a management and therapeutic opportunity for our patients. The objective of this ANMCO position paper is to encourage and facilitate early S/V administration in stabilized patients during hospitalization after an AHF episode, with the aim of improving care efficiency and clinical outcome.},
}

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
*COVID-19
Drug Combinations
*Heart Failure/drug therapy
Humans
Pandemics
Prospective Studies
SARS-CoV-2
Stroke Volume
Tetrazoles
Treatment Outcome
Valsartan

@article {pmid34570114,
year = {2021},
author = {Bisceglia, I and Gabrielli, D and Canale, ML and Gallucci, G and Parrini, I and Turazza, FM and Russo, G and Maurea, N and Quagliariello, V and Lestuzzi, C and Oliva, S and Di Fusco, SA and Lucà, F and Tarantini, L and Trambaiolo, P and Gulizia, MM and Colivicchi, F},
title = {[ANMCO Position paper: Cardio-oncology in the COVID-19 era].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {10},
pages = {800-825},
doi = {10.1714/3666.36511},
pmid = {34570114},
issn = {1972-6481},
mesh = {*COVID-19 ; Humans ; *Myocardial Infarction ; *Neoplasms/therapy ; Pandemics ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic and its impact on patients with cancer and cardiovascular disease have confirmed the particular vulnerability of this population. Indeed, not only a higher risk of contracting the infection has been reported, but also an increased occurrence of a more severe course and unfavorable outcome. Beyond the direct consequences of COVID-19, the pandemic has an enormous impact on global health systems. Screening programs and non-urgent tests have been postponed; clinical trials have suffered a setback. Similarly, in the area of cardiology care, a significant decline in ST-elevation myocardial infarction accesses and an increase in cases of late presenting heart attacks with increased mortality and complication rates have been reported. Health care systems must therefore get ready to tackle the "rebound effect" that will likely show a relative increase in the short and medium term incidence of diseases such as heart failure, myocardial infarction, arrhythmias and cardio- and cerebrovascular complications. Scientific societies are taking action to provide general guidance and recommendations aimed at mitigating the unfavorable outcomes of this pandemic emergency. Cardio-oncology, as an emerging discipline, is more flexible in modulating care pathways and represents a beacon of innovation in the development of multi-specialty patient management. In the era of the COVID-19 pandemic, cardio-oncology has rapidly modified its clinical care pathways and implemented flexible monitoring protocols that include targeted use of cardiac imaging, increased use of biomarkers, and telemedicine systems. The goal of these strategic adjustments is to minimize the risk of infection for providers and patients while maintaining standards of care for the treatment of oncologic and cardiovascular diseases. The aim of this position paper is to evaluate the impact of the COVID-19 pandemic on the management of cardio-oncologic patients with the-state-of-the-art knowledge about SARS-CoV-2 and COVID-19 in order to optimize medical strategies during and after the pandemic.},
}

*COVID-19
Humans
*Myocardial Infarction
*Neoplasms/therapy
Pandemics
SARS-CoV-2

@article {pmid34561208,
year = {2021},
author = {Sánchez-Álvarez, E and Quiroga, B and de Sequera, P and , },
title = {Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.},
journal = {Nefrologia},
volume = {41},
number = {4},
pages = {412-416},
pmid = {34561208},
issn = {2013-2514},
mesh = {*COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; *Nephrology ; RNA, Messenger ; SARS-CoV-2 ; *Vaccines ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide over the last year causing more than one million deaths. Several treatments have tried to modify the natural history of the coronavirus disease 2019 (COVID-19) but only corticosteroids have demonstrated to be effective in moderate or severe affectation. In that situation, the development of vaccines for preventing the SARS-CoV-2 infection has focused the attention of the scientific community. At present, available messenger RNA-based technology vaccines have received the approval of local and international sanitary authorities. In this position statement, the Spanish Society of Nephrology wants to state that patients with chronic kidney disease and healthcare workers are at high-risk for contagion and complications of COVID-19 so they must have priority in the vaccine administration.},
}

*COVID-19/prevention & control
COVID-19 Vaccines
Humans
*Nephrology
RNA, Messenger
SARS-CoV-2
*Vaccines

@article {pmid34532923,
year = {2022},
author = {Testino, G and Vignoli, T and Patussi, V and Allosio, P and Amendola, MF and Aricò, S and Baselice, A and Balbinot, P and Campanile, V and Fanucchi, T and Macciò, L and Meneguzzi, C and Mioni, D and Parisi, M and Renzetti, D and Rossin, R and Gandin, C and Bottaro, LC and Caio, G and Lungaro, L and Zoli, G and Scafato, E and Caputo, F},
title = {Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA).},
journal = {Addiction biology},
volume = {27},
number = {1},
pages = {e13090},
pmid = {34532923},
issn = {1369-1600},
mesh = {Alcoholics Anonymous ; Alcoholism/epidemiology/*therapy ; Ambulatory Care/organization & administration ; COVID-19/epidemiology/*prevention & control ; COVID-19 Vaccines/therapeutic use ; *Communicable Disease Control ; Delivery of Health Care/organization & administration ; Disease Susceptibility ; Drug Interactions ; Humans ; Immunosuppression Therapy/adverse effects ; Italy/epidemiology ; Liver Cirrhosis, Alcoholic/epidemiology/therapy ; Liver Transplantation ; Recurrence ; SARS-CoV-2 ; Societies, Medical ; Telemedicine ; COVID-19 Drug Treatment ; },
abstract = {Coronavirus disease 2019 (COVID-19) first emerged in China in November 2019. Most governments have responded to the COVID-19 pandemic by imposing a lockdown. Some evidence suggests that a period of isolation might have led to a spike in alcohol misuse, and in the case of patients with alcohol use disorder (AUD), social isolation can favour lapse and relapse. The aim of our position paper is to provide specialists in the alcohol addiction field, in psychopharmacology, gastroenterology and in internal medicine, with appropriate tools to better manage patients with AUD and COVID-19,considering some important topics: (a) the susceptibility of AUD patients to infection; (b) the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) the reorganization of the Centre for Alcohol Addiction Treatment for the management of AUD patients in the COVID-19 era (group activities, telemedicine, outpatients treatment, alcohol-related liver disease and liver transplantation, collecting samples); (d) AUD and SARS-CoV-2 vaccination. Telemedicine/telehealth will undoubtedly be useful/practical tools even though it remains at an elementary level; the contribution of the family and of caregivers in the management of AUD patients will play a significant role; the multidisciplinary intervention involving experts in the treatment of AUD with specialists in the treatment of COVID-19 disease will need implementation. Thus, the COVID-19 pandemic is rapidly leading addiction specialists towards a new governance scenario of AUD, which necessarily needs an in-depth reconsideration, focusing attention on a safe approach in combination with the efficacy of treatment.},
}

Alcoholics Anonymous
Alcoholism/epidemiology/*therapy
Ambulatory Care/organization & administration
COVID-19/epidemiology/*prevention & control
COVID-19 Vaccines/therapeutic use
*Communicable Disease Control
Delivery of Health Care/organization & administration
Disease Susceptibility
Drug Interactions
Humans
Immunosuppression Therapy/adverse effects
Italy/epidemiology
Liver Cirrhosis, Alcoholic/epidemiology/therapy
Liver Transplantation
Recurrence
SARS-CoV-2
Societies, Medical
Telemedicine
COVID-19 Drug Treatment

@article {pmid34528075,
year = {2021},
author = {Cenko, E and Badimon, L and Bugiardini, R and Claeys, MJ and De Luca, G and de Wit, C and Derumeaux, G and Dorobantu, M and Duncker, DJ and Eringa, EC and Gorog, DA and Hassager, C and Heinzel, FR and Huber, K and Manfrini, O and Milicic, D and Oikonomou, E and Padro, T and Trifunovic-Zamaklar, D and Vasiljevic-Pokrajcic, Z and Vavlukis, M and Vilahur, G and Tousoulis, D},
title = {Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA).},
journal = {Cardiovascular research},
volume = {117},
number = {14},
pages = {2705-2729},
pmid = {34528075},
issn = {1755-3245},
mesh = {Angiotensin-Converting Enzyme 2/metabolism ; COVID-19/*complications/enzymology/etiology/physiopathology/therapy ; Cardiometabolic Risk Factors ; Cardiovascular Diseases/enzymology/physiopathology/*virology ; Clinical Trials as Topic ; Humans ; Inflammation/complications/virology ; Microcirculation ; Sex Characteristics ; Post-Acute COVID-19 Syndrome ; },
abstract = {The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory and immune responses are characteristic features of severe COVID-19. Pre-existing cardiovascular disease and viral load are linked to myocardial injury and worse outcomes. The vascular response to cytokine production and the interaction between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and angiotensin-converting enzyme 2 receptor may lead to a significant reduction in cardiac contractility and subsequent myocardial dysfunction. In addition, a considerable proportion of patients who have been infected with SARS-CoV-2 do not fully recover and continue to experience a large number of symptoms and post-acute complications in the absence of a detectable viral infection. This conditions often referred to as 'post-acute COVID-19' may have multiple causes. Viral reservoirs or lingering fragments of viral RNA or proteins contribute to the condition. Systemic inflammatory response to COVID-19 has the potential to increase myocardial fibrosis which in turn may impair cardiac remodelling. Here, we summarize the current knowledge of cardiovascular injury and post-acute sequelae of COVID-19. As the pandemic continues and new variants emerge, we can advance our knowledge of the underlying mechanisms only by integrating our understanding of the pathophysiology with the corresponding clinical findings. Identification of new biomarkers of cardiovascular complications, and development of effective treatments for COVID-19 infection are of crucial importance.},
}

Angiotensin-Converting Enzyme 2/metabolism
COVID-19/*complications/enzymology/etiology/physiopathology/therapy
Cardiometabolic Risk Factors
Cardiovascular Diseases/enzymology/physiopathology/*virology
Clinical Trials as Topic
Humans
Inflammation/complications/virology
Microcirculation
Sex Characteristics
Post-Acute COVID-19 Syndrome

@article {pmid34452470,
year = {2021},
author = {Botti-Lodovico, Y and Nair, P and Nosamiefan, D and Stremlau, M and Schaffner, S and Agignoae, SV and Aiyepada, JO and Ajogbasile, FV and Akpede, GO and Alhasan, F and Andersen, KG and Asogun, DA and Ayodeji, OO and Badiane, AS and Barnes, K and Bauer, MR and Bell-Kareem, A and Benard, ME and Benevolence, EO and Blessing, O and Boehm, CK and Boisen, ML and Bond, NG and Branco, LM and Butts, MJ and Carter, A and Colubri, A and Deme, AB and DeRuff, KC and Diédhiou, Y and Edamhande, AP and Elhamoumi, S and Engel, EJ and Eromon, P and Fallah, M and Folarin, OA and Fry, B and Garry, R and Gaye, A and Gbakie, M and Gevao, SM and Gionet, G and Gladden-Young, A and Goba, A and Gomis, JF and Happi, AN and Houghton, M and Ihekwuazu, C and Iruolagbe, CO and Jackson, J and Jalloh, S and Johnson, J and Kanneh, L and Kayode, A and Kemball, M and Kingsley, OC and Koroma, V and Kotliar, D and Mehta, S and Metsky, HC and Michael, A and Mirhashemi, ME and Modjarrad, K and Momoh, M and Myhrvold, CA and Naregose, OG and Ndiaye, T and Ndiaye, M and Ndiaye, A and Normandin, E and Odia, I and Oguzie, JU and Okogbenin, SA and Okokhere, PO and Okolie, J and Olawoye, IB and Olumade, TJ and Oluniyi, PE and Omoregie, O and Park, DJ and Paye, MF and Petros, B and Philippakis, AA and Priscilla, A and Ricks, A and Rimoin, A and Sandi, JD and Schieffelin, JS and Schreiber, M and Seck, MC and Siddiqui, S and Siddle, K and Smither, AR and Sy, M and Sy, N and Tomkins-Tinch, CH and Tomori, O and Ugwu, C and Uwanibe, JN and Uyigue, EA and Victoria, DI and Vinzé, A and Vodzak, ME and Welch, N and Wurie, HI and Zoumarou, D and Grant, DS and Ndiaye, D and MacInnis, B and Sabeti, PC and Happi, C},
title = {The Origins and Future of Sentinel: An Early-Warning System for Pandemic Preemption and Response.},
journal = {Viruses},
volume = {13},
number = {8},
pages = {},
pmid = {34452470},
issn = {1999-4915},
support = {T32 GM007753/GM/NIGMS NIH HHS/United States ; },
mesh = {Africa, Western/epidemiology ; *Disaster Planning/methods ; Humans ; Lassa Fever/*epidemiology/genetics/prevention & control/virology ; Lassa virus/genetics/*physiology ; N-Acetylglucosaminyltransferases/genetics/immunology ; Nigeria/epidemiology ; Pandemics ; Polymorphism, Genetic ; Receptors, Virus/genetics/immunology ; },
abstract = {While investigating a signal of adaptive evolution in humans at the gene LARGE, we encountered an intriguing finding by Dr. Stefan Kunz that the gene plays a critical role in Lassa virus binding and entry. This led us to pursue field work to test our hypothesis that natural selection acting on LARGE-detected in the Yoruba population of Nigeria-conferred resistance to Lassa Fever in some West African populations. As we delved further, we conjectured that the "emerging" nature of recently discovered diseases like Lassa fever is related to a newfound capacity for detection, rather than a novel viral presence, and that humans have in fact been exposed to the viruses that cause such diseases for much longer than previously suspected. Dr. Stefan Kunz's critical efforts not only laid the groundwork for this discovery, but also inspired and catalyzed a series of events that birthed Sentinel, an ambitious and large-scale pandemic prevention effort in West Africa. Sentinel aims to detect and characterize deadly pathogens before they spread across the globe, through implementation of its three fundamental pillars: Detect, Connect, and Empower. More specifically, Sentinel is designed to detect known and novel infections rapidly, connect and share information in real time to identify emerging threats, and empower the public health community to improve pandemic preparedness and response anywhere in the world. We are proud to dedicate this work to Stefan Kunz, and eagerly invite new collaborators, experts, and others to join us in our efforts.},
}

Africa, Western/epidemiology
*Disaster Planning/methods
Humans
Lassa Fever/*epidemiology/genetics/prevention & control/virology
Lassa virus/genetics/*physiology
N-Acetylglucosaminyltransferases/genetics/immunology
Nigeria/epidemiology
Pandemics
Polymorphism, Genetic
Receptors, Virus/genetics/immunology

@article {pmid34423546,
year = {2021},
author = {Hamad, N and Ananda-Rajah, M and Gilroy, N and MacIntyre, R and Gottlieb, D and Ritchie, D and Harrison, S and Kennedy, G and Watson, AM and Greenwood, M and Doocey, R and Perera, T and Spencer, A and Wong, E and O'Brien, T and Shaw, P and Conyers, R and Milliken, S and Bardy, P and Larsen, S and Ho, PJ and Lai, H and Bajel, A and Butler, J and Tiley, C and D'Rozario, J and Johnston, A and Cochrane, T and Mills, T and Irving, I and Pullon, H and Purtill, D},
title = {Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement.},
journal = {Internal medicine journal},
volume = {51},
number = {8},
pages = {1321-1323},
pmid = {34423546},
issn = {1445-5994},
mesh = {Adult ; Australia/epidemiology ; *COVID-19/prevention & control ; *COVID-19 Vaccines ; Child ; Consensus ; Humans ; New Zealand/epidemiology ; Prospective Studies ; *Transplant Recipients ; Vaccination ; },
abstract = {Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as well as representatives from autologous transplant only centres in Australia and New Zealand collaborated with infectious diseases specialists with expertise in TCT on this consensus position statement regarding COVID-19 vaccination in TCT patients in Australia and New Zealand. It is our recommendation that TCT patients, should have expedited access to high-efficacy COVID-19 vaccines given that these patients are at high risk of morbidity and mortality from COVID-19 infection. We also recommend prioritising vaccination of TCT healthcare workers and household members of TCT patients. Vaccination should not replace other public health measures in TCT patients given the effectiveness of COVID-19 vaccination in TCT patients is unknown. Furthermore, given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.},
}

Adult
Australia/epidemiology
*COVID-19/prevention & control
*COVID-19 Vaccines
Child
Consensus
Humans
New Zealand/epidemiology
Prospective Studies
*Transplant Recipients
Vaccination

@article {pmid34399446,
year = {2021},
author = {Ku, CR and Jung, KY and Ahn, CH and Moon, JS and Lee, JH and Kim, EH and Kwon, H and Kim, HK and Suh, S and Hong, S and Ha, J and Roh, E and Kim, JH and Kim, MK and , },
title = {COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society.},
journal = {Endocrinology and metabolism (Seoul, Korea)},
volume = {36},
number = {4},
pages = {757-765},
pmid = {34399446},
issn = {2093-5978},
mesh = {COVID-19/epidemiology/immunology/*prevention & control ; COVID-19 Vaccines/administration & dosage/adverse effects/*standards ; *Endocrine System Diseases/epidemiology/immunology ; Endocrinologists/*standards ; Humans ; Practice Guidelines as Topic/standards ; Republic of Korea/epidemiology ; Societies, Medical/*standards ; Vaccination/*standards ; },
abstract = {Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients' health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders.},
}

COVID-19/epidemiology/immunology/*prevention & control
COVID-19 Vaccines/administration & dosage/adverse effects/*standards
*Endocrine System Diseases/epidemiology/immunology
Endocrinologists/*standards
Humans
Practice Guidelines as Topic/standards
Republic of Korea/epidemiology
Societies, Medical/*standards
Vaccination/*standards

@article {pmid34364845,
year = {2021},
author = {Roberts, DJ and Edlow, AG and Romero, RJ and Coyne, CB and Ting, DT and Hornick, JL and Zaki, SR and Das Adhikari, U and Serghides, L and Gaw, SL and Metz, TD and , },
title = {A standardized definition of placental infection by SARS-CoV-2, a consensus statement from the National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development SARS-CoV-2 Placental Infection Workshop.},
journal = {American journal of obstetrics and gynecology},
volume = {225},
number = {6},
pages = {593.e1-593.e9},
pmid = {34364845},
issn = {1097-6868},
support = {HHSN275201300006C/HD/NICHD NIH HHS/United States ; U54 MH118919/MH/NIMH NIH HHS/United States ; },
mesh = {COVID-19/*diagnosis ; COVID-19 Nucleic Acid Testing ; COVID-19 Testing/*methods ; Consensus ; Female ; Guidelines as Topic ; Humans ; Immunohistochemistry ; In Situ Hybridization ; Microscopy, Electron ; National Institute of Child Health and Human Development (U.S.) ; Placenta Diseases/*diagnosis/*virology ; Pregnancy ; Pregnancy Complications, Infectious/*diagnosis/*virology ; *SARS-CoV-2 ; United States/epidemiology ; },
abstract = {Pregnant individuals infected with SARS-CoV-2 have higher rates of intensive care unit admission, oxygen requirement, need for mechanical ventilation, and death than nonpregnant individuals. Increased COVID-19 disease severity may be associated with an increased risk of viremia and placental infection. Maternal SARS-CoV-2 infection is also associated with pregnancy complications such as preeclampsia and preterm birth, which can be either placentally mediated or reflected in the placenta. Maternal viremia followed by placental infection may lead to maternal-fetal transmission (vertical), which affects 1% to 3% of exposed newborns. However, there is no agreed-upon or standard definition of placental infection. The National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development convened a group of experts to propose a working definition of placental infection to inform ongoing studies of SARS-CoV-2 during pregnancy. Experts recommended that placental infection be defined using techniques that allow virus detection and localization in placental tissue by one or more of the following methods: in situ hybridization with antisense probe (detects replication) or a sense probe (detects viral messenger RNA) or immunohistochemistry to detect viral nucleocapsid or spike proteins. If the abovementioned methods are not possible, reverse transcription polymerase chain reaction detection or quantification of viral RNA in placental homogenates, or electron microscopy are alternative approaches. A graded classification for the likelihood of placental infection as definitive, probable, possible, and unlikely was proposed. Manuscripts reporting placental infection should describe the sampling method (location and number of samples collected), method of preservation of tissue, and detection technique. Recommendations were made for the handling of the placenta, examination, and sampling and the use of validated reagents and sample protocols (included as appendices).},
}

COVID-19/*diagnosis
COVID-19 Nucleic Acid Testing
COVID-19 Testing/*methods
Consensus
Female
Guidelines as Topic
Humans
Immunohistochemistry
In Situ Hybridization
Microscopy, Electron
National Institute of Child Health and Human Development (U.S.)
Placenta Diseases/*diagnosis/*virology
Pregnancy
Pregnancy Complications, Infectious/*diagnosis/*virology
*SARS-CoV-2
United States/epidemiology

@article {pmid34310563,
year = {2021},
author = {Caldarola, P and Murrone, A and Roncon, L and Di Pasquale, G and Tavazzi, L and Amodeo, V and Aspromonte, N and Cipriani, M and Di Lenarda, A and Domenicucci, S and Francese, GM and Imazio, M and Scotto di Uccio, F and Urbinati, S and Valente, S and Gulizia, MM and Colivicchi, F and Gabrielli, D},
title = {[ANMCO Position paper: Reorganization of cardiology in the era of the COVID-19 pandemic].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {8},
pages = {610-619},
doi = {10.1714/3641.36216},
pmid = {34310563},
issn = {1972-6481},
mesh = {*COVID-19 ; Cardiology/*organization & administration ; Cardiovascular Diseases/therapy ; Delivery of Health Care/*organization & administration ; Health Personnel/organization & administration ; Humans ; Italy ; National Health Programs/organization & administration ; },
abstract = {The COVID-19 pandemic represents an unprecedented event that has brought deep changes in hospital facilities with reshaping of the health system organization, revealing inadequacies of current hospital and local health systems. When the COVID-19 emergency will end, further evaluation of the national health system, new organization of acute wards, and a further evolution of the entire health system will be needed to improve care during the chronic phase of disease. Therefore, new standards for healthcare personnel, more efficient organization of hospital facilities for patients with acute illnesses, improvement of technological approaches, and better integration between hospital and territorial services should be pursued. With experience derived from the COVID-19 pandemic, new models, paradigms, interventional approaches, values and priorities should be suggested and implemented.},
}

*COVID-19
Cardiology/*organization & administration
Cardiovascular Diseases/therapy
Delivery of Health Care/*organization & administration
Health Personnel/organization & administration
Humans
Italy
National Health Programs/organization & administration

@article {pmid34307071,
year = {2021},
author = {McNabb, SJN and Magowe, M and Shaw, N and Berrian, AM and Wilkes, M and Shaikh, A and Gachuno, O and Perrone, LA and Murray, BL and Berman, E and Hansoti, B},
title = {Delivering Modern Global Health Learning Requires New Obligations and Approaches.},
journal = {Annals of global health},
volume = {87},
number = {1},
pages = {68},
pmid = {34307071},
issn = {2214-9996},
mesh = {Education, Distance/*methods ; Educational Measurement/methods ; Global Health/*education ; Humans ; International Cooperation ; *Learning ; Mentoring/*methods ; Problem-Based Learning/*methods ; },
abstract = {INTRODUCTION: The COVID-19 pandemic has forced a new look (or modernization) for both the obligations and approaches to achieve best-practices in global health learning. These best-practices have moved beyond traditional, face-to-face (F2F), classroom-based didactics to the use of innovative online, asynchronous and synchronous instructional design and the information and communication technology (ICT) tools to support it. But moving to this higher level of online in-service and pre-service training, key obligations (e.g., stopping neocolonialization, cultural humility, reversing brain drain, gender equity) must guide the modernization of instructional design and the supporting ICT. To positively impact global health training, educators must meet the needs of learners where they are.

PURPOSE: We describe a set of multi-communication methods, e-Learning principles, strategies, and ICT approaches for educators to pivot content delivery from traditional, F2F classroom didactics into the modern era. These best-practices in both the obligations and approaches utilize thoughtful, modern strategies of instructional design and ICT.

APPROACH: We harnessed our collective experiences in global health training to present thoughtful insights on the guiding principles, strategies, and ICT environment central to develop learning curricula that meet trainee needs and how they can be actualized. Specifically, we describe five strategies: 1. Individualized learning; 2. Provide experiential learning; 3. Mentor … Mentor … Mentor; 4. Reinforce learning through assessment; and 5. Information and communication technology and tools to support learning.

DISCUSSION: We offer a vision, set of guiding principles, and five strategies for successful curricula delivery in the modern era so that global health training can be made available to a wider audience more efficiently and effectively.},
}

Education, Distance/*methods
Educational Measurement/methods
Global Health/*education
Humans
International Cooperation
*Learning
Mentoring/*methods
Problem-Based Learning/*methods

@article {pmid34266813,
year = {2021},
author = {Beniczky, S and Husain, A and Ikeda, A and Alabri, H and Cross, JH and Wilmshurst, J and Seeck, M and Focke, N and Braga, P and Wiebe, S and Schuele, S and Trinka, E},
title = {Importance of access to epilepsy monitoring units during the COVID-19 pandemic: consensus statement of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology.},
journal = {Epileptic disorders : international epilepsy journal with videotape},
volume = {23},
number = {4},
pages = {533-536},
pmid = {34266813},
issn = {1950-6945},
mesh = {*COVID-19/diagnosis/prevention & control ; *Consensus ; *Electroencephalography/standards ; *Epilepsy/diagnosis/therapy ; *Health Services Accessibility/organization & administration/standards ; Humans ; *Neurophysiological Monitoring/standards ; *Outpatient Clinics, Hospital/organization & administration/standards ; Societies, Medical/standards ; },
abstract = {Restructuring of healthcare services during the COVID-19 pandemic has led to lockdown of epilepsy monitoring units (EMUs) in many hospitals. The ad-hoc taskforce of the International League Against Epilepsy (ILAE) and the International Federation of Clinical Neurophysiology (IFCN) highlights the detrimental effect of postponing video-EEG monitoring of patients with epilepsy and other paroxysmal events. The taskforce calls for action for continued functioning of EMUs during emergency situations, such as the COVID-19 pandemic. Long-term video-EEG monitoring is an essential diagnostic service. Access to video-EEG monitoring of the patients in the EMUs must be given high priority. Patients should be screened for COVID-19, before admission, according to the local regulations. Local policies for COVID-19 infection control should be adhered to during the video-EEG monitoring. In cases of differential diagnosis in which reduction of antiseizure medication is not required, home video-EEG monitoring should be considered as an alternative in selected patients.},
}

*COVID-19/diagnosis/prevention & control
*Consensus
*Electroencephalography/standards
*Epilepsy/diagnosis/therapy
*Health Services Accessibility/organization & administration/standards
Humans
*Neurophysiological Monitoring/standards
*Outpatient Clinics, Hospital/organization & administration/standards
Societies, Medical/standards

@article {pmid34253266,
year = {2022},
author = {Weber, DJ and Al-Tawfiq, JA and Babcock, HM and Bryant, K and Drees, M and Elshaboury, R and Essick, K and Fakih, M and Henderson, DK and Javaid, W and Juffras, D and Jump, RLP and Lee, F and Malani, AN and Mathew, TA and Murthy, RK and Nace, D and O'Shea, T and Pettigrew, E and Pettis, AM and Schaffzin, JK and Shenoy, ES and Vaishampayan, J and Wiley, Z and Wright, SB and Yokoe, D and Young, H},
title = {Multisociety statement on coronavirus disease 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel.},
journal = {Infection control and hospital epidemiology},
volume = {43},
number = {1},
pages = {3-11},
pmid = {34253266},
issn = {1559-6834},
mesh = {*COVID-19 ; COVID-19 Vaccines ; Child ; Delivery of Health Care ; Employment ; Humans ; SARS-CoV-2 ; United States/epidemiology ; Vaccination ; },
abstract = {This consensus statement by the Society for Healthcare Epidemiology of America (SHEA) and the Society for Post-Acute and Long-Term Care Medicine (AMDA), the Association for Professionals in Epidemiology and Infection Control (APIC), the HIV Medicine Association (HIVMA), the Infectious Diseases Society of America (IDSA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP) recommends that coronavirus disease 2019 (COVID-19) vaccination should be a condition of employment for all healthcare personnel in facilities in the United States. Exemptions from this policy apply to those with medical contraindications to all COVID-19 vaccines available in the United States and other exemptions as specified by federal or state law. The consensus statement also supports COVID-19 vaccination of nonemployees functioning at a healthcare facility (eg, students, contract workers, volunteers, etc).},
}

*COVID-19
COVID-19 Vaccines
Child
Delivery of Health Care
Employment
Humans
SARS-CoV-2
United States/epidemiology
Vaccination

@article {pmid34236416,
year = {2021},
author = {Geerts, JM and Kinnair, D and Taheri, P and Abraham, A and Ahn, J and Atun, R and Barberia, L and Best, NJ and Dandona, R and Dhahri, AA and Emilsson, L and Free, JR and Gardam, M and Geerts, WH and Ihekweazu, C and Johnson, S and Kooijman, A and Lafontaine, AT and Leshem, E and Lidstone-Jones, C and Loh, E and Lyons, O and Neel, KAF and Nyasulu, PS and Razum, O and Sabourin, H and Schleifer Taylor, J and Sharifi, H and Stergiopoulos, V and Sutton, B and Wu, Z and Bilodeau, M},
title = {Guidance for Health Care Leaders During the Recovery Stage of the COVID-19 Pandemic: A Consensus Statement.},
journal = {JAMA network open},
volume = {4},
number = {7},
pages = {e2120295},
doi = {10.1001/jamanetworkopen.2021.20295},
pmid = {34236416},
issn = {2574-3805},
support = {001/WHO_/World Health Organization/International ; },
mesh = {*COVID-19 ; Consensus ; Disaster Planning ; *Health Personnel/legislation & jurisprudence/organization & administration ; Humans ; *Leadership ; Models, Organizational ; *Pandemics ; SARS-CoV-2 ; },
abstract = {IMPORTANCE: The COVID-19 pandemic is the greatest global test of health leadership of our generation. There is an urgent need to provide guidance for leaders at all levels during the unprecedented preresolution recovery stage.

OBJECTIVE: To create an evidence- and expertise-informed framework of leadership imperatives to serve as a resource to guide health and public health leaders during the postemergency stage of the pandemic.

EVIDENCE REVIEW: A literature search in PubMed, MEDLINE, and Embase revealed 10 910 articles published between 2000 and 2021 that included the terms leadership and variations of emergency, crisis, disaster, pandemic, COVID-19, or public health. Using the Standards for Quality Improvement Reporting Excellence reporting guideline for consensus statement development, this assessment adopted a 6-round modified Delphi approach involving 32 expert coauthors from 17 countries who participated in creating and validating a framework outlining essential leadership imperatives.

FINDINGS: The 10 imperatives in the framework are: (1) acknowledge staff and celebrate successes; (2) provide support for staff well-being; (3) develop a clear understanding of the current local and global context, along with informed projections; (4) prepare for future emergencies (personnel, resources, protocols, contingency plans, coalitions, and training); (5) reassess priorities explicitly and regularly and provide purpose, meaning, and direction; (6) maximize team, organizational, and system performance and discuss enhancements; (7) manage the backlog of paused services and consider improvements while avoiding burnout and moral distress; (8) sustain learning, innovations, and collaborations, and imagine future possibilities; (9) provide regular communication and engender trust; and (10) in consultation with public health and fellow leaders, provide safety information and recommendations to government, other organizations, staff, and the community to improve equitable and integrated care and emergency preparedness systemwide.

CONCLUSIONS AND RELEVANCE: Leaders who most effectively implement these imperatives are ideally positioned to address urgent needs and inequalities in health systems and to cocreate with their organizations a future that best serves stakeholders and communities.},
}

*COVID-19
Consensus
Disaster Planning
*Health Personnel/legislation & jurisprudence/organization & administration
Humans
*Leadership
Models, Organizational
*Pandemics
SARS-CoV-2

@article {pmid34227785,
year = {2021},
author = {Gnanaraj, JP and Anne, PS and Majella, CM and Durairaj, P and Edwin, R and Kannan, K and Ramachandran, V and Jeyabalan, N and Mohanan, N and Krishnan, S and Somasundaram, S},
title = {Antithrombotic Therapy in COVID-19 - A Scientific Position Statement by Heart Disease Management Program, National Health Mission, Government of Tamil Nadu.},
journal = {The Journal of the Association of Physicians of India},
volume = {69},
number = {1},
pages = {82-87},
pmid = {34227785},
issn = {0004-5772},
mesh = {*COVID-19 ; Disease Management ; *Fibrinolytic Agents ; Government ; Humans ; India ; National Health Programs ; SARS-CoV-2 ; },
}

*COVID-19
Disease Management
*Fibrinolytic Agents
Government
Humans
India
National Health Programs
SARS-CoV-2

@article {pmid34212511,
year = {2021},
author = {Butsch, WS and Hajduk, A and Cardel, MI and Donahoo, WT and Kyle, TK and Stanford, FC and Zeltser, LM and Kotz, CM and Jastreboff, AM},
title = {COVID-19 vaccines are effective in people with obesity: A position statement from The Obesity Society.},
journal = {Obesity (Silver Spring, Md.)},
volume = {29},
number = {10},
pages = {1575-1579},
pmid = {34212511},
issn = {1930-739X},
support = {P30 DK040561/DK/NIDDK NIH HHS/United States ; UL1 TR001863/TR/NCATS NIH HHS/United States ; I01 BX003004/BX/BLRD VA/United States ; P30 DK045735/DK/NIDDK NIH HHS/United States ; I01 BX003687/BX/BLRD VA/United States ; },
mesh = {Adolescent ; Adult ; Aged ; COVID-19/*immunology/*prevention & control/virology ; COVID-19 Vaccines/*immunology ; Clinical Trials as Topic ; Humans ; Middle Aged ; Obesity/*immunology ; SARS-CoV-2/*immunology ; *Societies, Medical ; Young Adult ; },
abstract = {The position statement is issued by The Obesity Society in response to published literature, as well as inquiries made to the Society by patients, providers, Society members, policy makers, and others regarding the efficacy of vaccines in persons with obesity against SARS-CoV-2, the virus that causes COVID-19. The Obesity Society has critically evaluated data from published peer-reviewed literature and briefing documents from Emergency Use Authorization applications submitted by Pfizer-BioNTech, Moderna, and Johnson & Johnson. We conclude that these vaccines are highly efficacious, and their efficacy is not significantly different in people with and without obesity, based on scientific evidence available at the time of publication. The Obesity Society believes there is no definitive way to determine which of these three COVID-19 vaccines is "best" for any weight subpopulation (because of differences in the trial design and outcome measures in the phase 3 trials, elapsed time between doses, and regional differences in the presence of SARS-CoV-2 variants [e.g., South Africa B.1.351 in Johnson & Johnson trial]). All three trials have demonstrated high efficacy against COVID-19-associated hospitalization and death. Therefore, The Obesity Society encourages adults with obesity ≥18 years (≥16 years for Pfizer-BioNTech) to undergo vaccination with any one of the currently available vaccines authorized for emergency use by the US Food and Drug Administration as soon as they are able.},
}

Adolescent
Adult
Aged
COVID-19/*immunology/*prevention & control/virology
COVID-19 Vaccines/*immunology
Clinical Trials as Topic
Humans
Middle Aged
Obesity/*immunology
SARS-CoV-2/*immunology
*Societies, Medical
Young Adult

@article {pmid34187457,
year = {2021},
author = {Corby, S and Whittaker, K and Ash, JS and Mohan, V and Becton, J and Solberg, N and Bergstrom, R and Orwoll, B and Hoekstra, C and Gold, JA},
title = {The future of medical scribes documenting in the electronic health record: results of an expert consensus conference.},
journal = {BMC medical informatics and decision making},
volume = {21},
number = {1},
pages = {204},
pmid = {34187457},
issn = {1472-6947},
support = {R01 HS025141/HS/AHRQ HHS/United States ; T15 LM007088/LM/NLM NIH HHS/United States ; },
mesh = {*COVID-19 ; Documentation ; *Electronic Health Records ; Humans ; SARS-CoV-2 ; Workflow ; },
abstract = {BACKGROUND: With the use of electronic health records (EHRs) increasing and causing unintended negative consequences, the medical scribe profession has burgeoned, but it has yet to be regulated. The purpose of this study was to describe scribe workflow as well as identify the threats and opportunities for the future of the scribe industry.

METHODS: The first phase of the study used ethnographic methods consisting of interviews and observations by a multi-disciplinary team of researchers at five United States sites. In April 2019, a two-day conference of experts representing different stakeholder perspectives was held to discuss the results from site visits and to predict the future of medical scribing. An interpretive content analysis approach was used to discover threats and opportunities for the future of medical scribes.

RESULTS: Threats facing the medical scribe industry were related to changes in the documentation model, EHR usability, different payment structures, the need to acquire disparate data during clinical encounters, and workforce-related changes relevant to the scribing model. Simultaneously, opportunities for medical scribing in the future included extension of their role to include workflow analysis, acting as EHR-related subject-matter-experts, and becoming integrated more effectively into the clinical care delivery team. Experts thought that if EHR usability increases, the need for medical scribes might decrease. Additionally, the scribe role could be expanded to allow scribes to document more or take on more informatics-related tasks. The experts also anticipated an increased use of alternative models of scribing, like tele-scribing.

CONCLUSION: Threats and opportunities for medical scribing were identified. Many experts thought that if the scribe role could be expanded to allow scribes to document more or take on more informatics activities, it would be beneficial. With COVID-19 continuing to change workflows, it is critical that medical scribes receive standardized training as tele-scribing continues to grow in popularity and new roles for scribes as medical team members are identified.},
}

*COVID-19
Documentation
*Electronic Health Records
Humans
SARS-CoV-2
Workflow

@article {pmid34180546,
year = {2022},
author = {Korath, ADJ and Janda, J and Untersmayr, E and Sokolowska, M and Feleszko, W and Agache, I and Adel Seida, A and Hartmann, K and Jensen-Jarolim, E and Pali-Schöll, I},
title = {One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-CoV-2.},
journal = {Allergy},
volume = {77},
number = {1},
pages = {55-71},
pmid = {34180546},
issn = {1398-9995},
support = {//European Academy of Allergy and Clinical Immunology (EAACI)/ ; },
mesh = {Animals ; *COVID-19 ; Humans ; *One Health ; Pandemics ; Quality of Life ; SARS-CoV-2 ; },
abstract = {The latest outbreak of a coronavirus disease in 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), evolved into a worldwide pandemic with massive effects on health, quality of life, and economy. Given the short period of time since the outbreak, there are several knowledge gaps on the comparative and zoonotic aspects of this new virus. Within the One Health concept, the current EAACI position paper dwells into the current knowledge on SARS-CoV-2's receptors, symptoms, transmission routes for human and animals living in close vicinity to each other, usefulness of animal models to study this disease and management options to avoid intra- and interspecies transmission. Similar pandemics might appear unexpectedly and more frequently in the near future due to climate change, consumption of exotic foods and drinks, globe-trotter travel possibilities, the growing world population, the decreasing production space, declining room for wildlife and free-ranging animals, and the changed lifestyle including living very close to animals. Therefore, both the society and the health authorities need to be aware and well prepared for similar future situations, and research needs to focus on prevention and fast development of treatment options (medications, vaccines).},
}

Animals
*COVID-19
Humans
*One Health
Pandemics
Quality of Life
SARS-CoV-2

@article {pmid34170086,
year = {2021},
author = {Richter, D and Guasti, L and Koehler, F and Squizzato, A and Nistri, S and Christodorescu, R and Dievart, F and Gaudio, G and Asteggiano, R and Ferrini, M},
title = {Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice.},
journal = {ESC heart failure},
volume = {8},
number = {5},
pages = {3483-3494},
pmid = {34170086},
issn = {2055-5822},
mesh = {*COVID-19/complications ; *Cardiology ; Humans ; Pandemics ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; },
abstract = {Cardiovascular (CV) engagement in coronavirus disease 2019 (COVID-19) is a huge determinant of prognosis during the acute phase of the disease. However, little is known about the potential chronic implications of the late phase of COVID-19 and about the appropriate approach to these patients. Heart failure, type 1 and type 2 myocardial infarction, arrhythmias, myocarditis, pulmonary fibrosis, and thrombosis have been shown to be related to severe acute respiratory syndrome coronavirus 2 infection, and a 'long COVID-19' illness has been recognized with fatigue, chest pain, and dyspnoea among the most frequent symptoms reported after discharge from hospital. This paper focuses on some open questions that cardiologists are going to face during the next months in a general cardiology outpatient clinic, in particular how to evaluate a 'post-COVID' patient during follow-up of CV complications of the acute phase and how to manage new CV symptoms that could be the consequence, at least in part, of heart/vessels and/or lung involvement of the previous virus infection. Present symptoms and signs, history of previous CV disease (both preceding COVID-19 and occurring during viral infection), and specific laboratory and imaging measurements during the acute phase may be of interest in focusing on how to approach the clinical evaluation of a post-COVID patient and how to integrate in our standard of care the new information on COVID-19, possibly in a multidisciplinary view. Dealing with the increased COVID-associated CV risk burden and becoming acquainted with potential new e-cardiology approaches aimed at integrating the cardiology practice are relevant new challenges brought by severe acute respiratory syndrome coronavirus 2 infection and its sequelae.},
}

*COVID-19/complications
*Cardiology
Humans
Pandemics
SARS-CoV-2
Post-Acute COVID-19 Syndrome

@article {pmid34169495,
year = {2021},
author = {Gerotziafas, GT and Catalano, M and Theodorou, Y and Dreden, PV and Marechal, V and Spyropoulos, AC and Carter, C and Jabeen, N and Harenberg, J and Elalamy, I and Falanga, A and Fareed, J and Agathaggelou, P and Antic, D and Antignani, PL and Bosch, MM and Brenner, B and Chekhonin, V and Colgan, MP and Dimopoulos, MA and Douketis, J and Elnazar, EA and Farkas, K and Fazeli, B and Fowkes, G and Gu, Y and Gligorov, J and Ligocki, MA and Indran, T and Kannan, M and Kantarcioglu, B and Kasse, AA and Konstantinidis, K and Leivano, F and Lewis, J and Makatsariya, A and Mbaye, PM and Mahé, I and Panovska-Stavridis, I and Olinic, DM and Papageorgiou, C and Pecsvarady, Z and Pillon, S and Ramacciotti, E and Abdel-Razeq, H and Sabbah, M and Sassi, M and Schernthaner, G and Siddiqui, F and Shiomura, J and Slama-Schwok, A and Wautrecht, JC and Tafur, A and Taher, A and Klein-Wegel, P and Zhai, Z and Zoubida, TM and , },
title = {The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper.},
journal = {Thrombosis and haemostasis},
volume = {121},
number = {8},
pages = {992-1007},
pmid = {34169495},
issn = {2567-689X},
mesh = {COVID-19/diagnosis/*epidemiology/*prevention & control ; COVID-19 Testing/methods ; COVID-19 Vaccines/therapeutic use ; Disease Management ; Humans ; Immunization Programs/methods ; Pandemics/prevention & control ; *Public Health/methods ; Risk Assessment ; SARS-CoV-2/isolation & purification ; },
abstract = {BACKGROUND: One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis.

MANAGEMENT: Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic.

CURRENT ISSUES: The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments.

PERSPECTIVES: There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) Prevention of the SARS-CoV-2 infection, (2) Detection and early diagnosis of patients at risk of disease worsening, and (3) Anticipation of medical care (PDA).

CONCLUSION: The "PDA strategy" integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.},
}

COVID-19/diagnosis/*epidemiology/*prevention & control
COVID-19 Testing/methods
COVID-19 Vaccines/therapeutic use
Disease Management
Humans
Immunization Programs/methods
Pandemics/prevention & control
*Public Health/methods
Risk Assessment
SARS-CoV-2/isolation & purification

@article {pmid34155756,
year = {2021},
author = {Kanjanapan, Y and Blinman, P and Underhill, C and Karikios, D and Segelov, E and Yip, D},
title = {Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours.},
journal = {Internal medicine journal},
volume = {51},
number = {6},
pages = {955-959},
pmid = {34155756},
issn = {1445-5994},
mesh = {Australia/epidemiology ; *COVID-19 ; COVID-19 Vaccines ; Humans ; Medical Oncology ; *Neoplasms/epidemiology/therapy ; SARS-CoV-2 ; Vaccination ; },
abstract = {People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed.},
}

Australia/epidemiology
*COVID-19
COVID-19 Vaccines
Humans
Medical Oncology
*Neoplasms/epidemiology/therapy
SARS-CoV-2
Vaccination